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Breast cancer is the most prevalent form of cancer in women and accounts for 519,000 
annual deaths (WHO Statistics). It has long been established that oestrogen (E2) stimulates 
tumour growth of oestrogen receptor (ER) positive breast cancer and is involved in the 
pathogenesis of the disease. Consequently, therapeutic approaches targeting the ER were 
developed. The use of endocrine therapy is an integral component in treating breast cancer 
however resistance to such drugs is a major limitation. Unfortunately, even initially 
responding tumours eventually develop resistance - acquired resistance. 
The aim of this study was to determine which intracellular pathways may be important in 
conferring acquired endocrine resistance. In order to do so, a three-stage MCF-7 cell model 
emulating the clinical development of acquired endocrine was used. MCF-7/LCC1 (LCC1) 
and MCF-7/LCC9 (LCC9) cells lines were derived from the oestrogen dependent and anti-
oestrogen sensitive MCF-7 cell line. LCC1 cells remain responsive to endocrine therapies 
but their growth is not dependent on oestrogenic stimulus. LCC9 cells, on the other hand 
are fully resistant to endocrine therapies and completely oestrogen independent.  
 
A number of different cell membrane receptors and intracellular pathways have been 
implicated in endocrine resistance including HER receptor family, PI3K/Akt & MEK/ERK 
pathways. These pathways are of particular interest since they are able to activate ER in the 
absence of oestrogenic stimulus. It is likely that several pathways may be important in 
conferring resistance to endocrine therapies therefore the experiments in this study 
focussed on the transcriptional regulation of HER receptors, the activation of the Akt 
pathway and its implication to basic cellular processes.       
 
Following E2 treatment (48h), HER2/3/4 mRNA and protein levels were reduced in MCF-
7 and LCC1 but not in the endocrine-resistant LCC9 cell line as measured by QRT-PCR 
and Western blotting. The anti-estrogen fulvestrant (ICI 182,780) reversed the E2 
modulation. A previous study has shown that ER and the HER2 promoter compete for 
limiting amounts of SRC-1 in oestrogen-responsive ZR-75-1 cells, causing HER2 
repression after E2 stimulation (Newman et al.,Oncogene, 19, 490-7, 2000). ER RNAi 
abolished E2 repression of HER2 in MCF-7 and LCC1 cells. Furthermore, LCC9 cells have 
reduced SRC-1 recruitment to ER (assessed by ChIP) allowing SRC-1 to bind to the HER2 
 vi
promoter. SRC-1 RNAi reduced HER2 transcription in MCF7 cells in a manner similar to 
E2 whilst it did not restore E2 repression in LCC9 suggesting that the latter cells have 
alternative mechanisms regulating HER2 transcription. RNAis against the other two p160 
co-activators TIF2 and AIB1 did not restore E2 mediated HER2 repression in LCC9 cells. 
The importance of redundancy between p160 co-activators was also determined by 
performing double knockouts. SRC-1/TIF2 and TIF2/AIB1 double siRNAs had little effect 
on HER2 mRNA levels however SRC-1/AIB1 siRNA restored oestrogen mediated 
downregulation of HER2 transcription in LCC9 cells. This data indicates that SRC-1 and 
AIB1 co-activators play a role in the transcriptional regulation of HER receptor 
particularly in MCF-7 and LCC1 cells. The regulation of this transcriptional mechanism is 
altered in resistant LCC9 cells but, as evidenced by the double knockouts, p160 co-
activators are still able to affect HER expression in these cells. This mechanism was 
further studied in primary breast cancer tumour material. 
 
The importance of the Akt pathway in this cell line model was also investigated as 
phospho-Akt levels are elevated in LCC1 and LCC9 cells. This in turn was shown to 
activate mTOR and ER (Ser167 residue phosphorylation) thereby contributing to increased 
growth and ligand independent activation of the oestrogen receptor respectively. 
Activation of PI3K and PTEN is unchanged in LCC1 and LCC9 cells suggesting that these 
proteins are not responsible for elevated Akt phosphorylation. In contrast, these cells do 
express higher levels of phospho-IGFR due to the high availability of receptor ligands 
(IGFI & IGFII). This is likely to be, at least partially, responsible for the elevated Akt 
activation. Moreover, the role of Akt isoforms was also determined as they are known to 
have different functions. The levels of Akt 2 phosphorylation are higher in endocrine 
resistant cell lines in comparison to parental MCF-7 cells. Interestingly, the Akt 3 
phosphorylation is present in all cell lines whilst Akt 1 phosphorylation is minimal. 
Nevertheless, Akt RNAi studies reveal that Akt 1 and 2 siRNA dramatically reduce growth 
in MCF-7, LCC1 and LCC9 cells. These results suggest that Akt 2 phosphorylation may 
play a part in conferring endocrine resistance but the other isoforms are also important for 
normal cellular growth.   
 
The cell cycle profiles of LCC1 and LCC9 are very similar to MCF-7. Similarly, migration 
levels are unchanged in endocrine resistant cell lines. However, in the presence of anti-
oestrogenic drugs, apoptosis in LCC1 and LCC9 cells in reduced in comparison to the 
 vii
parental MCF-7 cell line. Furthermore, LCC1 and LCC9 cells have higher invasion rates. 
The deregulation of HER receptor expression and elevated Akt activation may together 
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1.1 Breast Biology 
Breast cancer is the most frequent type of cancer affecting women worldwide and the 
second leading cause of cancer deaths in females after lung cancer. The development of 
endocrine resistance in breast cancer is one of the major challenges in treatment of this 
condition.  
 
1.1.1 Normal Breast 
The development of the mammary gland begins in the womb and its structure is similar in 
females and males at birth. The breast tissue changes progressively throughout childhood 
but becomes strikingly different at puberty in women. The development of the mammary 
glad at puberty is dependent on the presence of the hormones oestrogen and progesterone 
produced by the ovaries (Russo et al, 2000). Later in life, the breasts undergo a relentless 
cycle of growth followed by involution (mediated by apoptosis) regulated by the menstrual 
cycles or by the pregnancy/lactation cycles (Ali et al, 2002).  
The mammary gland is comprised of a simple network of ducts originating during 
intrauterine life which later form lobules (each mammary gland may have up to 20 lobules) 
(Figure 1.1). At puberty, the ducts begin to grow and divide thereby increasing ductal 
branching and forming terminal end-buds. These structures will, in pregnancy, give rise to 
the alveolar buds that are responsible for milk synthesis. Each duct is made of two cell 
layers: an epithelial cell layer (milk production) surrounded by the contractile myoepithelial 











Figure 1.1 Anatomy of normal mammary gland. These are composed of fatty and connective 
tissue surrounding the lobes where the milk is produced. A network of ducts connects the lobes to 
the nipple (Reproduced from www.cancerbackup.org.uk). 
Introduction 
 3
1.1.2 Breast Cancer 
1.1.2.1 Incidence & Survival 
Breast cancer is detected in approximately 1 million women around the world each year. In 
the UK, 45,000 people are diagnosed with this type of cancer each year, 300 of which are in 
men (Cancer Research UK statistics). In the United States, around 250,000 new cases are 
diagnosed annually (American Cancer Society, 2007). After non-melanoma skin cancer, 
breast cancer is the most common cancer in the world and is the second leading cause of 
cancer death after lung cancer (Stewart et al, 2004). There is a lifetime risk of developing 
breast cancer of 1 in 9 which increases with age (Ali et al, 2002). Most women are 
diagnosed with breast cancer after menopause but there are a significant number of cases in 
women under 50 years of age perhaps due to familial and genetic predispositions (American 
Cancer Society, Cancer Facts & Figures, 2006). Breast cancer is responsible for an average 
of 40,000 and 12,000 deaths in the US and the UK respectively. Nevertheless, the death 
rates for this disease have actually reduced since 1990, particularly in younger women 
which is probably a result of increased awareness, early detection and improved therapeutic 
approaches (American Cancer Society, Cancer Facts & Figures, 2006).  
         
1.1.2.2 Epidemiology 
Breast cancer may be divided into a number of different categories based on the location 
and characteristics of the cancerous cells. Lobular carcinoma in situ (LCIS) refers to 
tumours confined to the breast lobules, the milk producing glands. Ductal carcinomas in 
situ (DCIS), on the other hand, are restricted to the lobule ducts. Both these types of breast 
cancer remain in the site of origin (hence the term in situ) and have not spread to the 
neighbouring breast tissue (Weigelt et al, 2009). DCIS morphologically resembles the 
ductal types of invasive breast cancers whilst LCIS are similar to invasive lobular breast 
cancer suggesting they may be precursors for more invasive breast cancer types (Buerger et 
al, 2000). Nevertheless, there is evidence to suggest that some DCIS cases are associated 
with invasive lobular carcinomas and that a small proportion of LCIS may give rise to 
invasive carcinomas of the ductal subtype (Millikan et al, 1995).  
Approximately 80% of diagnosed breast cancer cases are invasive ductal carcinomas 
making it the most common type of breast cancer followed by invasive lobular carcinomas. 
There are other more rare types of breast cancer such as inflammatory breast cancer (1-2%) 
and Paget’s disease (1-2%). Inflammatory breast cancer is characterised by inflamed breast 
Introduction 
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tissue due to the blockage of lymph ducts (Molckovsky et al, 2009). The symptoms 
associated with Paget’s disease include a red rash around the nipple and areola which if left 
may ulcerate. This condition is often mistaken for eczema and its causes remain unknown. 
Approximately 90% of women suffering from Paget’s disease have an underlying breast 
cancer usually DCIS or invasive ductal carcinoma (Dalberg et al, 2008).  
         
1.1.2.3 Stages of Breast Cancer 
Cancer staging is a helpful tool for both doctors and patients as it provides a means of 
placing the disease into context (Table 1.1). The staging system takes into account a number 
of tumour properties such as the size of the tumour, its aggressiveness and its invading 
potential. This mechanism enables patients a more in depth understanding of their 
condition, their prognosis and the appropriate therapeutic approaches. Furthermore, this 
method provides the health professionals involved in cancer treatment with a useful manner 
in which to communicate (Jeruss et al, 2008). 
 
    
Stages Description 
Stage 0 
Non-invasive breast cancer such as DCIS and LCIS 
Cancer has not spread from site of origin 
Stage I 
Invasive cancers; lymph nodes not affected 
Tumours < 2cm diameter 
A 
Cancer cells only present in axillary lymph nodes 
OR <2cm tumour and cancer cells found in lymph nodes 




2-5cm tumour; cancer cells present in axillary lymph nodes 
OR tumours >5cm diameter; no cancer cells found in lymph nodes 
A 
Tumours over 5cm diameter; cancer cells found in lymph nodes; characterised by clumping of 
lymph nodes and surrounding tissue 
B 
Tumours may be any size; tumour has spread to skin and chest wall; cancer cells present in 




Tumours may be any size; cancer cells have spread to lymph nodes in: armpit and under breast 
bone OR above/below collarbone 
Stage IV Tumours has spread to other parts of the body; Metastatic cancer 






 1.1.2.4 Role of Oestrogen in Breast Cancer 
Oestrogen has been implicated in breast cancer since 1896 when George Beatson showed 
that performing an oophorectomy suppressed breast cancer growth. As previously 
described, breast development at puberty is dependent on hormones produced by the 
ovaries such as oestrogen. Despite its crucial role in regulating mammary growth, high 
levels of oestrogen appear to be associated with an increase in breast cancer risk (Clemons 
et al, 2001).The exact mechanism by which oestrogen increases the risk of breast cancer is 
still to be fully determined (Yager et al, 2006).  
The exposure to endogenous and exogenous oestrogens during a woman’s lifetime seems to 
be a critical factor in breast carcinogenesis. Oral contraception and hormone-replacement 
therapies have both been shown to correlate with an increase in breast cancer risk 
(Collaborative Group on Hormonal Factors in Breast Cancer, 1996 & 1997). This will be 
further discussed later in this chapter (Section 1.1.2.5. (ii)). There are other well-recognised 
factors that should be taken into account referring to certain reproductive characteristics 
such as age at menarche, age at first birth, number of children and breastfeeding. The early 
onset of menarche and late menopause are linked to increased breast cancer risk probably 
due to the longer exposure to oestrogen (Clamp et al, 2002). Early first pregnancies, 
lactation and parity have all been shown to have a protective effect against breast cancer 
which may be due to the differentiation process of the terminal duct lobules or to the 
various hormones present at lactation (Albrektsen et al, 1999; Clamp et al, 2002). 
         
1.1.2.5 Risk Factors in Breast Cancer 
(i) Age 
Age is one of the major contributors in breast cancer as over 80% of cases occur in women 
over the age of 50 (Breakthrough Breast Cancer Statistics). However, the risk of developing 
breast cancer reduces dramatically following menopause probably due to the reduction of 
circulating oestrogen (Eerola et al, 2002). At menopause the ovaries cease to produce 








(ii) Hormone Replacement Therapy & Oral Contraceptives 
Hormone replacement therapies (HRT) are routinely used in menopausal women to reduce 
the effects of diminished levels of circulating oestrogen. These treatments improve patients’ 
quality of life and also prevent conditions such as osteoporosis, colon cancer and dementia 
(Bluming et al, 2009). Despite the advantages of HRT, a number of studies have 
highlighted that they may also increase the risk of diseases such as cardiovascular disease, 
breast cancer and stroke (Nelson et al, 2002). There are conflicting reports regarding the 
risk of breast cancer whilst on HRT. A few studies have not found any association between 
the two (Grady et al, 1992; Hemminki et al, 1997; Steinberg et al, 1994) whilst others, 
including the study from the Women’s Health Initiative published in 2002, claim that HRT 
use significantly increases the risk of breast cancer (WHI report, 2002; Sillero-Arenas et al, 
1992; Colditz et al, 1993). In spite of the contradicting results it is becoming apparent that 
women using oestrogen in combination with progesterone are at higher risk of developing 
breast cancer after 5 years treatment, more so than patients on oestrogen only treatment 
(Burger et al, 2003). Furthermore, reports also indicate an increase in risk with long term 
treatment (Nelson et al, 2002). 
 
Similarly to HRT use, there are conflicting results regarding the link between the oral 
contraceptive pill and breast cancer. A recent study suggested there was no association 
between breast cancer and the use of the oral contraceptive pill after examining data from 
over 4,500 women (Barnett et al, 2008). On the other hand, in 1996 data compiled from 54 
published reports suggested that women currently using combined oral contraceptives were 
found to be at higher risk of developing breast cancer. Furthermore, the risk increased after 
10 years of treatment (Collaborative Group on Hormonal Factors in Breast Cancer, 1996; 
Travis et al, 2003).  
 
(iii) Lifestyle  
There are a number of factors that have been linked to breast cancer, either as protective or 
as potential contributors to the disease. A number of studies suggest physical activity may 
have a role in preventing breast cancer, especially in post-menopausal women (Pan et al, 
2009). Obesity in post-menopausal women, on the other hand, has been strongly linked to 
increased risk (2 fold increase) of breast cancer (Dignam et al, 2006). There is conflicting 
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evidence regarding the role of diet with a suggested positive influence of fruits and high 
fibre foods compared to red meat and fatty dairy products (Soerjomataram et al, 2009). 
A few studies have also shown an association between alcohol consumption and increase in 
breast cancer risk (Smith-Warner et al, 1998; Hamajima et al, 2002). The mechanism 
behind this relationship is not fully understood. Certain studies propose alcohol may 
interfere with folate or oestrogen metabolism whilst other hypotheses suggest carcinogenic 
metabolites might be important (Chen et al, 2005). Interestingly, cohort studies show a 
dose-response relationship between the amounts of alcohol consumed and breast cancer risk 
(Zhang et al, 2007).  
The relationship between smoking and breast cancer is still undetermined due to a variety of 
discrepant studies (Palmer et al, 1993). Mutations of the p53 gene and smoking-specific 
DNA adducts have been detected in breast tissue suggesting an association (Rundle et al, 
2002; Conway et al, 2002). On the other hand, other studies have failed to detect any 
relationship between the two. The conflicting results probably reflect variation with the 
populations in each study (Palmer et al, 1993).          
 
1.1.2.6 Genetic Factors 
Most breast cancers are said to be sporadic as they occur in women with no family history. 
However, 20 to 30% of cases are linked to family history and a number of genes have been 
implicated in this mechanism (Edlich et al, 2005). 
 
(i) BRCA 1 & BRCA 2 
Most familial breast cancer cases are a result of germ line mutations in BRCA1 
(chromosome 17) or BRCA2 genes (chromosome 13). These susceptibility genes were first 
identified in the 1990s and have since been the focus of a number of studies (Miki et al, 
1994; Wooster et al, 1995). In women carrying such mutations, the lifetime risk of breast 
cancer by the age of 70 is estimated to be 80% (Krainer et al, 1997). The BRCA1 protein is 
involved in regulating cellular proliferation ensuring the fidelity of DNA replication. 
BRCA2 is also involved in maintaining genome integrity due to its role in DNA repair 
(Sakorafas et al, 2000). Both genes are large and over 250 and 100 disease-causing 
mutations have been described in BRCA1 and BRCA2 genes, respectively (Blackwood et al, 
1998; Couch et al, 1996). These mutations are not confined to particular regions of the gene 
however large family-linked studies have helped determine that few of these mutations are 
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recurrent making mutation screening more accessible (Couch et al, 1996). BRCA1 and 
BRCA2 are tumour suppressor genes since mutations reducing protein levels or rendering 
them not functional are associated with tumour formation (Stratton et al 1996).          
         
(ii) p53 
The p53 protein plays a part in regulating cell cycle checkpoint and is important in the 
response to DNA damage by inducing cell cycle arrest, DNA repair or apoptosis. In the 
absence of a functional p53 protein, cells are able to bypass apoptosis thereby replicating 
damaged DNA (Sakorafas et al, 1994). The p53 gene is found on chromosome 17 and is 
mutated in about 50% of all human cancer cases. It is known to be a tumour suppressor 
gene frequently inactivated by point mutations, particularly missense mutations (Sakorafas 
et al, 1994; Cho et al, 1994). Around 30% of invasive breast cancers are positive for p53 
mutations and these also seem to be associated with poorer prognosis of women with early-
stage breast cancer (de Cremoux et al, 1999; Linjawi et al, 2004).    
 
(iii) PTEN 
Mutations of the PTEN tumour suppressor gene have also been implicated in breast cancer 
as they often occur in patients suffering from Cowden Syndrome (80% of cases) (Lynch et 
al, 1997). This rare hereditary condition is characterized by an increase risk of developing 
certain cancers and by the formation of tumour-like growths (Hanssen et al, 1995). The risk 
of breast cancer in patients suffering with Cowden syndrome is between 30-50% by the age 
of 50 (Radford et al, 1996). The PTEN protein is an important regulator of the PI3K/Akt 
pathway and has also been shown to regulate p53 activity (Wan et al, 2003; Freeman et al, 
2003). To date, mutations of the PTEN gene have not been linked to increased breast cancer 
susceptibility outside families affected by Cowden Syndrome (Sakorafas et al, 2000). 
 
1.2 Oestrogen Receptor & Breast Cancer 
1.2.1 ER Structure & Function 
Oestrogen function is mediated by the oestrogen receptor (ER), a member of the 
steroid/thyroid/retinoid nuclear receptor superfamily of transcription factors. Oestrogen 
binding to ER induces conformational changes in the receptor which in turn leads to 
transcriptional activation of oestrogen-regulated genes. The ligand-bound receptor 
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dimerizes before binding to small palindromic DNA sequences (oestrogen response 
elements (EREs)) at the promoters of such genes. This triggers the recruitment and 
interaction with a number of co-activators leading to the assembly of the transcriptional 
machinery (Nilsson et al, 2001). Genes containing such oestrogen response elements are 
involved in an array of cellular processes which promote cellular growth. These may 
include gene important in regulating cell cycle progression such as Cyclin A or by 
promoting translation and survival via the PI3K/Akt pathway (Zilli et al, 2009).  
 
There are two oestrogen receptors: ERα and ERβ. ERβ was not identified until 1996 and its 
exact roles are still to be fully understood. The two receptors share a high degree of 
homology in certain domains, are both activated by oestrogen and inhibited by tamoxifen 
(Figure 1.2). ERα and ERβ are produced by distinct genes located on chromosomes 6 and 
14, respectively. The differences between the two receptors suggest they may have separate 
functions particularly in terms of gene transcription and cellular mechanisms activated (Zilli 






Figure 1.2 Oestrogen structural domains. The DNA-binding and ligand-binding domains are 
highlighted. The percentage values represent the similarities of each domain in the two receptors.  
 
The oestrogen receptors are composed of three functional domains: the NH2-terminal 
domain (A/B); the DNA-binding domain (C) and the ligand-binding domain (D/E/F) 
(Figure 1.2). The ligand-binding domain (LBD) at the COOH-terminus contains the 
activation function 2 (AF2) region whose activity is directly regulated by oestrogen binding 
(Herynk et al, 2004). Besides mediating ligand binding, the LBD also plays a part in 
receptor dimerization and nuclear translocation. The N-terminal domain is involved in 
protein-protein interactions and harbours the ligand-independent activation function 1 
(AF1) region (Nilsson et al, 2001). AF1 activity is mediated by phosphorylation and does 
not require the presence of ligands. The DNA-binding domain (DBD) also has an important 
role in receptor dimerization and binding to specific DNA sequences. This region contains a 





A C D E FB
A/B C D E/F
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promoters (Ali et al, 2002). The DBD and LBD of ERα and ERβ are highly homologous 
suggesting the two receptors are equally efficient at recognising and binding to EREs 
therefore promoting transcription. On the other hand, the AF1 domain appears to be active 
only in ERα which may account for the different ligand responses of the two receptors. The 
C and E domains contain a divided dimerisation domain. The two oestrogen receptors are 
able to form homo- and heterodimers and these two structural regions are thought to be 
involved in this process (Herynk et al, 2004).  
 
(i) Role of Transcription Factors 
Transcriptional regulation is crucial in maintaining control of cellular processes such as 
growth and differentiation. Transcription is mainly carried out by RNA polymerase but a 
number of other factors essential for successful transcriptional activation (Lee et al, 200). 
These transcription factors are involved in recognising promoter sequences, mediating 
conformational changes and assembling the transcriptional machinery. They are 
characterised by the presence of two main domains, a DNA-binding domain which 
recognises and binds to specific DNA sequences and a transactivation domain responsible 
for recruiting and binding other proteins necessary for transcription (Lee et al, 2000; Hahn 










Figure 1.3 Transcription initiation. RNA polymerase II requires a number of different 
transcription factors and co-activators. TFIIA blocks transcription inhibitors and stabilises binding to 
DNA; TFIIB binds Pol II and promoter DNA to help fix transcription start site; TFIID is a platform 
for assembly of TFIIB and TFIIA; TFIIE stabilises transcription complex; TFIIF is responsible for 
recruiting Pol II to the pre-initiation complex; Mediator (Med) and TFIIH are important to the their 
kinase, and respective acetyltransferases and helicase activities (Hahn et al, 2004). 
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1.2.2 Oestrogen Mediated Transcription 
The AF2 domain interaction surface is composed of six important aminoacids (helix 3, 4, 5 
& 12) as shown by crystallographic studies. Oestrogen binding alters the position of helix 
12 so it forms the surface for co-activator interaction. ER recruits the general transcriptional 
machinery thereby promoting gene transcription (Brzozowski et al, 1997). Co-activator 
complexes mediate the interaction between ER and the general transcriptional machinery 
and enable the recruitment of the ATP-dependent chromatin remodelling complexes such as 
SWI/SNF (switch/sucrose non-fermenting), the TRAP/DRIP/SMCC, the CREB-binding 
protein and p300/CBP associated factor (PCAF). Recruitment of histone acetyltransferases 
and methyltransferases present in these complexes lead to hyperacetylation of histones 
which is associated with actively transcribed regions. Therefore, they are crucial in 
facilitating access of the RNA polymerase II and the remaining members of the 
transcriptional machinery (Ali et al, 2002).  
The ER is also able to repress gene expression in response to antagonists. In the presence of 
such compounds (e.g. tamoxifen), the co-activator interaction surface is occluded and co-
repressors become associated with ER. Nuclear receptor co-repressor (NCOR) and 
silencing mediator of retinoid and thyroid receptor (SMRT) recruit histone deacetylases 
which repress gene transcription (Nilsson et al, 2001). 
 
The well characterized p160 co-activator family consists of three members: SRC-1 (p160-1, 
N-CoA1), TIF2 (SRC-2, GRIP1, N-CoA2) and AIB1 (SRC-3, P/CIP, ACTR, RAC3, 
TRAM1) (Nilsson et al, 2001) (Figure 1.4). All three members interact with a number of 
different nuclear receptors such as ER, the progesterone receptor (PR), and the thyroid 
receptor (TR). They bind to the receptors in a ligand dependent manner and increase the 
receptors ability to activate gene transcription (McKenna et al, 1999). Both SRC-1 and 
AIB1 contain histone acetyltransferases (HAT) activities and all three members of the SRC 
family directly or indirectly recruit a number of co-activators and other proteins that play an 
important role in chromatin remodelling, the assembly of the transcription machinery and 
transcription initiation (Xu et al, 2003) (Figure 1.4). The p160 co-activators are widely 
expressed in different tissues such as brain, liver and testis and share an overall 50% 
sequence similarity. All three co-activators contain three conserved LXXLL motifs 
responsible for mediating interaction with ER. They also contain two distinct activation 
domains involved in recruiting CBP/p300 co-activators, acetyltransferases and co-activator-
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associated arginine methyltransferase (CARM1). In vivo studies using knockout have shed 
some light on the individual contributions of each member of the p160 co-activator family. 
Mice lacking functional SRC-1 protein exhibited normal growth and fertility but oestrogen 
driven uterine growth appeared to be compromised. Furthermore, SRC-1 depletion reduced 
transcriptional activity of a number of steroid receptors (Xu et al, 1998). TIF2 knockout 
mice are also viable however they do display reproductive abnormalities (Mukherjee et al, 
2007). Unlike SRC-1¯/¯ and TIF2¯/¯, AIB1 knockout mice displayed growth retardation, 
reduced mammary gland alveolar formation and ovulation (Xu et al, 2000). On the other 
hand, double-knockout mice did not survive after birth suggesting functional redundancy of 
the p160 co-activators may be an important feature of this family (Nilsson et al, 2001; 
McKenna et al, 1999; Xu et al, 2003). Nevertheless, several studies have demonstrated 
these molecules retain a certain level of specificity. For instance, the progesterone receptor 
is preferentially regulated by SRC-1 whilst the glucocorticoid receptors mainly use TIF2 (Li 
et al, 2003).       
      
Members of the p160 co-activator family have also been implicated in breast cancer. The 
finding that AIB1 enhances oestrogen and progesterone receptor mediated transcription first 
pointed towards a potential role in breast carcinogenesis (Xu et al, 2003). AIB1 has since 
been found to be amplified and overexpressed in breast cancer (Anzick et al, 1997). 
Furthermore, AIB1 depletion inhibited epidermal growth factor receptor activation as well 
as reducing oestrogen driven proliferation (Torres-Arzayus et al, 2006). SRC-1 expression 
is also increased in breast cancer despite the minimal expression of this co-activator in 
human mammary cells (Qin et al, 2008). Additionally, SRC-1 expression is associated with 
HER2 positivity, disease recurrence, metastasis and resistance to endocrine therapies 
(Redmond et al, 2009; Wang et al, 2009; Fleming et al, 2004). The role of TIF2 in breast 
carcinogenesis is not as well defined. Recent studies suggest TIF2 RNAi significantly 
inhibited growth of the MCF-7 breast cancer cells, decreased cell cycle progression and 
promoted apoptosis suggesting this co-activator may be important in breast carcinogenesis 









1.2.3 ER Genomic & Non-Genomic Effects 
ERα is phosphorylated in response to oestrogen binding and specific signalling pathways. 
Phosphorylation of ERβ appears to be activated by the MAPK pathway but the effects of 
estradiol have not been fully determined (Nilsson et al, 2001). The AF1 domain at the N-
terminus is activated in the absence of ligand as first described by Lee et al (1989). It has 
been proposed that this domain is silenced due to the steric hindrance of the ligand binding 
domain which is reversed in the presence of oestrogen. Conversely, AF1 activation relieves 
AF2 repression. The two domains are thought to be able to activate transcription 
independently or act synergistically. However, whilst the AF1 domain plays a role in both 
ligand-dependent and independent ERα activation, AF2 is only able to stimulate 
transcription in response to ligand (Lannigan et al, 2003).  
 
The ligand dependent pathway requires direct interaction of oestrogen with the AF2 
domain. This activates the receptor leading to the phosphorylation of specific residues 
(Serine 106, 104 and 118) (Figure 1.5). These residues are highly conserved and once 
phosphorylated induce ERα mediated gene transcription (Lannigan et al, 2003). However, 
Joel et al (1995) have shown that Ser118 appears to be the major site of phosphorylation 
following ligand activation.  
 
ERα is also phosphorylated in the absence of ligand activation (Figure 1.5). This process is 
mediated via phosphorylation of residues in the AF1 domain by a number of signalling 
pathways such as MAPK and Akt (Figure 1.5). This mechanism bypasses the need for 
oestrogen therefore it has been suggested that it may play a part in endocrine resistance. 
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Proposed models suggest a number of ways in which ERα may confer resistance: increased 
ERα activation in the absence of oestrogen, hypersensitivity to low levels of circulating or 
















Figure 1.5 Phosphorylation of ERα. This oestrogen receptor may be phosphorylated in the 
presence of oestrogen or by protein kinases (Reproduced from Lannigan et al, 2003) 
 
 
Besides mediating gene transcription, oestrogen is also able to rapidly activate a number of 
signal transduction pathways (non-genomic pathway) (Figure 1.6). This is thought to be 
mediated by a small fraction of ERα or ERα transcriptional variants found near the plasma 
membrane (Arpino et al, 2008). Membrane ERα binds to membrane proteins of lipid rafts 
thus becoming attached to the inner face of the cellular plasma membrane (Razandi et al, 
2002). Studies suggest membrane ERα forms a complex including receptor tyrosine kinases 
(EGFR, HER2 and IGFR) and G-coupled proteins leading to activation of downstream 
signalling pathways (Razandi et al, 2004). Elevated MAPK and PI3K/Akt phosphorylation 
is able to activate ERα and recruit co-activators promoting gene transcription. The precise 













Figure 1.6 Oestrogen-regulated gene transcription. The oestrogen receptor is able to directly 
bind to DNA sequences and thereby activate gene transcription (genomic pathway). On the other 
hand, ERα is also able to activate protein kinases such as Akt and MEK/ERK which phosphorylate 
the receptor and induce transcription.     
 
 
1.2.4 Ligand Independent Activation: Role of Signalling Pathways 
(i) Epidermal Growth Factor (EGF) Receptor Family 
The epidermal growth factor family of transmembrane receptor tyrosine kinase is 
comprised of four members EGFR (HER1), HER2 (erbB2), HER3 (erbB3) and HER4 
(erbB4) (Figure 1.7). Ligand binding induces receptor dimerization followed by 
phosphorylation of tyrosine residues found at the SRC homology 2 (SH2) domain (Yarden 
et al, 2001). These phosphorylated residues trigger the recruitment of adaptor proteins and 
signal transducers thereby activating a number of signalling pathways regulating cellular 
processes such as proliferation, motility and apoptosis (Olayioye et al, 2000). A variety of 
ligands have been shown to activate EGF receptors. Despite this, the ligands have non-
overlapping functions (Figure 1.7). TGFα and EGF only bind to EGFR whilst neuregulin 
(heregulin) activates the HER3 and HER4 receptors (Jones et al, 1999). Inter-receptor 
interaction is crucial as HER3 has been shown to have no intrinsic kinase activity whereas 
HER2 has no identified ligand (Guy et al, 1994; Klapper et al, 1999). The specific 
signalling pathways activated and the “strength” of the signal is determined by the identity 
of the ligand and the receptors involved in the dimeric complexes. Adaptor proteins which 
associate with the phospho-tyrosine residues are also important in determining the 






























Figure 1.7 EGF receptor family and specific ligands. These comprise of a hydrophobic 
transmembrane domain, a tyrosine kinase domain found at the cytoplasmic side of the membrane 
and an extracellular ligand-binding domain. 
 
 
Epidermal growth factor receptors have often been implicated in cancer including breast 
cancer (Kurokawa et al, 2003). This pathway may become hyperactivated by a number of 
mechanisms such as receptor/ligand overexpression or constitutive activation. TGFα and 
heregulin are expressed in breast cancer tissues and have been linked to mammary 
carcinogenesis (Humphreys et al, 2000; Ram et al, 2000). Altered receptor expression has 
also been implicated in breast cancer. Overexpression of EGFR and its ligands are 
associated with reduced overall survival and anti-oestrogen resistance in breast cancer 
(Yarden et al, 2001). Mutations rendering EGFR constitutively active, due to the deletion of 
the extracellular domain, are also often reported in breast cancer (Moscatello et al, 1995).  
HER2 is probably the best studied member of the EGF receptor family. HER2 is 
overexpressed in 15-30% of invasive ductal carcinomas (Ellis et al, 2004). Elevated HER2 
expression has been linked to reduced survival and resistance to endocrine therapies and 
chemotherapy. Moreover, HER2 overexpression is also associated with tumour 
characteristics such as size, grade and spread to lymph nodes (Ross et al, 1998). Despite 
being devoid of intrinsic kinase activity, HER3 overexpression is found in 17-52% of breast 
carcinomas (Hamburger, 2008). This does not appear to be a result of gene amplification or 
mutation (Lemoine et al, 1992). High HER3 expression is positively associated with disease 


















the other EGF receptors, HER4 overexpression is associated with increased survival 
(Frogne et al, 2009). Lower HER4 expression is often observed in breast cancer and is 
indicative of a differentiated phenotype (Kew et al, 2000).  
            
(ii) MEK/ERK Pathway 
Epidermal growth factor receptors mediate cellular proliferation through a number of 
downstream signalling molecules such as the MEK/ERK pathway (Kurokawa et al, 2000). 
This pathway regulates several different mechanisms including survival, differentiation and 
motility (Roberts et al, 2007).  
Aberrant EGFR and HER2 receptor signalling has been shown to hyperactivate the 
MEK/ERK pathway (Kurokawa et al, 2003). Furthermore, elevated MEK/ERK activation is 
also demonstrated in long-term oestrogen deprived cell line models (Santen et al, 2005; 
Normanno et al, 2006). Studies have shown that activation of this signalling pathway is 
associated with oestrogen-unresponsive breast cancer cells (Shim et al, 2000) and with anti-
oestrogen resistance in MCF-7 cells (McClelland et al, 2001). MEK/ERK hyperactivity 
promotes co-activator association with ERα therefore inducing gene expression (Lavinsky 
et al, 1998). Moreover, activation of the MEK/ERK has also been shown to phosphorylate 
Ser118 in ERα (Kato et al, 1995). This induces ligand independent receptor activation thus 
potentially promoting resistance to anti-oestrogenic therapies.  
 
(iii) PI3K/Akt Pathway 
Activation of the phosphatidylinositol 3’-kinase (PI3K)/Akt pathway (Figure 1.8) is often 
implicated in human breast cancer (Perez-Tenorio et al, 2002). Akt signalling pathway 
regulates a number of cellular processes such as survival, proliferation and migration. 
Receptor-mediated activation of PI3K leads to the conversion of phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 then proceeds to 
recruit proteins to the plasma membrane (Figure 1.8) where they become activated 
(Shtilbans et al, 2008). Akt is one of these proteins. Activating mutations in the PI3K gene 
have been reported in breast carcinomas (Levine et al, 2005).  
PI3K-mediated Akt activation is further controlled by PTEN (phosphatase and tensin 
homologue) which removes the 3’ phosphate of PIP3 thus inhibiting phosphorylation of 
downstream signalling pathways (Dillon et al, 2007) (Figure 1.8). Loss of PTEN protein is 
observed in 30% of breast carcinomas suggesting this protein is important in carcinogenesis 
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(Garcia et al, 2004). Activating mutations and/or PTEN protein loss may be responsible for 
elevated Akt activation which is associated with tamoxifen resistance and reduced survival. 
 
The Akt protein kinases, also known as protein kinases B (PKBs), consists of 3 isoforms 
Akt 1 (PKB α), Akt 2 (PKB β) and Akt 3 (PKB γ). The Akt family is evolutionary 
conserved and the three isoforms share similar structural domains comprising the pleckstrin 
homology (PH) domain, a central kinase domain and a carboxyl-terminal regulatory domain 
(Scheid et al, 2003). Phosphorylation of threonine 308 (activation loop of the kinase 
domain) and the serine 473 (hydrophobic motif at the carboxyl domain) residues is required 
for the full activation of Akt (Hanada et al, 2004). 
Increased activity and dysregulation of Akt is a common feature in a number of cancers 
including breast cancers. Although many cancers exhibit a marked increase in constitutively 
activated Akt, mutations are relatively rare. Studies in human breast cancer patients have 
shown that Akt activation is often associated with triple negative (ER-, PR- and HER2-
negative) breast cancers (Umemura et al, 2007) and has been found to be a negative 
predictor of response to hormone therapy in metastatic cases (Tokunaga et al, 2006). 
Tamoxifen resistant MCF-7 cells express increased phosphorylated Akt levels suggesting 
this may contribute towards endocrine resistance (Jordan et al, 2004). This is further 
supported by immunohistochemical studies which report a link between Akt activation and 
reduced survival of breast cancer patients (Generali et al, 2008). Elevated Akt signalling is 
thought to mediate a variety of pathways leading to anti-oestrogen resistance. Shin et al 
(2002) have shown that Akt phosphorylation is associated with cyclin-dependent inhibitor 
p27 expression. Akt contributes towards cellular proliferation by phosphorylating p27, 
relieving its inhibitory effect of cyclin A (CDK2) thereby promoting cell cycle entry (Shin 
et al, 2002). Other studies have shown Akt is able to inhibit apoptosis by phosphorylating 
BAD (Franke et al, 1997) whilst it also appears to play a part in regulating cellular motility 
and invasion by influencing actin organization and enhancing matrix-metalloproteinase 2, a 
promoter of cellular invasion (Chin et al, 2009). Importantly, Akt is associated with 
epidermal mesenchymal transition (EMT) which promotes tumour progression to invasive 
and metastatic carcinomas (Grille et al, 2003).  
 
Although they share structural domains, Akt isoforms appear to mediate different cellular 
processes. Whereas Akt 1 is ubiquitously expressed in most tissues, Akt 2 is mainly 
expressed in insulin target tissues such as the liver (Ju et al, 2007; Hanada et al, 2004). Akt 
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3 is not as widely expressed as the other Akt isoforms and is mainly expressed in the brain 
and testis (Easton et al, 2005). Mouse model studies have shown isoform deletion result in 
viable animals however they do show reduced growth/weight and altered glucose regulation 
after Akt 1 and Akt 2 knockouts, respectively (Cho et al, 2001; Cho et al, 2001a). The fact 
that individual isoform deletions give rise to viable animals indicates that there may be 
some levels of redundancy and individual isoforms may compensate for the absence of any 
of the other members. Alternative kinases able to substitute for Akt function have also been 
identified and are thought to mediate the same pathways regulated by the Akt pathways 
(Brunet et al, 2001; Liu et al, 2001; Franke et al, 2003) 
 
All three Akt isoforms have been implicated in breast cancer despite regulating distinct 
cellular processes. Akt 1 induces the secretion of metalloproteinases thus promoting tumour 
invasion and metastasis (Larue et al, 2005; Thant et al, 2000) whilst Akt 2 appears to play 
an important role in the insulin pathway and is mainly expressed in insulin target tissues 
such as the liver (Hanada et al, 2004). Inactivating somatic Akt 1 mutations are present in 
8% of breast carcinomas (Carpten et al, 2007) and Akt 1 siRNA experiments have been 
shown to enhance breast cancer cell line migration and invasion (Irie et al, 2005). On the 
other hand, reports suggest that Akt 2 overexpression is linked to increased levels of β1-
integrin leading to higher invading ability of human breast cancer cells (Arboleda et al, 
2003). Activating Akt 2 kinase domain mutations and Akt 2 gene amplification have been 
identified in breast cancer (Bellacosa et al, 1995 & 2005) and Akt 2 downregulation is 
associated with increased apoptosis (MacKeigan et al, 2005). These results indicate Akt 1 
and Akt 2 may have specific, perhaps even opposing, non-redundant roles in breast cancer. 
The role of Akt 3 is not as clear, however there is evidence that this isoform may be 
involved in breast tumourigenesis (Dillon et al, 2007). Akt 3 expression is often 
upregulated in more advanced, ER-negative breast carcinomas (Zinda et al, 2001; Nakatani 
et al, 1999). Nevertheless, constitutive activation of Akt 3 in MCF-7 cells results in 
oestrogen independent tumour growth (Faridi et al, 2003) suggesting this isoform may be 





















Figure 1.8 PI3K/Akt Pathway. PIP3 is generated by PI3K and it leads to the phosphorylation of 
Akt which in turn activates mTOR and ERα. The PI3K/Akt pathway regulates a number of 
cellular processes such as growth, survival and motility (Reproduced from Hynes et al, 2006) 
 
 
Downstream components are also important in the PI3K/Akt pathway. The mammalian 
target of rapamycin (mTOR) is activated by Akt (Figure 1.8) and is associated with 
tamoxifen resistance in breast cancer (Hidalgo et al, 2000). mTOR is a serine/threonine 
kinase that regulates the function of p70S6 kinase and 4E-BP1 (Figure 1.8) which are 
involved in the control of transcriptional activation. Furthermore, Akt is also able to 
phosphorylate ERα in the absence of oestrogenic stimuli (Lannigan et al, 2003). Therefore, 
increased Akt activation is able to promote ligand-independent ERα phosphorylation and 
ERα-driven gene transcription.  
 
(iv) IGFR Signalling 
The insulin-like growth factor (IGF) system has also been linked to growth and survival of 
breast cancer cells (Jerome et al, 2003). Activation of this receptor stimulates cellular 
proliferation and survival. The IGF I receptor (IGFR) possesses ligand-activated tyrosine 
kinase activity hence ligand binding induces conformational changes in the intracellular 
domain followed by auto-phosphorylation (Sepp-Lorenzino et al, 1998). This then triggers 




for numerous SH2 domain containing proteins (Zhang et al, 2000). PI3K is amongst the 
proteins binding to IRS-1 and thus becoming activated. This suggests that the downstream 
Akt protein is also regulated by IGF signalling (Jerome et al, 2003). There are two ligands 
in the IGF signalling system, IGFI and IGFII, the former of which acts as a mitogen in 
breast cancer cells including MCF-7 cells (Ullrich et al, 1986). IGF signalling is quite 
complex particularly since IGFR and the insulin receptor are able to dimerize giving rise to 
a number of hybrid receptors (Leroith et al, 2003). Prospective studies have observed a 
correlation between circulating IGF I levels and the risk of developing breast cancer but 
only in pre-menopausal women (Hankinson et al, 1998) 
 
1.3 Current Therapies in Breast Cancer 
1.3.1 Surgery  
For the last decade, surgery has been at the forefront of breast cancer treatment. The 
procedures, however, have evolved due to technological advances and new therapeutic 
approaches. The adequate type of surgery is based on the stage and type of the breast cancer 
and its aggressiveness (Dixon et al, 2002). Breast-conserving surgery (or lumpectomy) 
involves the removal of the tumour and some of the surrounding tissue. Larger tumours, on 
the other hand, require the removal of all breast tissue (mastectomy) (Dixon et al, 2002). 
Patients are often treated with hormone therapies and/or chemotherapy after surgery 
(adjuvant) if there is evidence the cancer may have spread thereby reducing the changes of 
recurrence. Furthermore, some patients also receive such therapies before any surgical 
procedure (neo-adjuvant) (Houssami et al, 2006). This approach can allow either surgery in 
otherwise inoperable tumours or breast-conserving surgery instead of a mastectomy.         
 
1.3.2 Chemotherapy & Radiotherapy 
Radiotherapy is an important component of breast cancer treatment that relies on the use of 
radiation to damage cancer cells. All cells are susceptible to radiation however cells 
dividing at a fast rate, such as cancer cells, are more sensitive to it. Radiotherapy is 
routinely used following surgery allowing patients to retain their breast whilst also reducing 
the chances of recurrence (Early Breast Cancer Trialists’ Collaborative Group, 2005). 
Radiation is routinely applied externally but a less common method of internal radiation 
(brachytherapy) is also used with radioactive “seeds” which are temporarily placed at the 
tumour site (Patt et al, 2005).  
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Similarly to radiotherapy, chemotherapeutic drugs target rapidly diving cells but unlike 
radiation, chemotherapy is a systemic drug treatment. These drugs may be used in an 
adjuvant and neoadjuvant setting as they reduce tumour size prior to surgery and minimise 
the risk of recurrence. Chemotherapy is also used in recurrent breast cancer. There are 
different classes of drugs available targeting distinct cellular processes. Alkylators, such as 
cyclophosphamide, reduce cell growth; antimetabolites (e.g. 5’ fluorouracil) interfere with 
DNA production; antimitotic and antimicrotubule agents hinder the cells ability to undergo 
mitosis and affect cellular structure, respectively. Finally, there are also antibiotic drugs, 
such as doxorubicin and mitomycin C, that inhibit gene replication. These agents are often 
used in combination depending on the patient’s needs.  
 
1.3.3 Selective Oestrogen Receptor Modulators 
Once the role of oestrogen in breast carcinogenesis was established new therapies started 
being developed to target ER which mediates oestrogen function. The most widely used 
SERM is Tamoxifen which was first used in the 1970s and remains a crucial part of 
endocrine treatment for breast cancer patients (Figure 1.9). Tamoxifen acts as an antagonist 
as it competes with oestrogen for binding to the AF-2 domain of the receptor. This 
mechanism is further mediated by the ability of tamoxifen to repress co-activator binding 
(Shiau et al, 1998) and recruit co-repressors to the complex (Lavinsky et al, 1998). 
Oestrogen receptor activity in the breast epithelial is mainly mediated by the AF2 region 
hence tamoxifen acts as an antagonist. However, in other tissues where the AF1 activity is 
more significant, tamoxifen becomes an agonist (Metzger et al, 1995) (Figure 1.9).  
         
The roles of tamoxifen have increased throughout the years as a number of studies have 
shown it may play a role in prevention and be useful in a neo-adjuvant setting. It is 
routinely used in both pre and post menopausal women whose tumours are ER-positive. 
The effects of tamoxifen on ER-negative tumours appear to be limited. Tamoxifen has been 
shown to be particularly effective in preventing tumour recurrence as described by the Early 
Breast Cancer Trialists’ Collaborative Group. This study conclusively showed that annual 
recurrence decreased by 47% following 5 year treatment with tamoxifen. In addition, they 
also observed an overall reduction in mortality (26%) (Early Breast Cancer Trialists’ 
Collaborative Group, 1998). Metastatic breast cancers may also be treated with tamoxifen 
as 20% of women experience a 6 month reduction in disease progression (Osborne et al, 
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1998). Tamoxifen is also useful in a preventive setting. Studies such as the National 
Surgical Adjuvant Breast and Bowel Project revealed that tamoxifen reduced the risk of 
invasive and non-invasive cancer by 50%. They also observed a 69% overall decrease in the 
occurrence of ER-positive tumours but it did not affect the occurrence of ER-negative 
tumours (Fisher et al, 1998).  
 
Some adverse effects have been reported following tamoxifen treatment such as an 
increased incidence of endometrial cancer and benign uterine disease (Nordenskjöld et al, 
2005). Further studies have also observed an increase risk of stroke, deep-vein thrombosis 
and pulmonary embolism in tamoxifen treated patients (Fisher et al, 1998). On the other 
hand, the Scottish Cancer Trials Breast Group has shown that tamoxifen reduced the risk of 
myocardial infarction (McDonald et al, 1995). This was further confirmed by more recent 
studies which observed a 30% reduction in the risk of coronary disease after 5 year 
treatment with tamoxifen in comparison to 2 year treatment (Nordenskjöld et al, 2005). 
 
Despite the success of tamoxifen its agonistic effects and the development of resistance are 
areas of concern. As a result, second and third generation SERMs have been developed. 
Raloxifene was first approved for the treatment of osteoporosis but is also an oestrogen 
antagonist (Figure 1.9). Unlike tamoxifen, the anti-oestrogenic effects of raloxifene are 
observed in breast epithelial and in the endometrium hence there is no reported increase in 
the risk of endometrial cancer (Gasco et al, 2005; Ariazi et al, 2006). These results suggest 
that raloxifene may be a safer alternative to tamoxifen in the prevention setting. The MORE 
trial showed that raloxifene reduced the risk of in situ and invasive breast cancer by 60% in 
comparison to a placebo control (Dickler et al, 2001). Raloxifene was also found to be as 
effective as tamoxifen according to the STAR trial which compared the two drugs in 20,000 
women (Howell, 2008). Toremifene is another SERM routinely used in treating breast 





















Figure 1.9 Chemical structures of oestradiol and SERMs tamoxifen, raloxifene and fulvestrant 
(Reproduced from Howell, 2006). 
 
Unlike the above SERMs, faslodex (fulvestrant; ICI 180,780) is considered a pure anti-
oestrogen (Figure 1.9) as it prevents the activation of both AF1 and AF2 domains therefore 
acting as a true antagonist (Ali et al, 2002). Faslodex has also been shown to inhibit 
receptor dimerisation, reduces ER shuttling to the nucleus and increases protein turnover 
(Osborne et al, 1995; Dauvois et al, 1993; Dauvois et al, 1992). Like other SERMs, 
faslodex competitively binds to the oestrogen receptor but its affinity is much stronger than 
that of tamoxifen (Wakeling et al, 1991). Faslodex is recommended for the treatment of 
ER-positive metastatic breast cancer, particularly in patients that have developed anti-
oestrogen resistance (Buzdar et al, 2001). Two randomised trials have shown that faslodex 
is as effective as the aromatase inhibitor anastrozole in reducing tumour progression and in 
promoting overall survival. In addition, tamoxifen-resistant patients responded to faslodex 
treatment suggesting a lack of cross-resistance (Howell et al, 2002; Osborne et al, 2002). 
Since faslodex does not promote agonistic effects it has not been associated with an 
increase in endometrial cancer (Addo et al, 2002). These results suggest faslodex may be a 
good alternative to other anti-oestrogenic therapies.  
Despite the positive results, resistance to faslodex has been reported in cell line models 
(Shaw et al, 2006). Increased HER signalling has been implicated in this process and it 
appears that direct ER modulation may not be important (McClelland et al, 2001). These 
results suggest that resistance to faslodex in a clinical setting is more than likely.  
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1.3.4 Aromatase Inhibitors 
Aromatase inhibitors are an alternative to tamoxifen in treating post-menopausal ER-
positive breast cancers and as preventive approach. Such drugs reduce oestrogen levels by 
inhibiting or inactivating aromatase, a member of the cytochrome P-450 enzyme 
superfamily responsible for synthesising oestrogen from androgenic substrates (Smith et al, 
2003). The first aromatase inhibitors were proven to not be specific or powerful enough. 
The three currently available aromatase inhibitors (Figure 1.10) (anastrozole, letrozole and 
exemestane) are third-generation aromatase inhibitors (Macedo et al, 2009). There are two 
types of aromatase inhibitors, type I inhibitors are regarded as enzyme inactivators since 
they irreversibly bind to the aromatase molecule therefore blocking androstenedione from 
binding. Exemestane falls into this category. Type II inhibitors (anastrozole and letrozole), 
on the other hand, reversibly bind to aromatase (Smith et al, 2003) (Figure 1.10). 
Clinical trials testing anastrozole against tamoxifen have found that treatment with the 
aromatase inhibitor was associated with a decrease in tumour progression as well as a 
reduction in certain side effects such as thromboembolic events and vaginal bleeding 
(Nabholtz et al, 2000). The ATAC trial also reported a significant increase in disease-free 
survival in patients treated with anastrozole in comparison to tamoxifen alone whilst other 
trials have suggested that anastrozole may be effective in a neo-adjuvant setting (Smith et 
al, 2005).  
A study conducted by the International Letrozole Breast Group has shown that similarly to 
anastrozole, letrozole treated patients had higher survival rates than those treated with 
tamoxifen alone (Mouridsen et al, 2001). Studies on exemestane, on the other hand, suggest 









Figure 1.10 Chemical structures of aromatase inhibitors (Adapted and reproduced from Smith 





1.3.5 Monoclonal Antibodies 
Members of the epidermal growth factor receptor (EGF) family such as EGFR and HER2 
have been implicated in breast cancer development and have therefore become therapeutic 
targets. Monoclonal antibodies generated to specifically bind to these receptors have been 




The HER2 gene is amplified or overexpressed in approximately 30% of all breast 
carcinomas and in some other types of cancers (Yu et al, 2000). This gene encodes the 185 
kDa transmembrane tyrosine kinase receptor HER2, a member of the EGF family. Ligand 
binding leads to dimerization and consequent activation of such receptors which in turn 
activate a wide network of signalling pathways (Hudis, 2007). HER2 overexpression 
significantly correlates with reduced survival in breast cancer patients whilst it also appears 
to be a predictive marker for response to breast cancer treatments (Bange et al, 2001). 
Several studies have reported that HER2 overexpression was associated with lack of 
response to endocrine treatments (Sjogren et al, 1998; Borg et al, 1994) as well as 
chemotherapeutic approaches (Jarvinen et al, 1998; Gusterson et al, 1992).  
Herceptin (trastuzumab) was the first licensed monoclonal antibody used for targeted 
therapies. It comprises of a human IgG antibody with two antigen-specific sites that 
recognise and competitively bind to the extracellular domain of the HER2 receptor (Hudis 
et al, 2007). The exact mechanisms of herceptin function has not been fully determined but 
it has been proposed that this antibody may potentially interfere with receptor dimerization, 
induce an immune response leading to cell death or downregulate receptor levels due to 
increased endocytosis. Further studies have also suggested herceptin inhibits the MAPK and 
PI3K/Akt pathways (Jackson et al, 2004; Mohsin et al, 2005).  
Herceptin was first approved in 1998 and has proven to be effective in treating HER2-
positive metastatic breast cancer either alone (Vogel et al, 2002; Baselga et al, 2005) or in 
combination with chemotherapeutic agents (Slamon et al, 2001; Marty et al, 2005). The 
National Surgical Adjuvant Breast and Bowel Project and the North Central Cancer 
Treatment group trials compared adjuvant chemotherapy with or without concurrent 
herceptin following surgical removal of HER2-positive breast cancer. These studies 
reported a reduction in the risk of death (33%) and improved outcome in patients treated 
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with herceptin in combination with paclitaxel after chemotherapy (Romond et al, 2005). 
Treatment with adjuvant herceptin alone after adjuvant chemotherapy has also been linked 
to an increase in disease-free survival after a year of treatment (Piccart-Gebhart et al, 2005). 
Despite remaining HER2-positive, some tumours do not respond to herceptin treatment 
hence new combination treatments were explored. Herceptin in combination with tamoxifen 
reduced growth in BT 474 cell line by 44% (higher than each individual treatment) (Ropero 
et al, 2004). Furthermore, this combination appears to inhibit HER2 activity and induce G0-
G1 cell cycle accumulation (Wang et al, 2005).  
 
2C4 (Pertuzumab) is another available monoclonal antibody targeting the HER2 receptor. 
This antibody sterically blocks HER2 homo- and heterodimerization with EGFR and HER3 
thereby inhibiting the activation of downstream signalling pathways leading to cellular 
growth and survival. Similar to herceptin, 2C4 binds to the extracellular domain of HER2 
but it has been shown that the two antibodies bind to distinct epitopes (Takai et al, 2005). 
Xenograft studies revealed that 2C4 was able reduce tumour growth as efficiently as 
herceptin but unlike herceptin this is not dependent on HER2 expression levels since both 
low and high-HER2 expressing tumours are equally responsive (Agus et al, 2002). Clinical 
studies indicate a variety of tumours may respond to 2C4 treatment and that treatment with 
this antibody is well tolerated (Agus et al, 2005). A number of clinical trials are currently 
underway in a variety of cancers including ovarian, lung and prostate.  
 
1.3.6 EGF receptor & Tyrosine Kinase Inhibitors 
The EGF receptor (EGFR) has been shown to contribute to pathogenesis and tumour 
progression in breast cancer. EGFR expression is found in 50 to 70% of breast, lung and 
colon carcinomas. It has been proposed that EGFR expression is a modest prognostic 
indicator in breast cancer whilst others have shown an inverse correlation between the 
receptor expression and hormone receptor status (Klijn et al, 1992).  
In order to target this membrane receptor, small molecule tyrosine kinase inhibitors were 
developed. These compounds competitively bind the ATP-binding site of the EGFR thereby 
blocking ATP access (Nahta et al, 2004). Furthermore, these agents bind to the intracellular 
domain of the receptor suggesting they may be effective in inhibiting a truncated form of 
EGFR (EGFR vIII). This receptor is inaccessible to monoclonal antibodies as it lacks its 
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extracellular domain. The truncated EGFR is often found in breast cancer and is associated 
with highly aggressive tumours (Nahta et al, 2004).  
 
Gefitinib (Iressa, ZD1839) is a tyrosine kinase inhibitor targeting EGFR. The anti-tumour 
activity of this highly specific compound is not dependent on the expression levels of the 
receptor (Moasser et al, 2001). It has been proposed that response to anti-EGFR agents may 
be dependent on the total levels of HER receptors and ligands present in tumours which is 
further corroborated by the link between response to EGFR inhibitors and HER2/3 
expression (Normanno et al, 2005). Furthermore, some groups have recently found that 
herceptin in combination with gefitinib produces a synergistic anti-tumour effect in breast 
cancer (Normanno et al, 2002). Gefitinib has been shown to interfere with a variety of 
cellular processes. This inhibitor leads to cell cycle arrest (G1), reduced proliferation, 
elevated apoptosis and it also appears to have anti-angiogenic effect (Ciardiello et al, 2002; 
Hirata et al, 2002; Chan et al, 2002). Additionally, gefitinib appears to increase growth 
inhibition when in combination with chemotherapeutic agents and the response to endocrine 
therapies (Moulder et al, 2001).  
   
Tarceva (Erlotinib, OSI-774) is another EGFR tyrosine kinase inhibitor. Similarly to 
gefitinib, tarceva inhibits tumour progression, promotes cell cycle arrest and apoptosis 
(Arteaga, 2001; Slichenmyer et al, 2001; Elsayed et al, 2001). This EGFR inhibitor is well 
tolerated and induces responses in a variety of cancer including non-small-cell lung cancer, 
ovarian and breast cancer (Nahta et al, 2004). Ongoing clinical trials are investigating the 
combination of tarceva with HER2-targetting therapies such as herceptin and 2C4 (Mass, 
2004). A study from Friess et al (2005) reported additive anti-tumour effects of combining 
tarceva with 2C4 in breast cancer.  
 
Clinical response to EGFR tyrosine kinase inhibitors in metastatic breast cancer has been 
very limited. This is particularly obvious in patients who have been exposed to a number of 
treatments such as chemotherapy and endocrine therapies (Nahta et al, 2004). These 
observations suggest there is an intrinsic resistance mechanism in breast cancer tumours. 
Gefitinib has proven to be a success in treating non-small-cell lung cancer and its efficiency 
appears to be linked to the presence of specific EGFR mutations (Normanno et al, 2005). 
Such mutations have not been reported in cell lines or primary breast carcinomas. 
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Additionally, the activation of downstream signalling pathways such as the PI3K/Akt has 
been observed in the resistance to gefitinib (Ferrer-Soler et al, 2007). 





































This project was designed to determine the role of intracellular signalling pathways in 
conferring resistance to endocrine therapies in breast cancer. In order to achieve this, a three 
step MCF-7 cell-based model was used.  Each cell line differs in their oestrogen-sensitivity 
and response to anti-oestrogen therapies. Over the years a number of membrane receptors 
and downstream signalling cascades have been implicated in breast cancer.  
 
It is likely that endocrine resistance results from deregulation of more than a single 
pathway, particularly when protein interactions and pathway crosstalk are so widely spread. 
Therefore, this study was divided into two components: 
 
(i) Firstly, the role of epidermal growth factor family was assessed in this cell line model. 
HER2 transcriptional regulation has been shown to be downregulated following E2 
stimulation in oestrogen-responsive breast cancer cell lines (Newman et al, 2000). It has 
been proposed that this process is mediated by members of the p160 family of co activators, 
particularly SRC-1. These co activators are responsible for mediating ERα induced 
transcription but Newman et al (2000) suggest that these co activators are also able to 
directly mediate transcription of certain genes, including HER2. Given this evidence, the 
role of oestrogen-mediated HER2 regulation was established in the MCF-7 variant cells. 
Furthermore, the effects of oestrogen on the transcription of the other members of the EGF 
receptor family (EGFR, HER3 & HER4) were also determined.  Altered receptor tyrosine 
kinase transcriptional regulation is likely to contribute towards endocrine resistance.  
 
(ii) The second part of the project focussed on the downstream signalling pathways, 
particularly the PI3K/Akt pathway. Previous studies have shown that increased Akt 
activation is often observed in breast cancer and is associated with endocrine resistance 
(Tokunaga et al, 2006). The upstream regulators of Akt activation were also investigated as 
well as the downstream pathways activated by the Akt kinase. This is of particular interest 
considering the ability of signalling pathways to activate ERα in the absence of oestrogen 
(ligand-independent activation) which has been implicated in the advent of endocrine 





















Figure 1.12 Signalling pathways and ERα activation. This diagram depicts the main areas this 
study will be focussing on and how these aspects interact.  
 
 
The pathways investigated here regulate a number of cellular processes such as cell cycle 
entry, migration, invasion and apoptosis. Consequently, these were also studied in order to 
determine whether these cellular activities are altered in endocrine resistant cell line 
models.  
Primary tumour material was examined in order to test the major findings obtained in the 
cell line models. This will help evaluate the validity of the in vitro studies in comparison to 
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2.1 Materials  
All chemicals were obtained from Sigma Aldrich unless otherwise stated. Materials are 
listed according to technique. 
 
2.1.1 Cell Culture 
(i) Origin of Cell Lines 
In order to study and determine which factors are involved in the development of acquired 
resistance to anti-oestrogens a range of different breast cancer cell lines were used which 
were developed and characterized by Professor Robert Clarke’s group (Georgetown 
University, Washington DC).  
 
MCF-7 cells are the most commonly used oestrogen positive breast cancer cell line model. 
This cell line was first established in 1973, derived from a pleural effusion of a post-
menopausal patient with metastatic mammary carcinoma (Soule et al, 1973). This cell line 
is representative of the early stages of the disease and is the ultimate model of oestrogen-
dependent and anti-oestrogen sensitive breast cancer.  
Oestrogen-independent and tamoxifen resistant cells were derived from the MCF-7 cell line 
and provide an adequate model mimicking disease progression and endocrine resistance 
often observed in breast cancer patients (Clarke et al, 1994; Han et al, 2004). MCF-7 cells 
were inoculated into ovariectomized mice in order to select for oestrogen independent 
growth in vivo (Clarke et al, 1989) (Figure 2.1). The MCF7/LCC1 (LCC1) cell line was 
isolated from tumours growing in these mice and these cells acquired a hormone 
independent phenotype. However, this cell line still responds mitogenically to oestrogen 
stimulation (Clarke et al, 1989). LCC1 cells remain anti-oestrogen sensitive and their 
growth is fully blocked by treatment with such therapies (Brunner et al, 1993). 
The ICI 182,780 resistant MCF-7/LCC9 (LCC9) cell line was developed following in vitro 
stepwise selection of LCC1 cells (Figure 2.1). These cells were treated with increasingly 
higher concentrations of ICI 182,780 ranging from 10pM to 1μM (Brunner et al, 1997). 
LCC9 cells are also resistant to other anti-oestrogens such as tamoxifen and are completely 
oestrogen independent.   
 
Furthermore, ER negative MDA-MB 231 cells were also used in these studies (Calvo et 
al, 1983). This cell line provides a useful negative control for some of the experiments 
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performed and helps determine the role of the oestrogen receptor in the resistant cell line 
models used.  
 
 
Figure 2.1 Derivation of MCF-7 variant breast cancer cell lines (Reproduced from Brunner et 
al, 1997) 
 
(ii) Cell Lines 
The original MCF-7 cell line was obtained from the European Tissue Culture Collection 
(Porton Down, UK). MCF-7 derived MCF-7/LCC1 and MCF-7/LCC9 cell lines were 
kindly donated by Professor Robert Clarke (V.T. Lombardi Cancer Research Centre, 
Georgetown University Medical School, Washington, D.C.). The MDA-MB231 cell line 




- Freezing Mix: 10% DMSO in foetal calf serum.  
- SRB Dye: 0.4% SRB in 1% Acetic Acid. 
- Lysis Buffer: 50mM Tris (pH7.5), 5mM EDTA (pH 8.5), 150mM NaCl, 1%  Triton 
X-100, Aprotinin 10μg/ml & 1x protease inhibitor cocktail (Roche). 
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- 5x Loading Buffer: 125mg Tris Base, 1.25g SDS, 6.25ml β-mercaptoethanol, 12.5 
ml glycerol, 417μl bromophenol blue solution made up to total volume of 25ml with 
dH2O. 
- Tris Buffered Solution: 6.05g Tris base, 8.76 NaCl, made up to 1L with dH2O 
adjusted to pH 7.5. 
- Vindelovs Solutions 
   Stock Solution: 200mg Trisodium Citrate, 121mg Tris, 1044mg Spermine 
Tetrahydrochloride and 2ml Nonidet NP40 in 2L dH2O; pH adjusted to 7.6. 
   Solution A: 15mg Trypsin in 500ml Stock Solution 
   Solution B: 250mg Trypsin Inhibitor and 50mg of RNase A in 500ml of stock 
solution. 
   Solution C: 208mg propidium iodide and 500mg Spermine Tetrahydrochloride in 
500ml of stock solution.  
 - Citrate Buffer: 0.1M Citric Acid & 0.7M Sodium Citrate 
 
2.3 Methods 
2.3.1 Cell Culture 
(i) Routine Cell Culture  
The MCF-7 cell line was grown as a monolayer in DMEM (+ phenol red) supplemented 
with 1% Penicillin/Streptomycin and 10% heat inactivated foetal calf serum (inactivated 
by incubating  at 56ºC for 20 min). MCF-7 cells are grown in the presence of phenol red 
due to its oestrogenic effects. MCF-7 variant cells were routinely cultured in DMEM (-
phenol red) supplemented with 1% Penicillin/Streptomycin, 2mM Glutamine and 5% 
double charcoal stripped serum (DCSS). All cell lines were maintained in a humidified 
atmosphere at 37ºC and 5% CO2. 
 
(ii) Cell Harvesting  
In order to harvest cells, all cell lines were washed twice in phosphate buffered saline 
(PBS) pH 7.3. Cells were then detached by incubating with 3-5 ml of Trypsin/EDTA (1x) 
for 5 min at 37ºC. Trypsin was inactivated by adding growth medium and the cell 
suspension was centrifuged at 1,600 rpm for 5 min. The cell pellet was then resuspended in 
normal growth medium.  
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(iii) Cryopreservation & Liquid Nitrogen Cell Recovery 
Cells removed from liquid nitrogen were rapidly defrosted and spun down to obtain a cell 
pellet which was then resuspended in fresh media. Cells were transferred to a 25 cm² flasks 
and incubated. Cells to be stored in liquid nitrogen were prepared as mentioned above and 
cell pellets were resuspended in 1-2 ml of freezing mix. Cell suspension were transferred 
to a cryovial and frozen immediately at -70ºC then transferred to liquid nitrogen after 48h. 
 
(iv) Cell Counting  
In order to determine the appropriate cell concentration for experimental set up cells were 
harvested as described above, resuspended in 10 ml of growth medium and counted in a 
haemocytometer. Cells were then diluted to achieve the correct cell number for each 
experiment.  
 
(v) Dextran Charcoal Stripping of Foetal Calf Serum 
Functional experiments require a less rich medium, free of endogenous stimuli so the 
effects of growth factors on signalling pathways can be clearly determined. Endogenous 
steroids were removed from media by double charcoal stripped FCS. After thawing at 
room temperature, 1L of serum was heat inactivated for 30min at 56ºC. Serum was then 
incubated with 2000U of type IV sulphatase for 2h at 37ºC and the pH adjusted to 4.2 
using 2M HCl. A previously prepared charcoal mix was added to the mix and agitated 
overnight at 4ºC. The charcoal mix consisted of 5g charcoal and 25mg dextran T70  in 
50ml dH2O which had been stirred overnight. The charcoal was removed via 30min 
centrifugation at 10,000 rpm (4ºC). The pH was readjusted to 4.2 and a second charcoal 
mix added to the serum for a further 24h incubation at 4ºC. Serum was centrifuged as 
previously described with the inclusion of a second spin to remove residual traces of 
charcoal. The pH was returned to 7.2 with the addition of 2M NaOH. The serum was 
filtered sterilised and aliquoted for storage at -20ºC. 
 
(vi) Clonal Selection 
MCF-7 clones were derived from the original MCF-7 cell line. A cell suspension was 
diluted and plated onto four 96 well plates. The aim was to have one cell per well so the 
population would be derived from a single cell. The number of cells in each well was 
determined by microscopy and wells with more than one cell were discarded. The progress 
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of the one cell containing wells was monitored and when confluence was reached cells 
were trypsinised and transferred into a 24 well plate. Cells were transferred into 
progressively larger cell culture plates, dishes and flasks until there was an adequate cell 
number. Three clones were obtained referred to as Clones 1, 2 and 3.  
  
2.3.2 Functional Assays 
(i) Morphology Studies 
Cell lines were seeded in 6-well tissue culture plates at 2-5x104 cells per well in 5ml of 
growth media. Following 24h incubation, cells were washed twice with PBS and media 
was replaced with DMEM (- phenol red) containing 5% DCSS for a further 24h. The 
assays are performed in the presence of double charcoal stripped media as it provides a 
controlled environment so the responses to each individual growth factor are easily 
observed. Cells were treated with E2 (1nM) for 48h in quadruplicate wells. Morphology 
changes were noted by microscopy analysis. Images were taken using a Kodak MDS120 
camera.  
 
(ii) Growth Assays 
In order to study growth properties of these cells lines the sulforhodamine-B (SRB) 
colorimetric assay was used. SRB assay as described by Skehan et al, 1990 is used for cell 
density determination based on the measurement of protein content. Cells were seeded into 
96-well tissue culture plates. Cells were treated with E2 (1nM), TGFα (1nM) and a 
combination of endocrine drugs and inhibitors (Table 2.1). Cell lines were seeded 48h 
before treatment in phenol-red free DMEM containing 5% DCSS. Plates were treated for 
0, 3 and 5 days for each cell line. Treatment was halted by the addition of 50μl of 25% 
trichloroacetic acid (TCA) to each well for 1h at 4ºC. Plates were then washed 5 times with 
tap water and allowed to dry. Once plates were dry, 50μl of SRB dye solution was added 
for 30min at room temperature before washing with 1% glacial acetic acid (4x). Plates 
were again allowed to dry before resuspending in 150μl of 10mM Tris buffer (pH 10.5) 
and incubated for 1h at room temperature. Optical densities (OD) for each plate were 
determined at 540nm using a Biohit BP800 plate reader.  
 
The appropriate cell densities were determined in advance to experimental set up. The 
MCF-7 cell line was grown in DMEM (+ phenol red) containing 10% FCS. LCC1 and 
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LCC9 cells were grown in phenol red free DMEM (+ 5% DCSS). The optimal cell density 
for each cell line was determined taking into account the fact that growth factor treatment 
would increase cell number (Figure 2.2, 2.3 & 2.4). The relationship between optical 
density and cell number is considered linear if OD<3 as at higher OD values there is a risk 
that saturation may be playing a part. Following the results from the seeding density 
experiments, MCF-7 and LCC1 cell lines were plated at 2500 cells per well whilst LCC9 

































Drugs & Inhibitors Target Concentration 
Tamoxifen ERα 1μM 
ICI 182,780 ERα 100nM 
Herceptin/Trastuzumab HER2 100nM 
2C4/Pertuzumab HER2 100nM 
I-OMe AG538 IGFR 5-10 μM 
Figure 2.2 Optimum seeding density for SRB assays of MCF-7 cell line. OD values were taken 
at Day 0, 3 & 5. Each column presents the mean of 6 values. Error bars=SD. 
Figure 2.3 Optimum seeding density for SRB assays of LCC1 cell line. OD values were taken 






























2.4 Protein Detection 
2.4.1 Protein Extraction & Immunoprecipitation 
Cells were harvested as previously described and were seeded into 15 cm (diameter) plates 
at a density of 1x106  cells per plate for all cell lines. MCF-7 cells were plated in DMEM 
(+phenol red) containing 10% FCS for 24h at which point the media was replaced with 5% 
DCSS DMEM (phenol-red free) and grown for a further 48h. Variants cell lines were 
plated straight into 5% DCSS DMEM and also incubated for 48h. Cells were then treated 
according to the experiment requirements always in the presence of reduced charcoal 
stripped media. When cells were ready for protein extraction, plates were washed twice in 
ice-cold PBS and lysed in ice-cold lysis buffer for 10min in ice. Cells were scraped from 
culture dishes into eppendorf tubes and debris was cleared by centrifugation at 13,000 rpm 
for 6min at 4ºC. The amount of protein present in the supernatant was determined using the 
Bicinchoninic acid assay (BCA) according to manufacturers’ guidelines. Samples were 
prepared into 100μg aliquots and stored at -70 ºC. 
 
Immunoprecipitation detects protein-protein interactions. Briefly, cell lysates are incubated 
with specific antibodies to the protein of interest. A mix of agarose beads is then added to 
the solution which binds to the Fc region of the antibody. The proteins bound to the 
agarose beads are analysed by western blotting. For immunoprecipitation experiments, 
cells were lysed as described above and a volume of lysate containing 100μg of protein 
was agitated overnight at 4ºC with 1-10μl of relevant antibody. Following overnight 
Figure 2.4 Optimum seeding density for SRB assays of LCC9 cell line. OD values were 
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incubation, protein-G-agarose beads were washed in lysis buffer and 50μl of the bead 
slurry was added to the lysate/antibody mix. The samples were then incubated for 3 h as 
before. Beads were washed three times in ice cold lysis buffer. The lysate/antibody/bead 
slurry mixture was centrifuged for 2min at 2,000 rpm (4ºC) at the end of the three hour 
incubation and the supernatant was collected using a syringe. 500μl of lysis buffer (minus 
protease inhibitors) were then added to the solution followed by another spin at 2,000 for 2 
min. The supernatant was collected again and the wash was repeated twice more as 
described. 20μl of 1x loading buffer was added to the bead solution and sample was heated 
at 95ºC for 5min. Samples were then centrifuged at 13,000 rpm for 1 min and supernatant 
was removed for loading onto a polyacrylamide gel for Western Blot analysis.  
 
2.4.2 Western Blotting 
Cell lysates were prepared and quantified as described. Western blotting is routinely used 
to detect protein levels. Briefly, proteins are separated on a polyacrylamide gel. Antibodies 
are used to detect proteins of interest and the results are visualised using 
chemiluminescence. Aliquots of equal concentration were set up for each protein sample 
set and their volumes were equalised using lysis buffer. Samples were denatured at 95ºC 
for 5min in loading buffer and 25-100 μg of protein were used depending on the protein of 
interest and antibody efficiency. Samples were loaded onto a 7.5-12% polyacrylamide gel 
(determined by band size or separation required for proteins of interest) which were ran at 
80V for 15min and then 200V for 1h. Proteins were then transferred to a permeablised   
Immobilon-P membrane via a wet transfer method at 30V for 2-3 h. Membranes were then 
blocked for 1h with 1% blocking agent (diluted in TBS) at room temperature before 
incubating overnight (4ºC) with primary antibody in 0.5% blocking agent. Following 
primary antibody incubation, membranes were washed for 5min with TBS-Tween (TBS 
containing 0.1% Tween-20) three times and then with 0.5% blocking solution before 
incubating with the appropriate secondary antibody for 1h at room temperature. The final 
wash before developing consisted of three 5min washes with TBS-Tween followed by 
another set of three 5 min washes with TBS.  
Blots were visualised with either BM chemiluminescence kit or SuperSignal West Femto 
chemiluminescence substrate and developed using Hyperfilm. 
A summary of the antibodies used and the antibody conditions is described in Table 2.2 
and 2.3.   





Source Supplier Details 
EGF Family    
EGFR 1:1000 Rabbit #2232 Cell Signaling Tech. 
Total HER2 1:1000 Rabbit #2242 Cell Signaling Tech. 
Phospho-HER2 (Tyr 1248) 1:1000  #06-229 Upstate 
Total HER3 (1B2E) 1:1000 Rabbit #4754 Cell Signaling Tech. 
Phospho-HER3 (Tyr 1289) 1:1000 Rabbit #4791 Cell Signaling Tech. 
Total HER4 (111B2) 1:1000 Rabbit #4795 Cell Signaling Tech. 
Phospho-HER4 (Tyr 1284) 1:1000 Rabbit #4757 Cell Signaling Tech. 
Total IGF-I Receptor β 1:1000 Rabbit #3027 Cell Signaling Tech. 
Phospho-IGF Receptor β (Tyr 
1135/Tyr1136) 
1:1000 Rabbit #3024 Cell Signaling Tech. 
Akt Pathway    
Total Akt 1:1000 Rabbit #9272 Cell Signaling Tech. 
Phospho-Akt (Ser473) 1:1000 Rabbit #9271 Cell Signaling Tech. 
Phospho-Akt (Thr308) 1:1000 Rabbit #9275 Cell Signaling Tech. 
Akt 1 (2H10) 1:1000 Mouse #2967 Cell Signaling Tech. 
Akt 2 1:1000 Rabbit #2962 Cell Signaling Tech. 
Akt 3 1:1000 Rabbit #4059 Cell Signaling Tech. 
Total PTEN 1:1000 Rabbit #9552 Cell Signaling Tech. 
Phospho-PTEN(Ser 
380/Thr382/Thr383) 
1:1000 Rabbit #9554 Cell Signaling Tech. 
Total mTOR 1:1000 Rabbit #2972 Cell Signaling Tech. 
Phospho-mTOR (Ser2448) 1:1000 Rabbit #2971 Cell Signaling Tech. 
Total PI3 kinase p85 1:1000 Rabbit #4292 Cell Signaling Tech. 
Phospho-PI3K p85 (Tyr458) 1:1000 Rabbit #4228 Cell Signaling Tech. 
MEK/ERK Pathway    
Total MEK 1/2 1:1000 Rabbit #9122 Cell Signaling Tech. 
Phospho-MEK 1/2 (Ser217/221) 1:1000 Rabbit #9121 Cell Signaling Tech. 
Total ERK 1/2 1:1000 Rabbit #9102 Cell Signaling Tech. 
Phospho-ERK 1/2 (Thr202/Tyr204) 1:1000 Rabbit #9101 Cell Signaling Tech. 
Estrogen Receptor    
ERα (F10) 1:50 Mouse #sc-8002 Santa Cruz 
Phospho-ERα (Ser118) 1:1000 Rabbit #2515 Cell Signaling Tech. 
Phospho-ERα (Ser167) 1:1000 Rabbit #2514 Cell Signaling Tech. 
SRC-1 1:1000 Mouse #05-522 Upstate 
TIF2 1:250 Mouse #610984 BD Transduction Lab.
AIB1 1:500 Rabbit #MA1-845 Affinity Bioreagents 
PARP 1:1000 Rabbit #9542 Cell Signalling Tech. 
Actin   #CP01 
 
   Table 2.2 Primary Antibody List used in Western Blotting and Immunoprecipitation.  
 




Secondary Antibodies Dilution Factor Supplier Details 
Anti-Rabbit IgG HRP-linked 1:1000 #7074 Cell Signaling Tech. 
             Anti-Mouse IgG HRP-linked 1:1000 #7076 Cell Signaling Tech. 
Anti-Mouse IgM (Goat) Peroxidase 
Conjugate 
1:500 #401221 Calbiochem 
     Table 2.3 Secondary Antibodies used in Western Blotting. 
 
 
2.5 RNA extraction & quantitative RT-PCR 
2.5.1 RNA Extraction 
All cell lines were seeded at 0.5x106 cells per 10cm plate. As described previously for 
protein detection, MCF-7 cells were plated in DMEM (+phenol red) containing 10% FCS 
for 24h at which point the media was replaced with 5% DCSS DMEM and grown for a 
further 48h. Variants cell lines were plated straight into 5% DCSS DMEM and also 
incubated for 48h. Cells were then treated with the appropriate growth factor/inhibitor.  
RNA extraction was performed according to manufacturers’ instructions (Absolutely RNA 
Miniprep Kit, Stratagene). Briefly, 600μl of lysis buffer (+ β-Mercaptoethanol) was added 
to each plate, allowed to mix and incubated for a couple of minutes. RNA was then 
isolated using a RNA binding spin cup. The samples were then DNase treated (DNase 
digestion buffer & reconstituted RNase-Free DNase I) for 15min at 37ºC. After this 
incubation, the spin cups were washed with low-salt and high salt wash buffers and the 
RNA was then eluted in 50μl of elution buffer.  
 
RNA was quantified using the Nanodrop spectrophotometer.  
 
2.5.2 Quantitative RT-PCR 
QuantiTect SYBR Green System was used for performing one step RT-PCR according to 
manufacturers’ instructions. Briefly, RT-PCR allows mRNA to be amplified. Firstly, the 
mRNA is reverse transcribed into cDNA followed by PCR amplification cycles. The 
amount of product was detected using Sybr Green dye which binds to double stranded 
nucleic acids (Figure 2.5). Total reaction volume of 15μl: 7.5μl 2xQuantiTect SYBR Green 
Master Mix; 0.375μl primer mix (20μM); 0.15μl RT Mix; 2.975 RNase-free water and 4μl 
of RNA. Real time cycler conditions were RT: 50ºC for 30 min; PCR: initial activation 
95ºC for 15 min followed by 40 cycles of denaturation 94ºC for 15 sec, annealing 57ºC for 
30 sec, extension 72ºC for 30 sec, and a final extension of 72ºC for 60 sec.  










                    
 
 
Figure 2.5 Typical Real Time RT-PCR.amplification. The figure shows the amount of 
fluorescence generated by Sybr Green versus the number of PCR cycles. The samples with the 
most amount of mRNA can be found to the left of the graph. A greater number of specific mRNA 
results in amplification at a faster rate found at an earlier cycle.  
 
EGF Family  
EGFR 
 
fwd TGCACTCAGAGAGCTCAGGA\ rev CAGCGCTACCTTGT 
HER2 
 
fwd CTGAATGGGTCGCTTTTGTT\ rev CTCGTTGGAAGAGGAACAGC 
HER3 
 
fwd CTCCTTTGTGCACAGTTCCA\ rev GCGGCACTTTTCTCTACTGG  
HER4 
 
fwd GGAAATTGGAGCAGGTGTGT\ rev GCGGCACTTTTCTCTACTGG 
IGFR fwd GTTGGGAAGGGGATCATTTT\ rev ATGAAAACCATTGGCTGTG 
 
Akt Signalling  
Akt 1 fwd  ACCAGGTATTTTGATGAGGAGTTA\ revCGCTGTCCACACACTCCAT 
 
Akt 2 fwd  ATGCTGGCCGAGTAGGAGAA\ rev GCCCAGTCCATCACAATC  
 
Akt 3 fwd  AGGACCGCACACGTTTCTAT\ rev TTCTGGAGTGCCACAGAATG 
 
PTEN fwd GGACGAACTGGTGTAATGATAT\ revCTACTGTTTTTGTGAAGTACAG 
 
mTOR fwd CCAACAGTTCACCCTCAGGT\ rev CTGCCACTCTCCAAGTTTC 
 
PIK3CA fwd CCCCTCCATCAACTTCTTCA\ rev GGTTGCCTACTGGTTCAAT  
 
Estrogen Pathway  
ERα 
fwd CCACCAACCAGTGCACCATT\ rev GTCTTTCCGTATCCCACCTTTC 
  
SRC-1 fwd CATGCTTATGAGGCAGCAAA\ rev ATTCCAGTGCCAAACTGTCC 
 
TIF2 fwd AGCCTGTGAGAGGGCTGTTA\ rev AATGAGAGAGGGGAAGGGAA 
 
AIB1 fwd CCCTTTTATCTACTCTGTCATC\ rev CCAGATGTAGAGGAGGAGAC 
 
pS2 fwd TTGTGGTTTTCCTGGTGTCA\ rev CCGAGCTCTGGGACTAATCA  
  
Β-Actin fwd GATGGAGCCGCCATCCACACGG\ rev CTACGTCGCCCTGGACTTCG 
   Table 2.4 Primer Sequences used in Real Time RT-PCR.   
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2.6 Multiplexed Assays for PIK3CA Mutations 
The assay used here was based on a paper published by Board et al (2008) that combines 
two techniques for detection mutations: Amplification Refractory Mutation System 
(ARMS, Astrazeneca) and Scorpions (DxS). Together they provide a sensitive assay for 
the detection of PIK3CA mutations. The ARMS assay relies on the principle that extension 
only occurs when the 3’terminal base of a primer matches its target (Figure 2.6). Scorpion 
probes combine a PCR amplification primer and a probe which recognises the amplicon 
generated during the PCR reaction (Figure 2.6). Binding of probe to the target (amplicon-
specific sequence) produces a fluorescent signal, the strength of which is proportional to 
the amount of amplicon. Primer sequences described in Table 2.5. Scorpion primers were 
labelled with different fluorophores to allow multiplex mutational analysis. 
Cells were harvested as previously described and counted. Pellets containing 1x106 cells 
were then prepared and stored at -70ºC. DNA was extracted using the QIAamp DNA FFPE 
Kit (Qiagen) according to manufacturers’ instructions. Briefly, cell pellets were 
resuspended in 180μl of ATL buffer and incubated with proteinase K for 1h at 56ºC. 
Proteinase action was inactivated by heating at 90ºC for 1h. Samples were then spun at full 
speed for 2min and 150μl were transferred to new tubes before adding 300 μl of AL buffer 
/ethanol mix. Samples were loaded to a QIAamp MinElute column and centrifuged at 
8000rpm for 1min. The filtrate was discarded and the column was washed twice, first with 
AW1 buffer and then with AW2 buffer centrifuging in between washes. DNA was eluted 
from the column by incubating the dry membrane with 30μl of ATE buffer for 5min at 
room temperature. Each column was centrifuged at full speed for 1min to elute the DNA. 
        Table 2.5 Primer Sequences used in the Multiplex assay.   
ARMS Primers 
  
























































Figure 2.6 Overview of multiplex assay. The assay combines ARMS and Scorpion primers which 
are very specific in identifying mutations and produce a measurable fluorescence signal, 
respectively. Together they provide a sensitive assay.  
 
 
Total reaction volume of 25μl comprises of: 2.5μl of 1x HotGoldStar PCR Buffer; 2μl of 
4mM MgCl2; 1μl of 0.2mM dNTP; 1.25μl of 0.25 μM Control Scorpion; 1.25μl of 0.25 
μM Exon 20 Scorpion; 1.25μl of 0.25 μM Exon 9 Scorpion; 0.6μl of 0.12U/μl; 1.25μl of 
0.25 μM ARMS primers (H1047R and E542K) OR 1.25μl of 0.25 μM ARMS primers 
(H1047L and E545K). PCR conditions were: 95ºC for 10min followed by 45 cycles of 
90ºC for 30secs and 60ºC 60secs. Detection of different fluorescence using three different 
ARMS Primer Taq
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channels: FAM/Sybr, JOE and ROX. FAM-containing Scorpion primers detected 
mutations on exon 20 whilst Hex-containing Scorpion primers (JOE channel) detected on 













 Figure 2.7 Amplification plot for Multiplex analysis for PIK3CA mutations. FAM/Sybr and 
JOE channels detect mutations in exons 20 and 9, respectively. The ROX channel detects the control 
Scorpion primers.  
 
 
2.7 Flow cytometric Analysis of Cell Cycle 
Flow cytomety was used to study cell cycle. Flow cytometry requires cells to be suspended 
in a stream of fluid with a laser light directed into it. A number of detectors convert the 
light signals into electronic signals. In this case, flow cytometry was used to detect DNA 
content in these cells. Cells were prepared as previously described and 1x106 cells were 
plated into 10cm plates. Treatments were administered for 3 and 5 days. Cells were 
trypsinised as before taking extra care not to lyse cells. Trypsin was neutralised by adding 
2ml of 5% DCSS DMEM (-phenol red) media and the samples were transferred to FACS 
tubes before centrifugation at 17,000rpm for 4 min. The pellets were then resuspended in 
1ml of ice cold PBS and centrifuged again as before. The resulting pellets were this time 
resuspended in 200μl of Vindelovs Citrate buffer and stored at -20ºC. At the time of 
analysis, samples were thawed at room temperature before adding 450μl per tube of 
Solution A. The samples were briefly mixed and incubated for 3min. The samples were 
then neutrralised with the addition of 375μl of Solution B for 10min. Finally, 250μl of 
Allelic data for Cycling A.FAM/Sybr, Cycling A.JOE, Cycling A.ROX
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Solution C was added per tube and incubated on ice for a further 10min. Samples were 
immediately analysed in FACScalibur (Becton Dickinson) and the data was obtained with 
the CellQuest 1.2.2 programme. Results were further analysed using ModFit LT 1.01 













              Figure 2.8 Typical cell cycle profile generated using ModFit LT 1.01 Software. 
 
 
2.8 RNAi Studies 
siRNA transfections as described below were used in p160 cofactor studies (Chapter 4) 
and Akt isoform phosphorylation levels (Chapter 6). 
All cell lines were plated at 0.5x106 cells per 10cm plate. MCF-7 cells were plated in 
phenol red DMEM which was replaced with 5% DCSS DMEM (-phenol red) 24h later as 
previously described. LCC1 and LCC9 cells were seeded directly into phenol red free 
DMEM supplemented with 5% DCSS for 24h. Oligofectamine reagent (Invitrogen) was 
firstly diluted in Opti-MEM (#31985-070; Gibco) reduced serum media before adding the 
appropriate siRNA. This mixture was incubated at 37ºC for 15min. Cells were then 
transfected for 4 h. Oestrogen was then added if required and incubated for a further 48h 
before RNA and protein extractions performed as previously described. siRNA sequences 
(100nm) were as follows: Negative siRNA (Upstate M-003401); AIB1 (Qiagen 
#1024591); SRC-1 (Qiagen #1024927); SRC-2: 5’AAGTCAGATGTATCCTCTACA 
(Qiagen); ERα: 5’AAA-CAGGAGGAAGAGCTGCCA (40 nmol; Ambion, 
Cambridgeshire). 
G0-G1 G2-M
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Akt RNAis (2.5μl) were diluted in 250μl of Opti-MEM in 6-well plates. 7.5μl of 
Lipofectamine RNAiMAX  (Invitrogen) was then added to each well, mixed gently and 
incubated for 10-20min at room temperature. Cells were harvested as previously described 
and all cell lines were diluted to a concentration of 1.7x105 cells/ml in 5% DCSS DMEM (-
phenol red). 1.5ml of the cell dilution was added to the RNAi-lipofectamine complexes 
and incubated for 48h before RNA collection. For protein extraction plates were incubated 
for 72h. siRNAs were used at a concentration of 50nM from a stock solution of 20nM. 
siRNA sequences were as follows: Akt 1: 5’ACCTGACCAAGATGACAG; Akt 2: 5’ 
AAGTGGGTCCGCTGGT; Akt 3: 5’AGGAGGTACAAGCTTTTTA (Applied 
Biosystems UK) 
 
2.9 Migration & Invasion Assays 
2.9.1 Migration Assays 
In order to assess migration ability in these cell lines a Quantitative Cell Migration Assay 
Kit (Chemicon) was used. Three different kits were used as they were coated with different 
matrix proteins, collagen I, fibronectin and vitronectin. Experiments were performed 
according to manufacturers’ instructions. Briefly, this assay uses a system of Boyden 
chambers coated with specific matrix proteins to measure cell migration. Cells were plated 
at a concentration of 2.5x106 cells per well. Each cell line was plated in phenol red free 
DMEM supplemented with 5% DCSS in duplicate. There are two plates as part of the kit, 
one Test plate and a Control plate. The Test plate contains boyden chambers coated with 
the matrix protein (Collagen I, Fibronectin & Vitronectin). The Control plate, on the other 
hand, contains a row of matrix protein coated well and a row of BSA coated wells. The 
former serves as a adhesion control whilst the latter provides a control for migration. Plates 
were incubated for 24h in a tissue culture incubator. Each Boyden chamber was cleaned 
taking extra care not to touch the underside of the chamber as it contains the migratory 
cells. Boyden chambers were then stained with a crystal violet stain (400μl) for 30min at 
room temperature before washing in PBS three times. The clean chambers were then 
placed into extraction buffer (300μl) and shaken for 10min in order to elute stain. 100μl of 
the stained solution was transferred onto a clean microtitre plate and the absorbance was 
read at 560nm.  
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Cell migration was illustrated graphically by a “bar” chart by comparing migration in 
BSA-coated chambers with migration in matrix coated chambers. Cell migration in BSA-
coated chambers is usually very low due to the lack of stimulus thus these chambers are 
used as a blank measuring the amount of background staining.  
 
2.9.2 Invasion Assays 
Similarly to the migration assays, the Cell Invasion Assay Kit (Chemicon) used in these 
studies relies on a Boyden chamber system. Each 24-well tissue culture contained an insert 
coated with a thin layer of dried extracellular matrix (ECM) over a polycarbonate 
membrane (8μm pore size). Invading cells are able to travel through the ECM layer and 
attach to the bottom of the polycarbonate membrane. The kit was used according to 
manufacturers’ instructions. Briefly, plates were rehydrated for 2 h by adding reduced 
serum media (5%DCSS DMEM) to the interior of the inserts. After 2h, the media was 
removed and 500μl of cell suspension (in 5% DCSS DMEM) was added to each well 
(0.5x106 cells/ml). Media containing 10% foetal bovine serum was added to the lower 
chamber to act as a chemoattractant. Samples were loaded in quadruplicate. The plates 
were incubated for 48h in a tissue culture incubator. The chambers were then cleaned in 
order to remove any non-invading cells found in the insert, particularly in the interior of 
the inserts. The invading cells found on the lower surface of the inserts were stained for 20 
min at room temperature with crystal violet stain. After staining the inserts were washed in 
distilled water several times and allowed to dry. The crystal violet stain stain was dissolved 
in 10% acetic acid (150μl) and 100μl of the stained solution was transferred to a clean 96-
well plate. Absorbance was read at 560nm. 
 
2.10 Immunohistochemistry  
(i) Patients 
The breast tumour material used here has been previously used in a number of studies and 
was kindly donated by Professor John Bartlett (Edinburgh Cancer Research Centre, 
University of Edinburgh). It comprises 402 ERα-positive breast carcinomas belonging to 
patients diagnosed between 1983 and 1999 at Glasgow Royal Infirmary. ERα positivity 
had been previously determined and defined as 10% or more positive tumour cells staining. 
This is in accordance to current local pathology guidelines. Patients were treated with 
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adjuvant tamoxifen for an average of 5 years. Ethical approval was obtained from the local 
ethics committee.  
      
(ii) SRC-1 Immunohistochemistry 
Immunohistochemistry for SRC-1 (#2191, Cell Signalling) was performed on previously 
prepared tissue microarrays using a standard immunoperoxidase procedure. Sections were 
dewaxed and rehydrated before proceeding with antigen retrieval which was done by 
microwaving the slides under pressure for 10min in Citrate Buffer. The slides were then 
treated with 3% H2O2 for 10min in a stirrer in order to quench peroxidase activity before 
incubating in serum free block solution (Dako) for 20min to eliminate any unspecific 
background staining. Slides were incubated with primary antibody (1:600 dilution) 
overnight at 4ºC. The sections were washed twice in TBS-Tween for 5min. EnVision 
(Dako) was used for signal amplification and positive staining was detected by incubating 
with 3,3’diaminobenzidine solution (DAB, Vector Laboratories). Finally, the sections were 
counterstained with hematoxylin, dehydrated and mounted.    
 
(iii) Scoring of IHC Results 
Slides were digitized using Ariol, a commercially available image analysis system 
(Applied Imaging Inc., San Jose, California). Scores from 0 (Negative) to 3+ (strongly 
positive) were automatically generated by the Ariol image analysis software for each core 
based on the percentage of positive cells and the intensity of signal. The tumour tissue in 
each individual core was manually selected before automated scoring.  
 
(iv) Statistical Analysis 
The statistical package SPSS (version 9.0) was used for all the IHC statistical analysis. The 
































The three stage MCF-7 cell line model was used in this study as it mimics acquired 
endocrine resistance often observed in the clinical setting. LCC1 cells acquired oestrogen 
independence however remain anti-oestrogen sensitive whilst LCC9 cells are both 
oestrogen independent and endocrine resistant. MCF-7 and its derivative cell lines LCC1 
and LCC9 were first characterised to establish whether cellular processes such as growth, 




3.1 Growth Characterisation and Morphology 
The wild type MCF-7 breast cancer cell line is oestrogen dependent and is sensitive to anti-
oestrogens such as Tamoxifen and ICI 182,780. This is confirmed in Figure 3.1. Oestrogen 
(Fig. 3.1a) and TGFα (Fig. 3.1b) stimulate growth (twofold increase) in MCF-7 cells 
although oestrogen appears to be more effective. Tamoxifen reduces growth in the 
presence of oestrogen (Fig. 3.1a) but does not affect TGFα driven growth (Fig. 3.1b). In 
the absence of oestrogen or growth factor stimulus, growth of MCF-7 cells is negligible 
and the cells are said to be in a static state. Treatment with the pure anti-oestrogen ICI 
completely reverses oestrogen and TGFα stimulation in MCF-7 cells (Fig. 3.1). 
     
LCC1 cells are oestrogen independent as a result of growing in a low oestrogen 
environment but retain a certain level of oestrogen responsiveness. This is evident in 
Figure 3.1a. The effects of TGFα, on the other hand, appear to be minimal as the growth 
curve mimics that of control (Fig. 3.1b). Like the parental MCF-7 cell line, LCC1 are still 






















Figure 3.1 Growth characterisation of MCF-7 & LCC1 cells. Cells were treated in the presence 
of growth stimulatory factors E2 (a) and TGFα (b). Cell OD values were measured at Day 0, 3 & 5. 
Data plotted represent means of six OD values. Error Bars=SD.  
 
In contrast to MCF-7 and LCC1 cells, LCC9 cells are completely oestrogen independent 
and unresponsive to oestrogen as indicated by the fact that untreated and oestrogen treated 
LCC9 cells have comparable growth effects (Fig. 3.2a). TGFα treatment also appears to 
have little effect on growth in this cell line (Fig 3.2b). Moreover, LCC9 cells are fully 
resistant to tamoxifen and ICI 182, 780 as their growth fails to be inhibited by drug 









Figure 3.2 Growth characterisation of LCC9 cells. Cells were treated in the presence of growth 
stimulatory factors E2 (a) and TGFα (b). Cell OD values were measured at Day 0, 3 & 5. Data 




















































































































































Cellular morphology was another of the characteristics analysed to determine whether 
there are differences between endocrine sensitive and resistant cell lines. All cell lines were 
grown for 48 hours in charcoal-stripped serum and then treated with oestrogen.  
All three cell lines grow as monolayers although MCF-7 cells seem to distribute more 
evenly cross the surface whilst LCC1 and LCC9 cells appear to prefer to grow in clusters 
(Figure 3.3). Untreated MCF-7 cellular morphology is quite distinct creating what is often 
referred to as a “cobblestone” effect (Figure 3.3). In the presence of oestrogen, the 
appearance of MCF-7 cells changes to form clusters similar to those of LCC1 and LCC9 
cells under control conditions (Figures 3.4 & 3.5). Despite having little effect on growth 
rates, oestrogen did alter the morphology of LCC1 and LCC9 cells as the clusters appear to 









Figure 3.3 Cellular morphology of MCF-7 cell line. Cells were grown in stripped serum in the 








Figure 3.4 Cellular morphology of LCC1 cell line. Cells were grown in stripped serum in the 












Figure 3.5 Cellular morphology of LCC9 cell line. Cells were grown in stripped serum in the 
absence or presence of E2 for 48h. Magnitude x100. 
 
3.2 Clonal Selection 
It became evident during cell cycle experiments that MCF-7 cell line culture appeared to 
contain two different populations. A typical cell cycle profile would consist of two peaks 
representative of cells at the G0-G1 and G2-M phases. Figure 3.6 shows the profile obtained 
which present two peaks at the G0-G1 phases suggesting there are two cell populations 
present. This analysis does not however tell us the origin of this second cell population but 
it is possible that routine cell culture may have given rise to a secondary MCF-7 cell 
population. 
MCF-7 cells are the most routinely used breast cancer cell line and its popularity has 
resulted in the production of a number of different cellular stocks. To eliminate the risk of 
using a different subline of MCF-7 from the one routinely used in our lab, clonal selection 
was used to select clones from the MCF-7 stock with the suspected clonal variation (Figure 
3.7). The process began with a single cell per well (96 well plates) isolated by serial 
dilution hence it was assured that the population obtained was derived from a single cell. 
Three MCF-7 clones were collected and fully characterised to determine how they 
compared with the parental wild-type cell line. Furthermore, characterising each of the 



















Figure 3.6 Cell Cycle Analysis of MCF-7 cells. Figure representative of triplicate samples. Note 






                
 
              






The MCF-7 clones were first analysed by flow cytometry (Figure 3.8). This was to 
determine whether each clone contained one or more populations as previously observed in 
MCF-7 cells. This was not found to be the case in the MCF-7 clones as can be observed by 
the single peak representing cells at the G0-G1 phase and a second peak for cells in G2-M 
phase (Figure 3.8). It can therefore be concluded that, at least at the cell cycle level, MCF-
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Figure 3.8 Cell Cycle analysis of MCF-7 Clones: Clone 1 (a), Clone 2 (b) & Clone 3 (c). Figure 
representative of triplicate samples. This was a simple method to detect whether clonal selection was 
successful in eliminating a mixed population.  







































































































































































3.2.1 Growth Characterisation  
All three MCF-7 clones were static under control condition and require oestrogen or 
growth factor stimulation (e.g. TGFα) as previously described is the case in MCF-7 cells 
(Figures 3.9 & 3.10). The responses to tamoxifen were variable in the clones. Although 
growth is certainly reduced by tamoxifen in the presence of oestrogen in all three clones, 
the extent of response is different (Figures 3.9 & 3.10). This probably reflects the agonist 










ICI 182,780 effects on MCF-7 clones are also consistent with previous studies. In all 
clones ICI 182,780 completely reverses the growth stimulatory action of oestrogen and 
reduced growth to control levels (Figures 3.9 & 3.10). According to this data, growth 
responses to oestrogen and anti-oestrogens in MCF-7 clones are comparable to the 








Figure 3.10 Growth characterisation of MCF-7 Clone 1, 2 & 3. Cells were treated in the presence 
of growth stimulatory factor TGFα. Cell OD values were measured at Day 0, 3 & 5. Data plotted 
























































































Figure 3.9 Growth characterisation of MCF-7 Clone 1, 2 & 3. Cells were treated in the presence 
of growth stimulatory factor E2. Cell OD values were measured at Day 0, 3 & 5. Data plotted 
represent means of six OD values. Error Bars=SD.  
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3.2.2 General Morphology 
The morphology of the three MCF-7 clones was similar to that of MCF-7 (Figure 3.11 a, b 
& c). Interestingly, MCF-7 clone 3 appears to grow at a much slower rate than Clone 1 and 
2. This may reflect an actual difference between the clones. The phenotypic response to 
oestrogen also appears to be the same as previously observed. All three clones form a 
“cobblestone” effect which changes to form clusters following oestrogen treatment, an 
appearance very similar to that of LCC1 and LCC9 (Figure 3.11 a, b & c). 
Growth curves and phenotypic analyses indicate that the MCF-7 clones have properties 




















Figure 3.11 Cellular Morphology of MCF-7 Clone 1 (a), Clone 2 (b) & Clone 3 (c). Cells were 












3.2.3 Expression Profiling 
3.2.3.1 Signalling Proteins 
MCF-7 cells are an oestrogen receptor positive cell line so it was important to determine 













Figure 3.12 Western Blot analysis of ERα levels & oestrogen regulation of ERα in MCF-7 
clones. (a) Oestrogen downregulates ERα in the three clones (b) MCF-7 clones have lower basal ER 
levels than LCC1 cells as previously described (Kuske et al, 2006). 
 
ERα is expressed in the three clones and the protein is downregulated by oestrogen (Figure 
3.12a) as described in previous reports (Kuske et al, 2006). MCF-7 clone 1 was used to 
determine how the ERα expression in the clones relates to the expression in LCC1 and 
LCC9. As shown in Kuske et al (2006), ERα expression is higher in LCC1 cells in 
comparison to clone 1. Additionally, ERα levels are similar in MCF-7 clone 1 and in LCC9 
cells (Figure 3.12b).  
 
 3.2.3.2 Transcriptional Analysis 
Transcriptional regulation of pS2 and ERα were also investigated. As an oestrogen 
regulated gene, pS2 mRNA expression is markedly upregulated in the presence of 
oestrogen. In the three clones, pS2 mRNA expression is responsive to oestrogen, doubling 
after 24h and quadrupling after 48h (Figure 3.13a). However, the response to oestrogen 
after 48h oestrogen treatment is not as pronounced in clone 3 as in clones 1 and 2. 
MCF-7
Clone 1 LCC1 LCC9
E2 - +        - +         - +





E2 - +       - +       - +
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Statistically, changes in pS2 expression are most significant and consistent in clone 2. 
Oestrogen activates transcription of genes which in turn promote cell growth such as 
proteins involved in cell cycle regulation, cell adhesion and DNA replication. 
In contrast to pS2’s transcriptional regulation, oestrogen downregulates ERα transcription. 
Expression of ERα mRNA was reduced in all three MCF-7 clones following oestrogen 
treatment (Figure 3.13b). The more consistent and significant results are once again 
observed in clone 2.  
 















Figure 3.13 Regulation of oestrogen responsive pS2 (a) and ERα (b) genes in MCF-7 clones. 
Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to actin 
expression. Error Bars=SD. Statistical analyses between each control vs E2 (Student’s paired t test 









































































































































3.3 Signalling Pathways: Basal Characterisation 
The three isolated MCF-7 clones behaved as expected according to literature on MCF-7 
breast cancer cell line. They are oestrogen dependent, ERα positive and the regulation of 
protein/mRNA can be mediated by oestrogen. Nevertheless, there are a few subtle 
differences between the clones. The growth of clone 3, for example, appeared to be slower 
than the other two clones. In addition, oestrogen-mediated transcriptional regulation is only 
consistently significant in MCF-7 clone 2. 
In order to conduct further experiments one MCF-7 clone had was picked for comparison 
with LCC1 and LCC9 cells. Clone 2 was chosen and from this point onwards will be 
referred to as MCF-7 only.   
 
3.3.1 Epidermal Growth Factor Receptor Family  
Overexpression of EGF receptor family members is often implicated in breast cancer, 
particularly HER2 so it was important to establish the role of this family in this endocrine 
resistant model.  
Protein expression of EGFR is undetectable in MCF-7, LCC1 and LCC9 cells by standard 
western blotting although at the transcriptional level EGFR mRNA is significantly lower in 
oestrogen independent LCC1 and resistant LCC9 cells (Figure 3.15). HER2 protein 
expression levels are certainly not elevated in LCC1 and LCC9 cells, in fact they appear to 
be slightly lower when compared to the MCF-7 cell line (Figure 3.14). This appears to be a 
result of reduce transcription however the values are not statistically significant in LCC9 
cells (Figure 3.15). Interestingly, HER3 mRNA levels are reduced in LCC1 and LCC9 in 
comparison to the parental MCF-7 cell line (Figure 3.14). However, HER3 protein levels 
are only slightly lower in LCC9 (Figure 3.15). Of all the EGF receptor family members, 
HER4 is the only one whose protein is overexpressed in LCC1 and LCC9 at the basal and 
phosphorylated level (Figure 3.14 & 3.15). This is not the case at the transcriptional level 
which indicates that elevated protein expression is a result of altered post-transcriptional 
regulation. 
These results suggest that endocrine resistance in this three stage model is not being driven 
as a result of EGFR, HER2 or HER3 overexpression. HER4 expression, on the other hand, 
is elevated in LCC1 and LCC9 cells indicating that this receptor may be involved in 









Figure 3.14 Expression of EGF Receptor Family. Western blot analysis of EGFR, HER2, HER3 
and HER4 in MCF-7, LCC1 and LCC9. The MDA-MB 231 cell line (ER-negative) was used as a 







Figure 3.15 Transcription of EGF Receptor Family.  Each column presents mean of 
quadruplicate RT-PCR analysis for each sample relative to actin expression. Error Bars=SD. 
Statistical analyses between MCF-7 vs LCC1/LCC9 for each receptor (ANOVA test *P<0.05; 
**P<0.01; ***P<0.001). 
 
3.3.2 MEK/ERK Pathway  
The MEK/ERK pathway is important in regulating 
cell proliferation and transcriptional control 
(Kurokawa et al, 2003). Furthermore, this pathway 
has been shown to be able to phosphorylate ERα at 
the ser118 residue and therefore is often implicated 
in resistance to endocrine resistance in breast cancer 
(Kato et al, 1995).  
Activation of MEK and its downstream target ERK 
are similar in all three cell lines (Figure 3.16). This 
result indicates that this particular pathway is not 
important in conferring resistance in LCC1 and 
LCC9.  
Figure 3.16 MEK/ERK Pathway.  
Western blot analysis of MEK and 
ERK (basal & phosphorylated levels). 


















































3.3.3 PI3K/Akt Pathway 
The PI3K/Akt pathway mediates cellular processes 
such as cell cycle entry, migration and cell survival 
(Shtilbans et al, 2008). Similarly to the MEK/ERK 
pathway, Akt has the ability to phosphorylate 
Ser167 of ERα in the absence of oestrogen. 
Phosphorylation of Akt at Ser473 is elevated in 
LCC1 and LCC9 whilst the basal levels remain 
similar in the three cell lines (Figure 3.17).     
      
It is likely that increased phospho-Akt (Ser473) is involved in oestrogen independence and 
endocrine resistance. LCC1 and LCC9 cells may have the ability to activate ERα 
bypassing the need for oestrogen. This pathway and the role in this cell model are further 
discussed in Chapter 6. 
      
3.4 ERα: its role in this model of endocrine resistance 
3.4.1 ERα Basal Levels & Turnover 
Oestrogen regulation of ERα is invariably at the forefront of endocrine resistant studies. 
Loss of ERα expression is one of the major mechanisms involved in conferring resistance 
to endocrine therapies. LCC1 and LCC9 cells remain ERα positive (Figure 3.18) and the 
receptor expression is downregulated by oestrogen treatment as previously shown (Kuske 
et al, 2006). Interestingly, the expression of ERα is higher in LCC1 cells than in the 








Figure 3.17 Akt Pathway.  Western blot 
analysis of Akt levels & phosphorylation 
(Ser473). Results shown representative of 



























Figure 3.18 Western Blot Analysis of ERα levels & oestrogen regulation. Effects of Tamoxifen 
(a) & ICI 182,780 (b) on ERα regulation & protein expression in MCF-7, LCC1 and LCC9. Results 
representative of three independent experiments.  
      
 
ERα expression is reduced in the presence of ICI (Figure 3.18b) but not tamoxifen (Figure 
3.18a) in the MCF-7 cell line. This is also the case in the oestrogen independent LCC1 and 
fully resistant LCC9 cells. These results suggest that the regulation of ERα expression 
following treatment with anti-estrogens is not lost in this cell line model. Thus, LCC1 and 
LCC9 cell lines appear to retain ERα expression and respond to oestrogen and anti-
oestrogens in a manner similar to that observed in parental MCF-7 cells.   
 
3.4.2 ERα Basal Phosphorylation 
As shown above, basal ERα expression and regulation 
appears to be maintained in LCC1 and LCC9 cell lines 
in comparison to the parental MCF-7 cells. However, it 
is also important to determine whether ERα activation 
is altered in this endocrine resistance model. As can be 
observed in Figure 3.19, Ser118 phosphorylation is 
certainly not elevated in LCC1 and LCC9 cells.  
      
     
Figure 3.19 Western Blot analysis 
of ERα phosphorylation. Results 
shown representative of three 
independent experiments. 
E2               - +         +       - +        +      - +       +   
Tam        - - +       - - +      - - + 
MCF-7 LCC1 LCC9 
ERα
MCF-7 LCC1 LCC9 
E2 +     - +            +     - +          +       - +


















Consequently, it appears that phosphorylation at this residue is not directly associated with 
resistance in this cell line model. Phosphorylation at the Ser167 was also measured and the 
results are shown in Chapter 6 as they directly relate to Akt function.  
 
3.5 Regulation of Cellular Mechanisms & Endocrine Resistance 
In order to better understand endocrine resistance it was important to determine not only 
which pathways may be important in mediating resistance but also which cellular 
processes might be altered. Cell cycle, apoptosis, migration and invasion were all analysed. 
 
3.5.1 Cell Cycle Analysis 
MCF-7 growth in the absence of oestrogen is minimal and the cells are said to remain 
static. This is the result of a block at the G0-G1 cell cycle phase (Figure 3.20a) therefore all 
the treatments were administered in the presence of oestrogen. Herceptin and 2C4 did not 
affect cell cycle in MCF-7 cells. ICI 182,780 treatment, on the other hand, induces a 
significant increase in the percentage of cells at G0-G1 and significantly reduces the 
number of S phase cells.  
Similarly to MCF-7 cells, LCC1’s cell cycle is only affected by ICI 182,780 treatment 
(Figure 3.20b) in the same way as previously observed in the parental cell line. All other 
drug treatments do not induce a change in the cell cycle profile in comparison to control.  
Cell cycle distribution in LCC9 cells was unaffected by any of the drug treatments (Figure 




































Figure 3.20 Cell Cycle Analysis. Effects of drug treatments on cell cycle of MCF-7 (a), LCC1 (b) 
and LCC9 (c). Each column presents means of three independent experiments. Error Bars=SD. 
Statistical analyses between E2 vs treatment for each phase in MCF-7 cells and between control vs 
treatment for each phase in LCC1 & LCC9 cells (ANOVA test **P<0.01; ***P<0.001).  
 
3.5.2 Apoptosis 
Following observations showing that phosphorylation of the anti-apoptotic Akt is elevated 
in LCC1 and LCC9 cells it was crucial to establish whether apoptotic control was affected 
in endocrine resistance. Poly(ADP-Ribose) polymerase (PARP) cleavage was used as a 
marker or cells undergoing apoptosis. PARP (116 kDa) is involved in DNA repair and is 
important in mediating responses to damage. In apoptotic cells, PARP is targeted for 
























































































































In LCC1 cells, apoptosis as indicated by PARP cleavage is elevated following treatment 
with tamoxifen, herceptin and 2C4 (Figure 3.21). Furthermore, ICI treatment also induces 
apoptosis but the effects are not as pronounced as with the other inhibitors.  
Apoptosis levels in LCC9 cells do not appear to be particularly affected by any of the drug 
treatments (Figure 3.21). There are a certain number of cells undergoing apoptosis in 
LCC9 cells as indicated by the presence of the 89kDa fragment, however the ratio of 









Figure 3.21 Apoptosis levels in LCC1 and LCC9 cells. Western Blot analysis for PARP cleavage, 
a well known marker of apoptosis.  
 
 
 3.5.3 Migration and Invasion  
Migration and invasion were also measured in these three cell lines. A Boyden Chamber 
system was used to analyse cell migration in MCF-7, LCC1 and LCC9 cells in the 
presence of three different extracellular matrix proteins: collagen I, fibronectin and 
vitronectin. Cell migration is mediated by a number of different factors which in turn 










































Figure 3.22 Migration levels in MCF-7, LCC1 & LCC9. The number of migrating cells was 
measured using three matrix proteins: Collagen I (a), Fibronectin (b) & Vitronectin (c). Each column 
presents means of four independent experiments. Error Bars=SD. Statistical analyses between BSA 
control vs sample for each cell line (Student’s paired t test *P<0.05; **P<0.01; ***P<0.001) and 





































































































Collagen I and fibronectin induced migration at least in one of the cell lines whilst 
Vitronectin did not appear to do so (Figure 3.22). The number of MCF-7 migratory cells is 
significantly elevated in the presence of collagen I (Figure 3.22a) and fibronectin (Figure 
3.22b) in comparison to BSA control. Migration in LCC1 cells was only significantly 
increased in collagen I treated chambers whilst migration in LCC9 cells was significantly 
stimulated only in the presence of fibronectin. Furthermore, comparison between the 
numbers of migratory MCF-7 cells versus LCC1/LCC9 cells revealed that the parental 
cells appear to be the most migratory. However this is only observed in Collagen I treated 









Figure 3.23 Invasion levels in MCF-7, LCC1 & LCC9.  Each column presents means of four 
independent experiments. Error Bars=SD. Statistical analyses between MCF-7 vs LCC1/LCC9 
(Student’s unpaired t test ***P<0.001). 
 
Invasion was the last of the cellular processes to be examined. The assay was designed to 
measure the ability of cells to move through a thin layer of extracellular matrix. Invasion 
ability is progressively increased in LCC1 and LCC9 cell lines respectively in comparison 
to MCF-7 cells. However, invasion ability is only significant elevated in LCC9 cells 
(Figure 3.23).  
 
3.6 Discussion 
Various cellular processes were fully characterised in the MCF, LCC1 and LCC9 cell lines 

























mechanisms have previously been studied and the results presented here are consistent 
with published data (Brunner et al, 1993; Brunner et al, 1997).   
 
LCC1 and LCC9 cells were derived from MCF-7 cell lines hence these cells are considered 
to be the parental cell line and may be directly compared. As shown here and by previous 
studies (Power et al, 2003), MCF-7 cells are effectively static in the absence of oestrogenic 
stimulus and require this hormone in order to grow. They are also sensitive to the 
stimulatory effects of growth factors such as TGFα in agreement with published data 
(Keshamouni et al, 2002; Larsen et al, 1999). As reported by Kallio et al (2005) and 
Seeger et al (2003), tamoxifen inhibited oestrogen-driven MCF-7 cellular proliferation but 
had little effect when administered alone.  
MCF-7 cells were grown in ovariectomized mice in order to select for oestrogen 
independent growth in vivo. The LCC1 cell line was isolated from tumours growing in 
these mice and, as shown in this chapter, is characterized as having acquired oestrogen 
independent growth. This is supported by previous studies by Brunner et al (1993), Clarke 
et al (1993) and Arteaga et al (1999). Nevertheless, LCC1 cellular proliferation is still 
oestrogen-sensitive. Unlike the parental MCF-7 cell line, growth of LCC1 cells is not 
stimulated by the addition of TGFα. However, these cells resemble MCF-7 cells since they 
are sensitive to anti-oestrogens tamoxifen and ICI 182,780.  
In contrast to LCC1 cells, the LCC9 cell line was found to be completely insensitive to 
anti-oestrogens and growth factor/oestrogen stimulation which has been previously shown 
by a number of groups (Brunner et al, 1997; Clarke et al, 1987).  
      
Morphologically, MCF-7 cells look quite different from its derivative cell lines. Under 
control conditions without oestrogenic stimulation, MCF-7 cells have a flat “cobblestone” 
appearance and grow as adherent epithelial-like cells. The cell appearance is only altered in 
the presence of oestrogen which appears to promote cell-cell adhesion rather than cell-
matrix adhesion observed in the control as previously observed by Srivastava et al (2004). 
The study by Srivastava et al (2004) also suggested that tamoxifen treatment did not 
phenotypically alter MCF-7 cells whilst Stewart et al (1992) reported no morphologic 
alterations following TGFα treatment.  
The morphology of LCC1 and LCC9 cells was not as structured and organised as the 
parental MCF-7 cell line. Interestingly, MCF-7 cells treated with oestrogen adopt 
morphology not dissimilar to that of LCC1 and LCC9 cells. This may indicate that the 
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MCF-7 derivatives preferentially form cell-cell adhesion thereby giving rise to a more 
“clumpy” appearance.  
 
MCF-7 cells have become the most commonly used model for ER-positive breast cancer. 
The MCF-7 cell line is now distributed in laboratories throughout the world so it is not 
surprising that clonal variations have been reported since MCF-7 cells were first 
established in 1973 (Nugoli et al, 2003). Such clones mainly differ in their ability to 
respond to oestrogen and in their tumour formation ability (Seibert et al, 1983; Whang-
Peng et al, 1983; Butler et al, 1986). This was further demonstrated by Resnicoff et al 
(1987) as they have shown that MCF-7 fractionation gave rise to six different 
subpopulations. Most importantly, one of these cell lines bore the ability to generate all 
other 6 populations suggesting MCF-7 cells contain a fraction of stem cells which may 
generate clonal variability (Resnicoff et al, 1987; Nugoli et al, 2003).  
The MCF-7 cell line first used in this study was found to comprise of (at least) two cellular 
populations as observed by cell cycle analysis. As described above this is not an 
uncommon event however it was important to try to eliminate clonal variation is these cells 
to aid the interpretation of future results, particularly cell cycle studies. Three clones were 
isolated from the MCF-7 cell line and all three were fully characterised in term of 
phenotype, oestrogen response, ERα protein expression and gene expression. One of these 
clones was chosen to perform all future experiments as it behaved as MCF-7 cells, in 
agreement with previously published reports.  
 
The expression of EGF receptors and downstream signalling pathways in MCF-7, LCC1 
and LCC9 cells was fully investigated in order to establish whether these mechanisms are 
important in conferring oestrogen in independence and endocrine resistance.  
EGFR protein expression was undetected in all three cell lines however, EGFR 
transcription was significantly lower in oestrogen independent LCC1 and resistant LCC9 
cells. EGFR overexpression in breast cancer was a strong indicator for recurrence and is 
associated with reduced disease-free survival (Normanno et al, 2005). Additionally, EGFR 
expression is generally increased in ER-negative breast cancers (Normanno et al, 1994; 
Normanno et al, 2005) whilst EGFR signalling can promote tamoxifen resistance 
(Nicholson et al, 2004; Dowsett et al, 2001; Ellis et al, 2001). Similarly to EGFR 
expression, HER2 is not elevated in LCC1 and LCC9 suggesting overexpression of these 
receptors which is often implicated in endocrine resistant in breast cancer. The HER2 
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receptor became a major therapeutic target in breast cancer treatment following reports that 
this receptor is overexpressed in 15 to 30% of breast tumours (Ellis et al, 2004). However, 
the results presented here suggest the development of endocrine resistance in the cell line 
model used in this study is not dependent on the overexpression of the EGFR and HER2 
receptors unlike many of the other cell line models.  
HER3 overexpression has been observed in an average of 25% of invasive breast 
carcinomas (Karamouzis et al, 2007). HER3 expression is linked to HER2 positivity 
(Gasparini et al, 1994) and co-expression of the two receptors has been shown to 
significantly promote mammary tumourigenesis (Holbro et al, 2003) which is not 
surprising considering that the HER2/HER3 heterodimer has the most potent mitogenic 
ability of all the heterodimerisation possibilities (Citri et al, 2003). HER3 protein 
expression is relatively unchanged in LCC1 and LCC9 cells despite transcription being 
significantly reduced in comparison to parental MCF-7 cell line. Various studies have 
shown that HER3 plays a role in resistance to treatment, particularly to EGFR tyrosine 
kinase inhibitors and HER2-targeted therapies were it may compensate and help cells 
escape the inhibitory effects of these drugs (Kong et al, 2008; Normanno et al, 2009; 
Koutras et al, 2009). Of the four members of the EGF receptor family, HER4 was the only 
member overexpressed in LCC1 and LCC9 cell lines. This is surprising considering HER4 
activation is linked to antiproliferative and pro-apoptotic activity. Furthermore, HER4 
expression correlates with favourable prognostic factors such as ER/PR positivity, low 
histopathological grade (Witton et al, 2003) and increased overall survival in breast cancer 
(Koutras et al, 2008). However, recent studies reported HER4 mRNA levels was 
associated with poor outcome and reduced relapse-free survival in a subset of breast cancer 
patients (Bieche et al, 2003). HER4 receptor cleavage generates a soluble HER4 
intracellular domain (4ICD) and the localization of this domain appears to determine HER 
function thereby explaining the aforementioned contrasting results regarding HER4 as a 
prognosis indicator (Ni et al, 2001; Junttila et al, 2005). 
These results together suggest that direct deregulation of EGF, HER2 and HER3 
expression is not directly linked to endocrine resistance. However, HER4 expression is 
markedly elevated in oestrogen independent LCC1 and resistant LCC9 cells. Expression of 
the soluble intracellular domain and its localization was not determined in these cell lines 
however in this model HER4 appears to be associated with increased tumour formation 




Epidermal growth factor receptors mediate a number of cellular processes by activating a 
variety of downstream signalling pathways such as the ERK and Akt pathways. Elevated 
MEK/ERK activation is observed in oestrogen unresponsive and resistant MCF-7 cells 
(Santen et al, 2005; Normanno et al, 2006). Furthermore, the MEK/ERK pathway has the 
ability to phosphorylate and consequently activate the ERα receptor in the absence of 
oestrogenic stimulation (Kato et al, 1995). MEK and ERK levels are unchanged in LCC1 
and LCC9 cells, as previously reported (Kuske et al, 2006). Akt activation was also studied 
in this cell line model and Akt phosphorylation (Ser473) was shown to be increased in 
LCC1 and LCC9 cells suggesting this pathway may be important in conferring resistance. 
The Akt pathway is discussed in detail in Chapter 6.  
 
As previously reported (Kuske et al, 2006), LCC1 and LCC9 cells retain functional ERα 
expression since oestrogen still reduces ERα protein levels. It has been proposed this is due 
to proteasomal degradation, a process known to limit oestrogen signalling (Nawaz et al, 
1999). In addition, basal ERα expression is increased in LCC1 cells but less so in LCC9 
cells in comparison to the parental MCF-7 cell line as previously shown (Kuske et al, 
2006). Tamoxifen did not reduce ERα expression in any of the three cell lines whilst ICI 
182,780 reduced ERα levels in MCF-7, oestrogen independent LCC1 and resistant LCC9 
cell lines. These results suggest that oestrogen is still binding and activating the ERα in 
resistant cell lines as demonstrated by ERα protein turnover and that expression of this 
receptor is still regulated by anti-oestrogens in a manner similar to that of the parental cell 
line.  
Phosphorylation of ERα at the Ser118 was not elevated in resistant LCC9 cells and appears 
to be slightly reduced in LCC1. This indicates that endocrine resistance in this cell line 
model is not mediated by increased activation at the serine residue. The other main ERα 
phosphorylation site (Ser167) was also studied and the results are discussed in Chapter 6.  
    
Oestrogen and its receptor have also been shown to regulate cell cycle machinery (Planas-
Silva et al, 1997) therefore it was important to determine whether cell cycle is altered in 
endocrine resistance. Under control conditions in the absence of oestrogen, MCF-7 cells 
arrest in G0/G1 phase of the cell cycle as previously reported (Lukyanova et al, 2009). 
Oestrogen stimulation significantly increases the percentage of cells in S-phase of cell 
cycle which was attenuated to some extent in the presence of tamoxifen and fully 
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following ICI 182,780 treatment. These results are in agreement with previously published 
results (Prall et al, 1997; Abdelrahim et al, 2002; Hodges et al, 2003; Riggins et al, 2005).  
In contrast to the parental cell line, the percentage of LCC1 and LCC9 cells at the S-phase 
was markedly increased in relation to MCF-7 cells. This supports the cellular proliferation 
results which show increased growth rates of LCC1 and LCC9 cells in the absence of 
ligand stimulation. Furthermore, oestrogen stimulation did not induce cell cycle 
progression as observed in parental MCF-7 cells. In fact, the percentage of LCC1 cells in 
S-phase is slightly reduced post-treatment presumably due to the superfluous amount of 
ligand interfering with the cell cycle machinery. LCC1 and LCC9 cells also differ in their 
response to ICI 182,780 treatment since this anti-oestrogen induces G0/G1 arrest in LCC1 
but not in resistant LCC9 cells as previously reported (Riggins et al, 2005).   
Herceptin and 2C4 had little effect in the cell cycle of all three cell lines. Herceptin is 
thought to inhibit cell cycle progression by up-regulating expression of the p27KIP1 family 
of cyclin inhibitors thereby promoting arrest at the G0/G1 phase. In vivo studies, however 
have observed no herceptin-mediated cell cycle arrest in xenografts suggesting herceptin 
promotes transient cell cycle arrest (Warburton et al, 2004; Lane et al, 2000; Sliwkowski et 
al, 1999). The effects of herceptin on cell cycle were expected to be limited since MCF-7, 
LCC1 and LCC9 cells do not overexpress HER2. However, 2C4 which does not require 
HER2 overexpression, also has little effect suggesting that blocking HER2 heterodimer 
formation does not play a part in cell cycle regulation in these cell lines.  
Oestrogen has been shown to promote G1 progression by activating cyclin D1 which in 
turn activates Cdk4 and Cdk2 which regulate G1-S transition (Prall et al, 1997). Murray et 
al (2005) have reported that cyclin D1 expression is elevated in mammary tumours versus 
normal mammary tissue whilst Hodges et al (2003) observed that this cell cycle regulator 
is often upregulated in tamoxifen resistant breast cancer cells. Hence, cyclin D1 may be 
important in promoting cell cycle transition in oestrogen-independent LCC1 and resistant 
LCC9 cell lines in the absence of ligand stimulation. 
 
 
The apoptotic response of these cells to a variety of treatments was also established in 
LCC1 and LCC9 cells. Apoptosis levels were determined by measuring the levels of PARP 
cleavage. The PARP enzyme is implicated in DNA damage and repair mechanisms. 
During apoptosis, PARP is cleaved by caspase- 3 thereby generating an 85kDa fragment 
from the native 116 kDa sized protein (Oliver et al, 1998). Most drug treatments induced 
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apoptosis in LCC1 cells, particularly tamoxifen, herceptin and 2C4. In resistant LCC9 
cells, on the other hand, apoptosis is markedly reduced. Reduced apoptotic drive in LCC9 
has been linked to the expression of the transcription factor interferon regulator factor-1 
(IRF-1). This tumour suppressor is downregulated in LCC9 cells and stable transfection of 
dominant-negative IRF-1 eliminated ICI 182,780-mediated apoptosis in MCF-7 cells 
(Bouker et al, 2004). Furthermore, the nuclear factor κB (NFκB) transcription factor 
family has also been implicated in the apoptotic control of this MCF-7-based cell line 
model. The expression of two members of this nuclear factor family, the p65 subunit and 
the upstream regulator IκB, is elevated in the resistant LCC9 cell line and inhibition of 
these proteins restored ICI 182,780 sensitivity in these cells (Riggins et al, 2005). 
 
Finally, the cellular motility and invading ability of these cell lines was also investigated. 
Migration was analysed in the presence of three difference extracellular matrix proteins, 
collagen, fibronectin and vitronectin. Collagen was the most effective in promoting cellular 
migration in all three cell lines whilst vitronectin had little effect. However, in the presence 
of collagen and fibronectin, MCF-7 cells appear to be the most migratory of the three cell 
lines. This is supported by their phenotypes and growth characteristics since the parental 
cell line grows as a flat sheet of cells, whilst LCC1 and LCC9 cells tend to form “clumps”. 
Nevertheless, previous studies have reported an association between increase migration 
and tamoxifen resistance (Castro et al, 2005; Hiscox et al, 2006). 
Invasion, on the other hand, is slightly increased in oestrogen-independent LCC1 cells and 
significantly elevated in endocrine resistant LCC9 cells in contrast to the MCF-7 cell line. 
This is in agreement with previously published results which show tamoxifen resistant 
MCF-7 cells display a loss of cell-cell junctions and overexpress proteins involved in 
epithelial to mesenchymal transition an important step in progression and metastasis of 
breast cancer (Ree et al, 1998; Hiscox et al, 2006; Planas-Silva et al, 2005).  
 
      






EGF Receptor Family: Oestrogen Regulated Transcriptional 
























A number of studies have previously shown that oestrogen potently inhibits HER2 
transcription of ER-positive cell lines such as ZR-75-1, T47D and MCF-7 cells (Dati et al, 
1990; Read et al, 1990; Russell et al, 1992). Furthermore, EGF treatment also suppresses 
HER2 protein expression but this is a result of post-translational alterations rather than at the 
transcriptional level (Antoniotti et al, 1994). 
 
Expression of ERα is necessary and sufficient for oestrogen mediated HER2 repression and 
this mechanism may be reversed by the addition of anti-oestrogens such as tamoxifen and 
ICI 182,780 (Russell et al, 1992; Taverna et al, 1994). The effect of oestrogen on HER2 
expression is mediated by a 409 bp region found within the first intron of the HER2 gene 
(Bates et al, 1997) and in vitro footprinting revealed that there are four transcription factor 
binding sites in this oestrogen-suppressible enhancer (Newman et al, 2000). The activator-
protein 2 (AP-2) family of transcription factors consisting of five members (AP-2α; AP-2β; 
AP-2γ; AP-2δ; AP-2ε) is one of such transcription factors able to bind to HER2. 
Additionally, this protein family has been shown to drive HER2 overexpression often 
present in breast cancer cases (Eckert et al, 2005). The binding sites for AP-2 proteins are 
located within the transcription binding sites described by Newman et al (2000) suggesting 
the AP-2 family is required for oestrogenic suppression (Orso et al, 2004). ERα mutational 
analysis has shown that the DNA binding domain alone did not repress HER2 transcription. 
However, removal of the C-terminus containing the AF2 domain completely abrogated 
HER2 inhibition (Newman et al, 2000). This domain is important in activation following 
oestrogen stimulation and crucial in initiating the assembly of the transcriptional machinery. 
These results indicate that the regulation of HER2 repression by oestrogen essentially occurs 
off the DNA hence it is unlikely that the AP-2 proteins are required in this mechanism 
(Newman et al, 2000).  
 
The region of ERα involved in the oestrogenic repression of HER2 is also important in 
recruiting p160 co-activators to the receptor in preparation for transcriptional activity 
suggesting that this cofactor family may be important in regulating this mechanism. This 
observation led to Newman et al (2000) proposing a model whereby activated ERα and 
HER2 enhancer compete for binding of p160 co-activators leading to HER2 inhibition. 
They found that SRC-1 transfection into ZR75-1 breast cancer cell lines relieved 
repression and restored HER2 enhancer activity. On the other hand, the two other co-
activators TIF2 and AIB1 did not show significant effects (Newman et al, 2000). 
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According to these results, the p160 co-activator family is important in oestrogen mediated 
HER2 transcriptional repression hence the role of these proteins in our cell line model was 
established.  
 
4.1 Oestrogen Mediated Repression of HER Receptors 
   
4.1.1 Oestrogen Downregulation of HER2 is reduced in endocrine resistant 
cells 
In MCF-7 and LCC1 cells, oestrogen treatment for 48h leads to a marked reduction in HER2 
expression at the protein level which can be reversed by the addition of the anti-oestrogen 
ICI 182,780 (Figure 4.1a). Further analysis reveals that this is also observed at the 
transcriptional level (Figure 4.1b) since HER2 mRNA levels are significantly reduced in the 
presence of oestrogen (MCF-7 p-value 0.001; LCC1 p-value 0.007). In resistant LCC9 cells 
oestrogen mediated HER2 repression is far less prominent (Figure 4.1).  
The effects of oestrogen are not only observed at the receptor level. Activation of the 
MEK/ERK pathway is also reduced after oestrogen treatment in MCF-7 cells and to a small 
extent in LCC1 cells. Phospho-ERK levels are particularly reduced in MCF-7 (Figure 4.2). 
Basal levels of MEK and ERK are not altered following oestrogenic stimulus. As previously 
observed for HER2 protein expression, the MEK/ERK pathway remains unchanged in 
LCC9 cells (Figure 4.2).  
Oestrogen downregulation of MEK/ERK pathway is likely to be a result of the upstream 
HER2 repression. Membrane receptors such as HER2 are able to activate a variety of 
downstream pathways including the MEK/ERK pathway hence reducing HER2 protein 
expression is likely to affect phosphorylation of these downstream effectors. This is 




















Figure 4.1 Oestrogen downregulates HER2 in MCF-7 and LCC1 but minimally in LCC9 cells. 
Cells were treated with E2 (1nM) for 48h. Western Blotting was used to measure protein expression 
(a) (representative of three independent experiments) whilst mRNA levels were determined by 
quantitative RT-PCR (b). Each column presents mean of quadruplicate RT-PCR analysis for each 
sample relative to actin expression. Error Bars= SD. Statistical significance noted for oestrogen 















Figure 4.2 Effects of oestrogen on MEK/ERK pathway. Western blot analysis of pathways 
downstream from HER2. Results representative of three independent experiments.   
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4.1.2 Oestrogen Regulation of EGFR, HER3 & HER4 
Following the observation that oestrogen was able to repress HER2 transcription it was 
important to determine whether this effect is restricted to HER2 or if other members of the 
EGF receptor family are also affected.  
EGFR mRNA levels are unchanged in the presence of oestrogen in MCF-7, LCC1 and 
LCC9 cells (Figure 4.3). Protein expression could not be measured since EGFR protein is 
not detected by western blotting in these cells as previously shown in Chapter 3. Unlike 
EGFR, HER3 mRNA expression is also downregulated in the presence of oestrogen in 
MCF-7 and LCC1 cells, though the latter does not reach significance (Figure 4.4b). This is 
also observed at the protein level (Figure 4.4a). As previously observed for HER2, HER3 









Figure 4.3 EGFR transcriptional regulation. Expression of EGFR mRNA by quantitative RT-
PCR. Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to 










Figure 4.4 Oestrogen Regulation of HER3 Expression. (a) Protein expression was measured by 
western blotting. Results representative of three independent experiments (b) HER3 mRNA levels 
were determined by quantitative RT-PCR. Each column presents mean of quadruplicate RT-PCR 
analysis for each sample relative to actin expression. Error Bars= SD. Statistical significance noted 
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Similarly to HER2 and HER3, HER4 expression is downregulated by oestrogen in MCF-7 
and LCC1 cells (Figure 4.5 & 4.6). MCF-7 cells express very low levels of HER4 hence 
protein was not detectable by western blotting. Nonetheless, oestrogen does reduce HER4 
mRNA levels in MCF-7 suggesting that this may also be the case at the protein level. 
HER4 transcription in LCC9 cells is not responsive to oestrogen as previously observed 
(Figure 4.5 & 4.6).  
 
These results show that not only does oestrogen mediate HER2 transcription it also affects 
the transcription of HER3 and HER4. Receptor expression is downregulated by oestrogen 
in endocrine sensitive MCF-7 and LCC1 cells but this is lost in the resistant LCC9 cells. 
This suggests that transcriptional regulation of these receptors is altered in endocrine 











Figure 4.5 Oestrogen mediated transcriptional regulation of HER4. HER4 mRNA levels were 
determined by quantitative RT-PCR. Each column presents mean of quadruplicate RT-PCR analysis 
for each sample relative to actin expression. Error Bars= SD. Statistical significance noted for 








Figure 4.6 HER4 protein expression is downregulated by oestrogen. Protein expression was 
measured by western blotting. Results representative of three independent experiments. 
HER4
Actin
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4.2 HER2 Transcriptional Control: Role of ERα and SRC-1 
Previous studies have demonstrated oestrogen mediated HER2 repression in several human 
breast cancer cell lines including MCF-7 which is reversed in the presence of tamoxifen 
and ICI 182,780 and the data presented here is in agreement with this (Dati et al, 1990; 
Read et al, 1990). HER2 transcriptional repression by oestrogen appears to be mediated by 
a region within the first intron of HER2 with the ability to act as an oestrogen-suppressible 
enhancer (Hurst et al, 1997). Reports have also shown that the AF2 domain of ERα is 
essential for HER2 transcriptional suppression (Newman et al, 2000). Furthermore, 
overexpression of SRC-1, a member of the p160 coactivator family, appears to relieve 
oestrogen repression in a dose dependent manner (Newman et al, 2000). Following these 
observations they proposed a model whereby ERα (through the AF2 domain) and HER2 
enhancer compete for SRC-1. In the presence of oestrogen, SRC-1 preferentially binds to 
ERα consequently reducing HER2 transcription whilst in anti-oestrogenic conditions, 











                  Figure 4.7 Proposed model for HER2 transcriptional regulation.  
 
 
In our three step cell line model for endocrine resistance, the oestrogenic effects on 
transcription of HER2, HER3 and HER4 appear to differ between endocrine sensitive and 
endocrine resistant cell lines. According to previously published data, SRC-1 and ERα are 
important in the control of this mechanism hence the interactions between these two 
















     
 
 
      
 
 
Figure 4.8 SRC-1 binding to ERα gene is observed in MCF-7 & LCC1 but not in LCC9 cells.  
Oestrogen induced SRC-1 recruitment to ERα promoter was determined by ChIP after 10 min 
treatment. Data was normalized to basal levels and presented as the mean ±SE for three independent 
experiments. 
 
ChIP experiments performed in our laboratory by Dr Catherine Naughton have revealed 
that oestrogen triggered SRC-1 recruitment to the ERα gene is lost in LCC9 cells (Figure 
4.8). In MCF-7 and LCC1 cells on the other hand, SRC-1 is recruited as part of the ERα-
cofactor transcriptional complex after oestrogen treatment (Figure 4.7).  
This data in combination with previously published results were used to outline a potential 
model for oestrogen mediated transcriptional repression of HER2 whereby in MCF-7 and 
LCC1 cells oestrogen treatment leads to ERα sequestering SRC-1 from HER2 enhancer 
consequently reducing transcription (Figure 4.9). In LCC9 cells SRC-1 does not appear to 
be recruited to ERα and is therefore able to bind to the promoter region of HER2. This 
model would explain why HER2 mRNA and protein levels are reduced in MCF-7 and 











Figure 4.9 Proposed model for oestrogen-mediated HER2 transcriptional repression in 
endocrine resistance. In MCF-7 and LCC1 cells oestrogen induces SRC-1 recruitment to ERα and 
is therefore no longer available to bind to the HER2 promoter. In LCC9 cells, on the other hand, 












































4.2.1 ERα RNAi Reverses Oestrogen-mediated HER2 Downregulation 
According to the proposed model, HER2 repression is a result of competition between ERα 
and HER2 enhancer for SRC-1. If this is the case reducing ERα protein by siRNA would 
effectively restore HER2 protein expression in the presence of oestrogen. ERα RNAi 
restores HER2 protein levels to control levels in MCF-7 and LCC1 thereby reversing the 
effects of oestrogen. There is also a slight increase in HER2 protein expression in LCC9 
cells (Figure 4.10). These results support the proposed model for HER2 transcriptional 
regulation however it is possible that ERα RNAi is having secondary effects such as 










Figure 4.10 ERα RNAi reverses oestrogen repression of HER2 in MCF-7 cells. Western Blot 
analysis of HER2 protein expression following treatment with ERα siRNA. Results representative of 
four independent experiments.  
 
4.3 Loss of SRC-1 mediated HER2 Regulation in Endocrine Resistance 
 
4.3.1 SRC-1 is not a limiting factor in resistant LCC9 cells 
The proposed model for HER2 regulation suggests that in LCC9 cells oestrogen does not 
suppress HER2 mRNA and protein levels as SRC-1 is not as readily recruited to ERα as in 
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This implies SRC-1 is a limiting factor in MCF-7 
and LCC1 cells. Reducing the amount of SRC-1 
should mimic oestrogen action and help establish 
whether oestrogen-mediated HER2 repression is 
lost in LCC9 simply due to higher SRC-1 
availability.        
SRC-1 RNAi does not restore HER2 protein 
repression by oestrogen in LCC9 cells (Figure 
4.11), suggesting that this mechanism is not only 
dependent on SRC-1 availability.  These results 
mirror the conclusions of the study by Naughton et 
al, 2007 where transcription in LCC9 cells was 
found to be independent of p160 co-activators.  
 
4.3.2 SRC-1 RNAi mimics E2 downregulation of HER2 in MCF-7 cells 
The above results showing SRC-1 RNAi does not restore oestrogen mediated HER2 
transcriptional repression in LCC9 cells highlight that this cofactor may not be as 
important as first proposed. It was therefore crucial to determine the precise role of SRC-1 
in MCF-7 and LCC1 cells. According to the model, SRC-1 is sequestered by ERα after 
oestrogen treatment in these cells hence effectively the amount of SRC-1 protein available 








Figure 4.12 SRC-1 RNAi mimics oestrogen downregulation of HER2 in endocrine sensitive 
MCF-7 cells. Western blot analysis following treatment with SRC-1 RNAi in the absence of 
oestrogen. Results representative of three independent experiments. 




E2                              - +            - - - +            - -
SRC-1 RNAi     - - +             - - - +            -





E2                         +          +            +
SRC-1 RNAi       - +            -
Neg RNAi           - - + 
LCC9 
Figure 4.11 SRC-1 RNAi does not 
restore oestrogen mediated HER2 
repression in LCC9 cells. Western blot 
analysis following treatment with SRC-1 




If the availability of SRC-1 is the determining factor in regulating HER2 transcription of 
MCF-7 and LCC1 cells then oestrogen treatment and SRC-1 RNAi should produce similar 
results. SRC-1 RNAi treatment in the absence of oestrogenic stimulus mimics oestrogen 
treatment in MCF-7 cells (Figure 4.12). This however does not appear to be the case in 
LCC1 cells. This data suggests that the proposed mechanism for HER2 regulation appears 
to apply to MCF-7 and in part to LCC1 cells. The involvement of other p160 family 
members in the resistant cell line was considered next.  
 
4.4 p160 Co-activators & their Role in HER2 Regulation 
   
4.4.1 p160 Co-activators & Endocrine Resistance 
The well characterized coactivator family consists of three members: SRC-1, TIF2 and 
AIB-1. These cofactors bind to the receptors in a ligand dependent manner and increase the 
receptors ability to activate gene transcription (McKenna et al, 1999).            
The expression levels of the three p160 co-activators were previously measured in this cell 
line model (Naughton et al, 2007). SRC-1 and TIF2 protein levels are similar in MCF-7 
and LCC1 cells. LCC9 cells, on the other hand appear to have lower SRC-1 and TIF2 
expression in comparison to the other two cell lines. AIB1 protein expression is lower in 
LCC1 and lower still in LCC9 in relation to parental MCF-7 cells (Naughton et al, 2007). 
These results indicate that endocrine resistant LCC9 cells consistently express lower levels 
of p160 co-activators than endocrine sensitive cells.   
Protein expression of p160 co-activators appears to differ between endocrine sensitive and 
endocrine resistant cell lines suggesting their role may be altered in LCC9 cells. Previous 
studies within our laboratory have determined the effects of SRC-1, TIF2 and AIB1 RNAis 
on cellular growth of MCF-7, LCC1 and LCC9 cells (Naughton et al, 2007). They 
demonstrated that all three co-activator RNAis induced similar growth responses therefore 
the data was presented as the mean of all cofactor RNAis. Cell proliferation is significantly 
reduced after siRNA treatment in MCF-7 and LCC1 whilst the growth of LCC9 cells 
remains unaffected. These results suggest that cofactor requirement and expression is 






4.4.2 Role of TIF2 & AIB1 
Previous results have shown that SRC-1 is important in regulating HER2 transcription of 
MCF-7 cells but control of this mechanisms appears to change in oestrogen independent 
LCC1 and be effectively lost in resistant LCC9 cells. The p160 family as mentioned above 
share a number of similar structures and functional domains therefore it was important to 
determine the role of the other two members of this family, TIF2 and AIB1.  
 
4.4.2.1 TIF2 & AIB1 RNAis do not mimic E2 in downregulating HER2       
As previously shown SRC-1 RNAi mimics oestrogen in downregulating HER2 protein 
expression in MCF-7 cells. HER2 protein expression following TIF2 (Figure 4.13a) or 
AIB1 RNAi (Figure 4.13b) is not reduced as observed in the presence of oestrogen and is 
comparable to the control levels. Therefore, unlike SRC-1 RNAi, TIF2 and AIB1 RNAi 
treatment in the absence of oestrogen does not mimic oestrogenic repression of HER2 in 
MCF-7 cells.  This implies that this mechanism is dependent on SRC-1 activity but does 
















Figure 4.13 TIF2 & AIB1 RNAis do not mimic oestrogen in downregulating HER2 expression. 
Western blot analysis following treatment with TIF2 (a) & AIB1 (b) RNAis in the absence of 
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4.4.2.2 TIF2 & AIB1 RNAis: limiting factors in LCC9 cells 
It was first proposed that oestrogen mediated HER2 repression was not observed in LCC9 
cells since ER did not sequester SRC-1 leaving this cofactor free to bind to the enhancer 
region of HER2. According to this theory, HER2 transcription in LCC9 cells is unaffected 
as a result of unchanged SRC-1 availability. Yet mimicking oestrogen mediated SRC-1 
reduction by treating LCC9 cells with SRC-1 RNAi did not restore HER2 repression 
suggesting that control of this mechanism is perhaps altered in these cells.  
One possible explanation may include the remaining members of the p160 coactivator 
family as they have been shown to be highly homologous to SRC-1 (Nilsson et al, 2001). 
TIF2 and AIB1 did not restore HER2 repression after oestrogen treatment in LCC9 cells 
(Figure 4.14). This suggests p160 co-activators cannot individually restore oestrogen 








Figure 4.14 TIF2 & AIB1 RNAis do not restore oestrogen-mediated repression in resistant 
LCC9 cells. Western blot analysis following treatment with TIF2 (a) & AIB1 (b) RNAis in the 
presence of oestrogen. Results representative of five independent experiments. 
 
4.5 Redundancy & p160 Co-activator Family 
The p160 co-activators have similar structures and functional domains so it is not surprising 
that several studies have shown some level of redundancy between the members of this 
family (Nilsson et al, 2001; McKenna et al, 1999; Xu et al, 2003). Consequently it was 
important to consider redundancy in the mechanism being studied here. Individual 
coactivator RNAis are unable to restore oestrogen mediated HER2 repression in LCC9 cells 
however redundancy between the members of this family may account for the non effect. 
Double coactivator knockdowns should shed some light into role of this family in HER 


















4.5.1 SRC-1/TIF2 Double RNAi 
SRC-1 and TIF2 RNAis are efficient in significantly reducing protein expression. SRC-
1/TIF2 RNAi did not restore oestrogen mediated HER2 repression in LCC9 cells as HER2 
mRNA expression is unchanged between RNAi and negative (Figure 4.15). These 
experiments were performed in the presence of oestrogen including control samples. In 
MCF-7 and LCC1 cells, SRC-1/TIF2 RNAi does not appear to have a significant effect on 
HER expression (Figure 4.15).  It is important to note that these double knockout 
experiments were performed in the presence of oestrogen. This could account for the 
absence of HER2 transcriptional repression in MCF-7 cells following treatment with SRC-1 












Figure 4.15 SRC-1/TIF2 double RNAi does not restore oestrogen mediated HER2 repression in 
LCC9 cells. RNAi efficiency and effects on HER2 expression were measured by quantitative RT-
PCR. Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to 
actin expression. Error Bars= SD. Statistical significance noted for each treatment vs matched 
negative control (Student’s paired t-test *P<0.05; **P<0.01; ***P<0.001). 
 
4.5.2TIF2/AIB1 Double RNAi 
AIB1/TIF2 double RNAi treatment also did not restore HER2 repression in LCC9 cells 
despite RNAis significantly reducing AIB1 and TIF2 mRNA expression (Figure 4.16). In 
MCF-7 and LCC1 cells, HER2 expression is not altered by AIB1/TIF2 RNAi (Figure 4.16) 
though it is important to bear in mind TIF2 RNAi does not appear to be particularly 
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Figure 4.16 TIF2/AIB1 double RNAi does not restore oestrogen mediated HER2 repression in 
LCC9 cells. RNAi efficiency and effects on HER2 expression were measured by quantitative RT-
PCR. Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to 
actin expression. Error Bars= SD. Statistical significance noted for each treatment vs matched 
negative control (Student’s paired t-test *P<0.05; **P<0.01). 
 
4.5.3 SRC-1/AIB1 Double RNAi 
SRC-1/AIB1 double knockdowns are the only pair to significantly reduce HER2 mRNA 
expression in LCC9 cells suggesting that AIB1 and SRC-1 may be equally important in 
regulating HER2 in these cells (Figure 4.17). This data also indicates that HER2 
downregulation is achieved in LCC9 cells by interfering with co-activator expression 
hence the mechanism in these cells is in part regulated in a similar way to MCF-7 cells. 
Furthermore, HER2 expression was elevated in MCF-7 cells following treatment with 
SRC-1/AIB1 RNAi (Figure 4.17). This appears to also be the case in LCC1 cells though 
not significant which is likely to be a result of reduced protein knockdown by AIB1 RNAi. 
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Figure 4.17 SRC-1/AIB1 double RNAi appears to restore oestrogen mediated HER2 repression in 
LCC9. RNAi efficiency and effects on HER2 expression were measured by quantitative RT-PCR. 
Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to actin 
expression. Error Bars= SD. Statistical significance noted for each treatment vs matched negative 




Previous studies have suggested oestrogen potently inhibits HER2 transcription in ER-
positive cell lines such as MCF-7 (Dati et al, 1990; Read et al,1990; Russell et al, 1992). 
The results shown in this Chapter suggest that altered regulation of this mechanism may be 
important in conferring resistance as oestrogen does not downregulate HER2 protein and 
mRNA expression in resistant LCC9 cells. In addition to HER2, oestrogen also 
downregulated HER3 and HER4 expression in MCF-7 and LCC1 cells, yet similarly to 
HER2, this was not observed in resistant LCC9 cells. Expression of EGFR, on the other 
hand, did not appear to be affected by oestrogen. HER2 amplification or enhanced 
expression has been previously associated with increased growth rate and poor prognosis 
of breast cancer tumours (Yu et al, 2000). Oestrogen-independent LCC1 and endocrine 
resistant LCC9 cells do not overexpress this receptor unlike other anti-oestrogen resistant 
cell line models (Knowlden et al, 2003; Jordan et al, 2004). However, deregulated 
transcriptional control of HER2 may prove important in activating downstream signalling 
pathways which in turn may be play a part in conferring resistance. 
 
The expression of ERα was found to be necessary and sufficient for oestrogen mediated 
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found that the AF2 region of the oestrogen receptor was crucial in this regulatory 
mechanism as its removal effectively abrogated HER2 transcriptional inhibition. 
Furthermore, this ERα region is also important for p160 co-activators recruitment to the 
receptor ahead of transcriptional activity (Newman et al, 2000). Following these results a 
model was proposed whereby ERα and HER2 compete for p160 co-activator binding. 
Consequently, SRC-1 transfection was found to relieve oestrogen-mediated HER2 
repression in ZR75-1 cells (Newman et al, 2000). 
 
In line with this proposed model, ERα RNAi reversed the effects of oestrogen and restored 
HER2 protein expression back to basal levels in MCF-7 and LCC1 cells, even in the 
presence of 17β-oestradiol. Furthermore, SRC-1 RNAi alone mimicked oestrogen in 
downregulating HER2 protein expression suggesting this co-activator may be the limiting 
factor in MCF-7 cells. Previously published ChIP assays show that SRC-1 is not recruited 
to ERα in resistant LCC9 cells thus freeing SRC-1 to drive HER2 transcription (Naughton 
et al, 2007). This suggested HER2 expression in LCC9 is not reduced by oestrogen due to 
elevated SRC-1 availability as this cofactor may not be recruited to ERα. However, SRC-1 
depletion by RNAi did not restore oestrogen repression of HER2 expression indicating that 
in these cells SRC-1 may not be the limiting factor. The role of TIF2 and AIB1 was also 
determined but both these activators were found to not mimic oestrogen in the same way 
SRC-1 did and specific RNAi treatment also did not restored HER2 repression in the 
presence of oestrogenic stimulation.  
Redundancy has often been described in this co-activator family and is particularly evident 
in mouse studies (Nilsson et al, 2001; McKenna et al, 1999; Xu et al, 2003). Given that no 
single cofactor restored oestrogen driven HER2 inhibition in resistant LCC9 it was 
important to establish by double knockouts whether redundancy was a factor. AIB1/SRC-1 
double knockout significantly reduced HER2 transcription suggesting that the enhancer 
sequence in this gene is still responsive to p160 co-activator regulation. It also indicates 
that AIB1 may be involved in this mechanism despite its individual knockdown having 
little effect. AIB1 expression is essential in HER2-driven oncogenesis in mice (Fereshteh 
et al, 2008) and is often upregulated in tamoxifen resistant human breast cancers (Anzick 
et al, 1997; Torres-Arzayus et al, 2004). Oestrogen independence in LCC1 and endocrine 
resistant in LCC9 are not associated with increased AIB1 expression as previously 
observed by our group (Naughton et al, 2007). In fact, these cells appear to express lower 




A recent study by Hurtado et al (2009) have suggested that HER2 transcription is tightly 
regulated by paired box 2 gene product (PAX2) whose exact function was yet to be 
determined. PAX2 siRNA treatment in MCF-7 and ZR75-1 cells abrogated oestrogen 
mediated inhibition of HER mRNA and lead to elevated HER2 protein expression. 
According to their study, AIB1 also regulates HER2 transcription by promoting HER2 
transcription hence they suggest there is a stoichiometric balance between the repressor 
PAX2 and the co-activator AIB1 affecting binding and activation of HER2 (Hurtado et al, 
2009). This may explain why AIB1 siRNA in conjunction with SRC-1 siRNA reduced 
HER2 mRNA expression in LCC9 cells. 
 
A series of studies have shed further light onto the mechanisms regulating HER2 in 
mammary epithelial cells. A member of the forkhead/winged helix transcription factor 
family, the FOXP3 protein had been found to bind and repress the HER2 promoter (Zuo et 
al, 2007). Downregulation of the FOXP3 gene is commonly present in breast cancer 
tumours and directly correlates with HER2 expression (Karanikas et al, 2008; Zuo et al, 
2007). In addition, the Ets transcription factor PEA3 has also been implicated in HER2 
inhibition (Hurst et al, 2001). PEA3 expression has been associated with HER2 status in 
primary breast tumour samples (Fleming et al, 2004) and with a decrease in HER2-driven 
tumourigenesis in breast cancer cell lines (Xing et al, 2000).  Interestingly, PEA3 
expression has been found to be associated with SRC-1 expression and tumours positive 
for both proteins were at a higher risk of recurrence (Fleming et al, 2004). These results 
provide a link between two proteins with opposing effect on HER2 transcriptional 
regulation since SRC-1 is thought to promote HER2 expression whilst PEA3 inhibits this. 
Furthermore, increased levels of AP-2γ in relation to AP-2α expression was linked to 
oestrogen repression of HER2 despite both of them being equally effective activator of 
HER2 promoter (Orso et al, 2004). This emphasises that HER2 regulation may not only be 
dependent on certain proteins, it may also be determined by the stoichiometric balance 
between them. 
      
These studies together with the results presented here suggest that transcriptional 
regulation of the HER2 gene is mediated by a number of transcriptional factors (AP-2, 
PAX2, FOXP3 and PEA3) and co-regulators (SRC-1 and AIB1). These cofactors appear to 
promote HER2 transcription whilst the transcription factors are mostly inhibitory. This 
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suggests that stoichiometric balance between these proteins may be important and that 
different activation/inhibition mechanisms may be regulated by distinct transcription 
factors or co-factors. In tamoxifen resistant cell lines overexpressing HER2, PAX2 
expression is reduced whilst AIB1 expression is elevated (Hurtado et al, 2009). It is 
possible that a similar mechanism is at work in resistant LCC9 cells where no oestrogen-
mediated HER2 inhibition is observed. In our three-step MCF-7-based cell line model of 
endocrine resistance, SRC-1 and AIB1 cofactor expression are crucial in promoting HER2 
transcription. These factors may be displaced from the promoter or may be replaced by 
transcriptional inhibitors following oestrogen treatment thereby reducing HER2 
expression. This may not be the case in resistant LCC9 cells hence HER2 expression 
remains unaffected. A summary of proteins involved in HER2 transcriptional regulation is 














Figure 4.18 Summary of proteins involved in HER2 transcriptional activation and inhibition.     
HER2 promoter
Promoting Transcription:











HER Family Regulation and p160 Co-activator Family: Analysis 























   
Transcriptional regulation of the HER family members appears to be in part mediated by 
the p160 co-activator family as shown in Chapter 4. The data shown here and in previous 
studies (Newman et al, 2000) refers to work performed in breast cancer cell lines. 
Therefore, it was important to investigate further using primary tumour material. Breast 
carcinoma samples were kindly donated by Professor John Bartlett’s laboratory (Edinburgh 
Cancer Research Centre) and have been extensively used in a number of different studies. 
(Kirkegaard et al, 2007; Kirkegaard et al, 2005; Cannings et al, 2007; Tovey et al, 2005; 
McGlynn et al, 2009).  
Immunohistochemical staining was performed for SRC-1 as this co-activator appears to be 
the crucial member of the p160 family in terms of HER transcriptional regulation. These 
tissue microarrays (TMAs) have also been previously stained for AIB1 (Kirkegaard et al, 
2007) and HER1, 2 & 3 (Tovey et al, 2005) thus it was possible to analyse SRC-1 
expression in relation to these markers.    
 
  
5.1 Clinical & Pathological Properties 
A total of 402 breast carcinomas samples were collected between 1989 and 1999. Tissue 
microarrays were constructed containing triplicate samples of tumour areas selected from 
each individual block by a pathologist. These TMAs have been used in a variety of studies 
consequently reducing the number of samples available for SRC-1 immunohistochemical 
staining. Some cases were also excluded due to loss of core or the presence of insufficient 
tumour material. Therefore, not all of the 402 breast carcinoma samples were included in 
the analysis of SRC-1 staining. A total of 251 samples were available for SRC-1 staining. 
This series consisted of ERα-positive cases only. Patients were treated with tamoxifen for a 
median duration of 5 years (varying between 6 months and 18 years) and followed up for a 








     
 









Table 5.1 Clinical & Pathologic Tumour Variables. These are in reference to the tumours     
stained with the SRC-1 antibody only.  
 
 
5.2 SRC-1 Protein Expression 
SRC-1 protein expression was evaluated in 206 of 251 (82.1%) breast carcinomas. SRC-1 
protein expression was confined to invasive breast carcinoma cells with no staining of 
normal breast epithelial cells (Figure 5.1). SRC-1 protein expression was primarily 
localised in the nuclei of tumour cells although weak staining was also observed in the 
cytoplasm. The median SRC-1 histoscore was 150. In subsequent analysis, SRC-1 
histoscores above the median histoscore (upper quartile) were categorized as high 













   0                                                    119/251                             47.3 
 1-3                 65/251    25.9 
  4+                 40/251    15.8 
Grade 
  1                 57/251    22.7 
  2               112/251    44.5 
  3                 26/251    23.8 
Size (mm) 
  T1 (<20)                93/251     37 
  T2 (20-50)              126/251        50.1 





















Figure 5.1 Photomicrographs of immunohistochemical staining in breast carcinomas with 
SRC-1 antibody. SRC-1 protein was mainly detected in the cellular nucleus (A). Breast tumours 










Figure 5.2 Histogram depicting distribution of SRC-1 histoscores in breast cancer patients 
used in this study.  
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5.3 SRC-1 Expression & Known Prognostic Factors    
The expression of the SRC-1 co-activator was then compared to known prognostic factors 
such as nodal status, tumour grade and size. The Bloom-Richardson grading scheme was 
used to determine tumour grade in these breast carcinomas (Meyer et al, 2005). This 
system takes into account three morphologic features: tumour tubule formation, mitotic 
activity and nuclear pleomorphism. The resulting scale is divided into three categories: low 
grade (well differentiated tumour), intermediate grade (moderately differentiated tumour) 
and high grade (poorly differentiated tumour). There appears to be no association between 
SRC-1 and tumour grade (Table 5.2). 
The tumours were also categorized according to nodal status (number of positive nodes) 
into four categories: 0, 1-3 and 4+. Similarly to tumour grade, there appears to be no 
correlation between SRC-1 protein expression and nodal status (Table 5.2). Moreover, 
there was no association between tumour size (3 categories: <20 mm; 20-50 mm; >50 mm) 
and SRC-1 expression (Table 5.2).  
 




  SRC-1 Positive  
 No. of 
Patients/Tumours 
% Within Subgroup p value 
Tumour Grade    
I 17 24.6 0.683 
II 31 23.8 0.688 
III 20 29.4 0.524 
Nodal Status    
0 19 19.99 0.179 
1-3 42 29.6 0.092 
4+ 5 0.29 0.170 
Tumour Size (nm)    
< 20 20 21.5 0.184 
20-50 16 24.2 0.143 
> 50 12 29.3 0.233 
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5.4 SRC-1 Expression & Patient Outcome     
The role of SRC-1 expression in regulating patients’ response to tamoxifen and relapse 
was also determined. After 5 years tamoxifen treatment, patients expressing higher SRC-1 
levels appear to have reduced response to treatment. This is only a trend as the p-value is 
far from reaching significance (p=0.178) (Figure 5.3a). Furthermore, SRC-1 expression 
had no effect at all on the overall survival of these patients (p=0.367) as can be observed 
by the fact that the two plots for high and low SRC-1 expression are practically 












Figure 5.3 Kaplan-Meier Survival Curves showing cumulative disease-free survival between 
SRC-1 positive and negative patients. (a) Cumulative disease-free survival in this case refers to 
breast cancer disease relapse whilst on tamoxifen. (b) Breast Cancer relapse cases in relation to 
follow-up (years). P-values obtained by log-rank testing for differences in cumulative disease-free 
survival between the two groups.  
 
5.5 Association between SRC-1 and AIB1 Expression 
As previously published (Kirkegaard et al, 2007), high AIB1 expression was linked to 
relapse whilst on tamoxifen treatment. Once again this appears to be just a trend as the p-
value fails to reach significance (p-value=0.141) (Figure 5.4a). On the other hand, high 
AIB1 expression is significantly associated with reduced survival (p-value=0.012) as 
previously published (Figure 5.4b).  
Following evidence that AIB1 may play a part in patient outcome, the expression of this 
co-activator was compared to SRC-1 expression. There was no direct correlation between 








expression appear to be more likely to relapse whilst on tamoxifen treatment. However, 
this is not significant (p-value=0.124) (Figure 5.5a).  
With regards to overall survival high SRC-1/AIB1 expression appears to be linked to lower 
survival (p-value=0.036). This value is most probably significant due to the effect of AIB1 











Figure 5.4 Kaplan-Meier Survival Curves were plotted to determine the effects of AIB1 
positivity in breast cancer patients. Cumulative disease-free survival in reference to time on 
tamoxifen treatment (a) and follow-up (years) (b). P-values obtained by log-rank testing for 












Figure 5.5 Kaplan-Meier Survival Curves demonstrating cumulative disease-free survival 
differences between patients positive and negative for SRC-1 & AIB1. As described before, 
cumulative disease-free survival was established in relation to time on tamoxifen treatment (a) and 
follow-up (year) (b). P-values obtained by log-rank testing for differences in cumulative disease-



















5.6 p160 Coactivator & HER Receptor Expression 
As shown by Tovey et al (2005), patients expressing more than one HER family member 
are linked to increased relapse on tamoxifen and reduced survival (Figure 5.6). 
Furthermore as shown in Chapter 4, SRC-1 may be important in regulating HER receptor 
expression hence it was important to determine the relationship between receptors and 
SRC-1 expression. There appears to be no correlation between SRC-1 & AIB1 expression 
and HER2 amplification (p-values=1 & 0.129 respectively). Moreover, the expression of 
SRC-1 or AIB1 did not correlate with the expression of at least one of the HER1-3 











Figure 5.6 HER receptor expression and response to tamoxifen (a)/ overall survival (b). Kaplan-
Meier survival curves determining cumulative disease-free survival differences between patients 
positive and negative for Her1-3 (positive for one of the receptors). P-values obtained by log-rank 
testing for differences in cumulative disease-free survival between the two groups. 
 
 
The effects of high HER receptor and co-activator expression on tamoxifen response and 
overall survival were also assessed. Overexpression of SRC-1 or AIB1 in HER1-3 positive 
tumours did not significantly affect patients’ response to tamoxifen treatment (p-
value=0.473 & 0.573 for SRC-1 and AIB1 respectively) though SRC-1/HER1-3 
overexpression appears to have a protective effect against tamoxifen relapse for the first 5 
years of treatment (Figure 5.7a/b). SRC-1 and AIB1 overexpression in HER1-3 positive 
tumours also did not affect the overall survival in relation to follow-up (years) (p-values= 






















Figure 5.7 Kaplan-Meier survival curves determining cumulative disease-free survival 
differences (vs time on tamoxifen) between SRC-1/HER 1-3 (A) & AIB1/HER 1-3 (B) 
overexpressing tumours in relation to other tumours. Negative in this case refers to SRC-1 
staining. p-values obtained by log-rank testing for differences in cumulative disease-free survival 
between the two groups.  
 











Figure 5.8 Kaplan-Meier survival curves determining cumulative disease-free survival 
differences (vs follow-up (years)) between SRC-1/HER 1-3 (A) & AIB1/HER 1-3 (B) 
overexpressing tumours in relation to other tumours. Negative in this case refers to SRC-1 
staining. p-values obtained by log-rank testing for differences in cumulative disease-free survival 





























As shown in Chapter 4, transcriptional regulation of the epidermal growth factor receptor 
family is altered in endocrine resistant cell lines. This mechanism appears to be mediated by 
p160 co-activators, particularly SRC-1 and AIB1. Oestrogen inhibits p160 co-activator 
mediated transcription of HER2, HER3 and HER4 receptors in endocrine sensitive cells 
however this is not observed in resistant LCC9 cells. In the presence of oestrogenic 
stimulation, SRC-1 preferentially binds to ERα hence it is not available to stimulate receptor 
transcription. This is not observed in the endocrine resistant cell line. 
 
The results obtained in the MCF-7, LCC1 and LCC9 cells suggest there may be a direct link 
between p160 co-activators and epidermal growth factor receptor expression. Furthermore, it 
also highlights that this mechanisms may be important in conferring endocrine resistance. In 
order to investigate this further, breast cancer patient tissue was used thereby giving a 
clinical perspective. Previous studies (Newman et al, 2000) together with the results 
presented in Chapter 4 have shown SRC-1 co-activator is of particular interest hence this 
protein was the focus of immunohistochemical analysis. The breast carcinoma samples 
donated by Professor John Bartlett have been previously used in a variety of studies and have 
been immunohistochemically stained for AIB1 and HER1/ 2/3. Consequently, it was 
possible to compare the SRC-1 results with the previously published results. 
 
There appears to be no association between SRC-1 and prognostic factors such as tumour 
grade, tumour size and nodal status. This is in contrast to previous reports which suggest that 
SRC-1 is linked to nodal positivity (Fleming et al, 2004) and reduced tumour size (Green et 
al, 2008). Furthermore, elevated SRC-1 expression following 5 year tamoxifen treatment 
was present in patients with reduced response rates (not significant) but did not affect overall 
patient survival. Recent studies have reported conflicting results in relation to SRC-1 and 
patient survival. Redmond et al (2009) report that SRC-1 is a strong predictor of reduced 
disease-free survival whilst Green et al (2008) suggest high SRC-1 expression is a marker 
for longer overall and disease-free survival. However, most of the available literature 
supports the view that SRC-1 expression is negatively associated with overall survival and 
directly associated with disease recurrence and endocrine resistance (Scott et al, 2007; Myers 
et al, 2004; Fleming et al, 2004; Myers et al, 1998). Despite not achieving statistical 




Previous immunohistochemistry analysis using AIB1 antibody in this breast cancer tumour 
microarray (Kirkegaard et al, 2007) has revealed no association between the AIB1 
expression and relapse during tamoxifen treatment or overall survival. However, there does 
appear to be a trend suggesting that high AIB1 expression was associated with development 
of tamoxifen resistance despite not reaching statistical significance. The results show here 
appear to indicate that AIB1 expression is strongly associated with reduced disease-free 
survival (p=0.012). This is supported by a number studies indicating that AIB1 expression is 
elevated in mammary malignant tissue (Hudelist et al, 2003; Henke et al, 2004; List et al, 
2001) and it is linked to short term disease free survival (Dihge et al, 2008). On the other 
hand, other groups report that AIB1 did not predict survival (Thorat et al, 2008), endocrine 
resistance (Murphy et al, 2002) nor is it linked to any clinico-pathological factors (Iwase et 
al, 2003). 
The association between AIB1 and SRC-1 expression was also established. AIB1/SRC-1 
positive tumours are not associated with relapse during tamoxifen treatment yet patients 
expressing high levels of the two isoforms do appear to have reduced disease-free survival. 
There was no significant association between expression of these two co-activators in 
contrast to the findings by Redmond et al (2009) which have recently observed that SRC-1 
and AIB1 expressions are significantly linked. This is probably a reflection of higher 
numbers of tumours available in comparison to the study presented in this chapter. 
      
The interaction of EGF receptor family and p160 co-activators was also investigated. As 
previously shown by Tovey et al (2005) HER1-3 positive breast tumours are more likely to 
become resistant to tamoxifen treatment. Conversely, HER1-3 expression did not affect 
overall patient survival. According to results presented in Chapter 4 there may be a 
correlation between p160 co-activator and HER1-3 expression. However, there was no 
correlation between AIB1/SRC-1 and HER1-3 expression. AIB1/HER1-3 and SRC-1/HER1-
3 expressions did not alter tumour’s response to tamoxifen treatment and overall disease-free 
survival. This is surprising considering is has been previously published that high AIB1 
expression in tumours expressing one or more of HER1, HER2 or HER3 is linked to an 
increased risk of relapse whilst on tamoxifen treatment (Kirkegaard et al, 2008). This 
discrepancy is probably a reflection of the reduced number of tumours analysed in this study 
in comparison to the work performed by Kirkegaard et al, 2008. Furthermore, there appears 
to be no association between SRC-1/AIB1 expression and HER2 amplification. These results 
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suggest there may not be such a straightforward link involving the EGF receptor family and 
p160 co-activators. Nevertheless, a positive correlation between SRC-1 and AIB1 expression 
and HER2 status has been observed by a number of different groups suggesting there may be 
a positive association between them (Bouras et al, 2001; Myers et al, 2004; Fleming et al, 
2004; Thorat et al, 2008; Yamashita et al, 2008).  
      






























6.1 Akt and Endocrine Resistance 
Akt has been shown to play an important role in regulating cell proliferation (Kandel et al, 
1999) and cell cycle (Liang et al, 2002) whilst also promoting cell survival (Nicholson et 
al, 2002). Elevated Akt protein expression and Akt gene amplification are often observed 
in human cancers such as gastric adenocarcinomas, pancreatic, ovarian and breast cancers 
(Shtilbans et al, 2008).  
Akt activation is significantly associated with resistance to endocrine therapy and reduced 
disease-free survival (Tokunaga et al, 2006) and increased levels of phospho-Akt have 
been reported in Tamoxifen-resistant MCF-7 cells (Jordan et al, 2004). Furthermore, 
expression of constitutively active Akt protects against tamoxifen induced apoptosis 
(Campbell et al, 2001) and ionizing radiation (Liang et al, 2003). 
The aim of this chapter was to determine the role of the PI3K/Akt pathway in the 
development of endocrine resistance in our cell line model.  
 
6.1.1 Increased Akt phosphorylation in endocrine resistant cell lines 
Following the previous reports suggesting Akt is involved in conferring resistance it was 
important to determine whether this pathway plays a part in the cell line models (MCF-7, 
LCC1 and LCC9) used in this project.  
 
The expression levels of total Akt protein 
(antibody detects Akt 1, 2 and 3 isoforms) are not 
markedly different in the three cell lines (Figure 
3.1). Akt is phosphorylated at two sites, threonine 
308 (Thr308) and serine 473 (Ser473). Studies 
have shown that Ser473 may regulate 
phosphorylation of T308 and is required for full 
Akt activation (Scheid et al, 2002). Levels of 
Ser473 are elevated in LCC1 and LCC9 (Figure 
6.1) 
 
These results mirror the results published by Jordan et al (2004) and Yoo et al (2008) in 
different resistant cell line models.    
 
Figure 6.1. Western Blot analysis of Akt 
phosphorylation in parental MCF-7, 
oestrogen independent LCC1 and fully 
resistant LCC9 cells. Phospho-Akt 
antibody detects the three Akt isoforms. 















6.2 Akt Pathway: Potential activation of downstream proteins 
Elevated Akt phosphorylation is quite possibly an important mediator of acquired 
resistance in these cell line models however the precise mechanism needs to be 
determined.  
 
6.2.1 Mammalian Target of Rapamycin (mTOR) & translational 
regulation 
mTOR is phosphorylated by Akt following activation of the PI3K/Akt pathway and 
consequently activates the 40S ribosomal protein S6 kinase and inhibits the eukaryotic 
initiation factor 4E binding proteins (Hynes et al, 2006). This triggers enhanced function 
of the translational machinery therefore promoting cell growth (Wullschleger et al, 2006). 
Due to its location at the interface of a number of pathways mTOR is now a major target 







Figure 6.2. (a) Western Blot Analysis of basal expression of mTOR and phospho-mTOR. 
Results  are representative of 3 independent experiments (b) Expression of mTOR mRNA in MCF-7, 
LCC1 and LCC9 by quantitative RT-PCR. Each column represents the mean of quadruplicate RT-
PCR analysis for each sample relative to actin expression. Error Bars= SD. Statistical significance 
noted for LCC1 compared with parental MCF-7 (Student’s unpaired t-test **P<0.01).  
 
The levels of mTOR mRNA are significantly lower in LCC1 (p-value=0.005) but not in 
LCC9 when compared to parental MCF-7 cell line (Figure 6.2b) however this does not 
seem to associate directly with the levels of total mTOR protein which are elevated in 
LCC1 and LCC9 cells (Figure 6.2a). It is therefore not surprising that phosphorylated 
mTOR (Ser2448) is also higher in these cells when compared to levels in MCF-7 cells 
(Figure 6.2a). It becomes difficult to determine whether the increased mTOR activation is 
a result of enhanced Akt phosphorylation or just a consequence of high total mTOR 



























mTOR is not due to gene amplification or deregulated transcriptional activity since the 
mTOR mRNA levels are not higher in LCC1 and LCC9, and in fact the contrary is true. 
This suggests that the elevated mTOR protein expression may be due to changes at the 
translational level. High levels of phospho-mTOR in LCC1 and LCC9 suggests that 
translation may be enhanced in these cells therefore promoting growth.  
 
One of the translational mediators activated by 
mTOR is the ribosomal S6 kinase which in turn 
phosphorylates 40S ribosomal protein S6 
(Gingras et al, 2001). Levels of phospho-S6 
(Ser371) are dramatically increased in LCC1 and 
LCC9 cells in comparison to parental MCF-7 
(Figure 6.3). 
 
6.2.2 ERα Phosphorylation: Ser 167 
Oestrogen receptors have two activation domains, 
the oestrogen dependent and oestrogen 
independent domains, the latter being often 
implicated in acquired resistance. Previous 
studies have shown MAPK phosphorylates ERα 
at Ser118 in the absence of oestrogen (Nilsson et 
al, 2001). This ligand independent activation of 
ERα is one route to conferring resistance to 
endocrine therapies.  
 
Campbell et al (2001) have shown that Akt also phosphorylates ERα at the oestrogen-
independent activation domain (Ser167 residue). Phosphorylation of Ser167 is elevated in 
LCC1 and LCC9 cells. Ser 118 phosphorylation, on the other hand remains similar across 
the cell lines, perhaps even slightly reduced in LCC1 (Figure 6.4). The MAPK pathway is 
not altered in this model (as shown in Chapter 3) hence there is no change in Ser118 
phosphorylation. Ser167 phosphorylation is effectively a downstream target of Akt as 
observed by Campbell et al (2001) so high levels of phospho-Ser167 are likely to be a 
result of elevated Akt phosphorylation.  
Figure 6.4 Western Blot analysis of 
ERα phosphorylation levels at two 
phosphorylation sites Serine 118 
(Ser118) and Serine 167 (Ser167). 
Results representative of three 
independent experiments.  
Figure 6.3 Western Blot analysis of 
phospho-S6 in MCF-7, LCC1 and 
LCC9 cells. Results representative of 

















6.3 Upstream Mediators of Akt Activation 
Having established that in our endocrine resistant model Akt activation is elevated it was 
crucial to investigate which upstream pathways are involved in this increase in phospho-
Akt.  
 
6.3.1 PTEN Tumour Suppressor  
Protein phosphatases are important in regulating Akt activity. PTEN negatively regulates 
PI3K by dephosphorylating its phosphoinositide products. Though PTEN mutations are 
relatively uncommon, PTEN protein loss due to promoter methylation or regulation at 
RNA/protein level is observed in 30% of breast cancers (Singh et al, 1998; Garcia et al, 







Figure 6.5 PTEN Expression a) Western blotting analysis of basal expression of PTEN and 
phospho-PTEN. Results representative of 3 separate experiments. b) Expression of PTEN mRNA in 
MCF-7, LCC1 and LCC9 by quantitative RT-PCR. Each column presents mean of quadruplicate 
RT-PCR analysis for each sample relative to actin expression. Error Bars= SD. Statistical 
significance noted for LCC1 compared with parental MCF-7 (Student’s unpaired t-test *P<0.05).  
 
At the mRNA level, LCC1 cells have significantly reduced PTEN mRNA levels in 
comparison to parental MCF-7 cells (p-value=0.014) (Figure 6.5b). This is not the case at 
the protein level since PTEN remains the same in all three cell lines (Figure 6.5a). This 
suggests that the increase in Akt phosphorylation is not due to loss of PTEN protein.  
 
6.3.2 PI3K 
Akt kinase activity is induced following PI3K activation by a number of growth-factor 
receptor-driven signalling cascades. Due to the link between PI3K and many cellular 
processes such as cell growth, proliferation and survival, it is not surprising that this 
kinase has been implicated in cancer (Franke et al, 2003). 


























The antibody used for these experiments recognises the p85 regulatory subunit. PI3Ks are 
heterodimeric molecules consisting of a p110 catalytic and a regulatory p85 subunit 
(Dillon et al, 2007). PI3K function requires the activation of both p85 and p110 subunits. 
Following receptor activation the regulatory p85 subunit is recruited and phosphorylated at 
the cell membrane which in turn activates the catalytic p110 subunit (Chang et al, 2003). 
Therefore activation of p85 is a marker for PI3K activation. 
      
Phosphorylated PI3K is slightly elevated in LCC1 
but certainly not in LCC9 where it is lower than 
in MCF-7 (Figure 6.6). p85 and thereby PI3K 
activation is not elevated in LCC1 or LCC9 cells 
suggesting that increased PI3K phosphorylation 
is not responsible for the high levels of phospho-
Akt in these cells.  
 
Activating mutations in the gene encoding the catalytic subunit p110 α (PIK3CA) have 
been identified in a number of cancers, including breast cancer. A multiplexed assay 
developed by Board et al (2008) was used to detect PIK3CA mutations in this cell line 
model. This technique focuses on the most commonly reported mutations on exons 9 and 
20 (H1047L; H1047R; E542K and E545K) (Levine et al, 2005) (Table 6.1). The exon 9 
G1633A mutation was identified in MCF-7 cells as previously observed (Saal et al, 2005). 
LCC1 and LCC9 cells also carry the same mutation suggesting a mutational alteration is 










        Table 6.1 Most common PIK3CA mutations in breast cancer cell lines.  
 
Figure 6.6 Western blotting analysis of 
PI3K p85 regulatory subunit. Result 
representative of three separate 
experiments.  
PIK3CA mutations in breast cancer cell lines
CatalyticH1047LA3140C20
T47-D 
















 6.3.3 Insulin-Like Growth Factor Receptor (IGFR) 
Altered IGFR function is frequently observed in breast cancer. IGFR signalling is known 
to activate PI3K and may therefore be responsible for elevated Akt phosphorylation in 
endocrine resistant cells. IGFR protein levels are similar in the three cell lines (Figure 
6.7a) despite mRNA levels being greatly reduced in LCC1 and LCC9 (p-values 0.0001 
and 0.001 respectively) (Figure 6.7b). Phospho-IGFR is elevated in LCC1 and LCC9 
(Figure 6.7a) hence this pathway may be responsible for high phospho-Akt levels 









Figure 6.7 IGF Receptor Expression a) Western blotting analysis of basal expression of IGFR and 
Phospho-IGFR. Results representative of 3 separate experiments. b) Expression of IGFR mRNA in 
MCF-7, LCC1 and LCC9 by quantitative RT-PCR. Each column presents mean of quadruplicate 
RT-PCR analysis for each sample relative to actin expression. Error Bars= SD. Statistical 




The IGF signalling system is comprised of two ligands (IGFI and IGFII) which are 
significantly overexpressed in LCC1 and LCC9 cells when compared to the parental 
MCF-7 cell line (Figure 6.8). This is in agreement with previous studies that have shown 
increased IGFI expression in a number of breast cancer cell lines. The same study also 
reports that overexpression of IGFI and IGFII in MCF-7 leads to an increase in cell 





















































Figure 6.8 Expression of IGFR ligands IGF I and II mRNA in MCF-7, LCC1 and LCC9 by 
quantitative RT-PCR. Each column presents mean of quadruplicate RT-PCR analysis for each 
sample relative to actin expression. Error Bars= SD. Statistical significance noted for LCC1 and 




Following the above observations, an IGFR inhibitor was used to investigate the role of 
this pathway in acquired endocrine resistance. I-OMe AG538 inhibits IGFR 
autophosphorylation by competing with IGFR tyrosines (Nahta et al, 2005). The results 
show that this inhibitor did not reverse resistance to tamoxifen or ICI in LCC9. In the 
parental MCF-7 cells, I-OMe AG538 at 5 and 10 μM did significantly reduce growth (p-
value 0.04 at both concentrations). Furthermore, combination of ICI and I-OMe AG538 
also reduce growth in MCF-7 and LCC1, however this is probably due to the ICI effect 






























































Figure 6.9 Effects of IGFR inhibitor I-OMe AG538 on the growth of MCF-7 (a), LCC1 (b) and 
LCC9 (c). MCF-7 experiments were conducted in the presence of E2. Each column presents means 
of 6 OD values. Error Bars=SD. ANOVA test: statistical significance noted for ICI, 5Me, 10Me, 


























































































































6.4 Akt Isoforms: Roles of Akt 1, 2 and 3 
To date three Akt isoforms (Akt 1, 2 and 3) have been identified, all of which have been 
implicated in breast cancer (Jordan et al, 2004).  
 
6.4.1 Basal Characterisation of Akt isoforms 
Akt isoform activation has been linked to a variety of cancers. Elevated Akt 1 and 2 kinase 
activity has been reported in primary breast tumour material. In our cell line model, 
expression of Akt1 and 2 are significantly reduced in LCC1 (p-values=0.0001 & 0.013 
respectively) and in LCC9 cells (p-values=0.002 & 0.009 respectively) in comparison to 
parental MCF-7 (Figure 6.10). On the other hand, Akt 3 mRNA expression is elevated in 









Figure 6.10 Expression of Akt isoform’s mRNA in MCF-7, LCC1 and LCC9 by quantitative RT-
PCR. Each column presents mean of quadruplicate RT-PCR analysis for each sample relative to 
actin expression. Error Bars= SD. Statistical significance tested between cell lines (MCF-7 Akt 1, 
LCC1 Akt 1 & LCC9 Akt 1; ANOVA test *P<0.05;**P<0.01; ***P<0.001). 
 
MCF-7, LCC1 and LCC9 cells expressed equal 
levels of Akt 1 and Akt 2. Akt 3 protein expression, 
on the other hand is elevated in LCC1 and LCC9 
cells (Figure 6.11). This is in contrast to the low 
expression of Akt3 expression in MCF-7 cells, a 
result that is supported by previous reports (Nakatani 
et al, 1999).  
This data suggests that Akt3 expression is elevated 
in LCC9 due to increase transcription.  
 
Figure 6.11 Western blotting analysis 
of Akt isoforms (Akt 1, 2 & 3). Result 



































6.4.2 Elevated Akt 2 Phosphorylation in Resistant LCC9 Cells 
Unfortunately, there are no readily available phospho-Akt antibodies specific to each of 
the Akt isoforms. To overcome this, immunoprecipitation was performed using Akt 
isoform specific antibodies. The immunoprecipitates were then probed with anti-phospho-
Akt antibody to reveal which isoforms are activated in each of the cell lines. 
    
In the three cell lines, Akt 3 is highly 
phosphorylated (Figure 6.12). This is surprising 
particularly in MCF-7 since they have low Akt 3 
expression. The level of Akt 3 phosphorylation 
becomes progressively higher in LCC1 and LCC9 
in comparison to MCF-7. Perhaps more relevant 
is the striking difference in the levels of phospho-
Akt2 between MCF-7 and the other cell lines. 
Phosphorylation of the Akt 2 isoform is high in 
LCC1 and LCC9. This is in contrast to the 
minimal phosphorylation levels observed in 
parental MCF-7 cells (Figure 6.12).  
      
      
The high  levels of Akt 3 phosphorylation in MCF-7 cells is surprising considering Akt 3 
basal levels in this cell line are very low as shown in Figure 6.11. As Akt 3 
phosphorylation is present in all cell lines it is unlikely that this isoform is important in 
conferring resistance in this cell line model. On the other hand, Akt 2 phosphorylation 
may be of particular interest as it is only observed in oestrogen-independent LCC1 and 
endocrine resistant LCC9.  
 
 
6.5 Functional Studies: Effects of Akt RNAi 
6.5.1 Akt RNAi efficiency  
Both Akt 1 and Akt 2 RNAis specifically reduced both RNA and protein levels of Akt 1 
and Akt 2 isoforms, respectively (Figure 6.13a & b). However, Akt 3 RNAi appears to 
poorly reduce protein levels despite reducing mRNA levels as determined by quantitative 
Figure 6.12 Phosphorylation of Akt isoforms. 
Samples were immunprecipitated with Akt 1, 2 
& 3 specific antibodies. Western Blots were 
then performed using these lysates and probed 
for phospho-Akt. The non-IP control was 
incubated with IgG rather than isoform specific 
antibody. Result representative of 3 
independent experiments.  







RT-PCR (Figure 6.13a & b). The figure shows the results obtained for LCC9 cells since 






   
Figure 6.13 Akt RNAi efficiency and specificity in LCC9 cells analysed by western blotting (a) 
and quantitative RT-PCR (b) Each column presents mean of quadruplicate RT-PCR analysis for 
each sample relative to actin expression. Error Bars= SD. Statistical significance tested between each 
Akt RNAi and appropriate negative (Student’s Unpaired t-test *P<0.05;**P<0.01). All results shown 
are representative of three independent experiments 
 
6.5.2 Effects of Akt RNAi on Growth 
Parental MCF-7 cells were sensitive to Akt 1 and Akt 2 specific RNAis as cell number is 
dramatically reduced (Figure 6.14a). The number of viable cells at day 5 is 4 times lower 
in wells treated with these RNAis in comparison to negative RNAi treated wells. Akt 3 
RNAi, on the other hand did not induce such a response. Taking into account the level of 
Akt 3 phosphorylation in all three cell lines, it would be expected that Akt 3 would yield 
the most dramatic effects which is not the case in MCF-7 (Figure 6.14a). This may be a 
reflection of little protein knockdown by Akt 3 RNAi. Interestingly, Akt 3 protein 
knockdown is more effective in LCC1 and LCC9 cells which, as shown in Figure 6.11, 
overexpress Akt 3 in comparison to parental MCF-7 cells. However, the lack of response 










































































































Figure 6.14 Effects of Akt 1, 2 & 3 RNAi on growth of MCF-7 (a), LCC1 (b) and LCC9 (c). 
MCF-7 experiments were conducted in the presence of E2. Each point (Day 0, 3 & 5) presents the 
mean of 6 OD values. Negative RNAi is used as a negative control. This ensures that any variations 
observed are due to the RNAi effect and not down to the effects of the transfection process. Results 





















































LCC1 cells are particularly sensitive to all three Akt RNAi as they all reduced growth (at 
least 8 times lower than control negative RNAi (Day 5 values taken into account)). 
Furthermore, in LCC1 cells Akt 3 RNAi appears to inhibit growth as efficiently as Akt 1 
and Akt 2 RNAi (Figure 6.13b).  Similarly to LCC1, LCC9 cellular growth is inhibited by 
all three Akt RNAis but not quite as dramatically as in LCC1 cells (Figure 6.14c). 
Furthermore, it is interesting to note that Akt 2 RNAi in LCC9 cells reduced growth but 
did not inhibit it to the same level of the other Akt RNAis. This is surprising considering 
previous results showing increased Akt 2 phosphorylation in LCC9 cells. Also interesting 
is the fact that LCC9 cells “recover” from Akt RNAi transfection much faster than any of 
the other cell lines. At Day 3, LCC9 cells begin to grow again whilst for MCF-7 and 
LCC1 cells growth inhibition is still observed after 5 days of treatment (Figure 6.14c).  
These results suggest all three isoforms are important in the three cell lines, despite 
previous observations that Akt 2 and 3 are the prime targets for phosphorylation. Akt 
RNAis consistently reduced growth in endocrine sensitive and resistant cell lines 
suggesting that the role of these isoforms may be critical to cell growth.  
 
6.5.3 Effects of Akt RNAi on Drug Response 
LCC9 cells are resistant to endocrine therapies such as Tamoxifen and ICI 182,780 (ICI). 
This may be linked to the high Akt phosphorylation levels in these cell lines. Hence the 
effects of drug treatments following Akt RNAi transfection were investigated.  
As previously observed in Chapter 3, MCF-7 cells require oestrogen to grow and are 
particularly sensitive to the anti-oestrogen ICI. Akt 1 and Akt 2 RNAi equally abrogated 
oestrogen response in these cells. Cell number remains unchanged in the presence of these 
Akt RNAis regardless of drug treatment as can be inferred by the unchanged OD values 
between day 3 and 5 (Figure 6.15).  
Response to oestrogen in LCC1 cells is also lost after RNAi treatment but unlike in MCF-
7 cells, all three Akt RNAis have this effect. In these cells, Akt 1 RNAi seems to yield the 
most pronounced responses whilst the effects of Akt 2 and AKt 3 RNAi are comparable 
(Figure 6.15). Growth of LCC9 cells is also reduced in the presence of Akt RNAi. Once 
more Akt 1 RNAi produces the most dramatic effects particularly at Day 3. 
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The growth inhibition mediated by ICI also appears to be altered following Akt RNAi 
treatment. In MCF-7 cells, ICI is still growth inhibitory following Akt 1 & 2 RNAi 
treatment (p-values 0.018 and 0.0001 respectively; E2 vs ICI for each Akt RNAi).  
Similarly, growth of LCC1 cells is also reduced in the presence of ICI and Akt RNAi (Akt 
1, 2 & 3 RNAi p-value 0.0001 for all three). Resistant LCC9 cells remain unresponsive to 
ICI in the presence of Akt 2 and Akt 3 RNAi (p-values 0.702 & 0.645 respectively). 
Interestingly, Akt 1 RNAi renders these cells sensitive to ICI treatment (p-value 0.018). 



















Figure 6.15 Effects of Akt RNAi on drug response in MCF-7 cells at day 3 and 5. Each column 
presents the mean of 6 OD values. Negative RNAi is used as a negative control. This ensures that 
any variations observed are due to the RNAi effect and not down to the effects of the transfection 
process. Error Bars=SD. Statistical analyses between each Akt RNAi treatment vs Negative RNAi 



























































Figure 6.16 Effects of Akt RNAi on drug response in LCC1 cells at day 3 and 5. Each column 
presents the mean of 6 OD values. Negative RNAi is used as a negative control. This ensures that 
any variations observed are due to the RNAi effect and not down to the effects of the transfection 
process. Error Bars=SD. Statistical analyses between each Akt RNAi treatment vs Negative RNAi 















Figure 6.17 Effects of Akt RNAi on drug response in LCC9 cells at day 3 and 5. Each column 
presents the mean of 6 OD values. Negative RNAi is used as a negative control. This ensures that 
any variations observed are due to the RNAi effect and not down to the effects of the transfection 
process. Error Bars=SD. Statistical analyses between each Akt RNAi treatment vs Negative RNAi 
























































































































 6.5.4 Akt RNAi and ERα Activation 
Taking into account the elevated Akt phosphorylation and consequent ERα activation 
(Ser167) in LCC1 and LCC9 cells it was important to establish the role of each Akt 







Figure 6.18 Western Blot analysis of Akt RNAi and the effects on ERα phosphorylation 
(Ser167) in LCC9 cells. All results shown are representative of three independent experiments. 
LCC1 western blot is not shown as these cells were found to be particularly sensitive to Akt RNAis 
and did not routinely yield enough protein to be able to run this experiment.  
 
Neither Akt RNAi reduced Ser167 levels in LCC9 (Figure 6.18). This seems to suggest 
that none of the Akt isoforms are solely essential in mediating the high Ser167 levels 
observed in LCC1 and LCC9 cells. It is however important to consider that previous 
reports have suggested there may be a level of functional redundancy between these 
isoforms (Franke et al, 2000).       
 








Figure 6.19 Effects of Akt RNAi on oestrogen receptor regulation. Each column presents mean 
of quadruplicate RT-PCR analysis for each sample relative to actin expression. Error Bars=SD. 










































































































The effects of Akt RNAi on transcriptional regulation of ERα and pS2 were also 
investigated. ERα transcription in LCC1 appears to be higher following Akt RNAi 
transfection. This is particularly true when treated with Akt 1 and Akt 3 RNAi. Expression 
of ERα mRNA is not affected by Akt RNAi in LCC9 cells (Figure 6.19). pS2 regulation in 
LCC1 mirrors that of ERα as Akt 1 and Akt 3 RNAis also seem to induce an increase in 
mRNA levels (Figure 6.20). In LCC9 cells pS2 transcriptional regulation remains 
unchanged regardless of Akt RNAi treatment used (Figure 6.20).       These results suggest 
the regulation of oestrogen responsive genes is not affected by reducing the expression of 














Akt mediates a number of cellular processes such as apoptosis, cell cycle, cellular 
proliferation and motility. It is therefore not surprising that this protein kinase is often 
deregulated in human disease including cancer (Nicholson et al, 2007). Constitutively 
activated Akt has been observed in a number of breast cancer cell lines (Clark et al, 
2002¸Jordan et al, 2004 & Tokunaga et al, 2006) and is often associated with tamoxifen 
resistance in ER-positive breast cancer cells (Campbell et al, 2001; Kurokawa et al, 2003; 
Frogne et al, 2005). Elevated Akt phosphorylation is observed in LCC1 and LCC9 cells in 
comparison to the parental MCF-7 cell line suggesting Akt activation may be important in 














































































Figure 6.20 Effects of Akt RNAi on oestrogen regulated gene pS2. Each column presents mean 
of quadruplicate RT-PCR analysis for each sample relative to actin expression. Error Bars=SD. 
Statistical analyses between each Akt RNAi treatment vs Negative RNAi (Student’s unpaired t test 
*P<0.05; **P<0.01).  
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Regulation of Akt kinase activity is mediated by various growth factor-driven receptors. 
PI3K activation by such signalling cascades generates 3’ phosphorylated 
phosphoinositides which specifically bind and activate Akt (Franke et al, 2003). 
Phosphorylated PI3K is elevated in LCC1 however this is certainly not the case in LCC9 
cells. These results suggest that increased phosphorylation at the Ser473 is not dependent 
on PI3K activation. A number of other kinases have been proposed to be Ser473 kinases 
including mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) and 
integrin-linked kinase (ILK) (Shaw et al, 1998 & Delcommenne et al, 1998). Proteomic 
studies have revealed ILK depletion was associated with inhibition of Ser473 
phosphorylation (McDonald et al, 2008). MAPKAP-K2 has also been shown to activate 
Akt and mutational analysis showed this kinase specifically targeted Ser473 and did not 
affect Thr308 phosphorylation (Alessi et al, 1996). The results in MCF-7, LCC1 and 
LCC9 cells suggest that the mechanism(s) regulating Ser473 phosphorylation may bypass 
PI3 kinase activation.  
     
Mutations in the p110 catalytic subunit α of PI3K (PI3KCA) have been linked to tumour 
growth/invasion and have been implicated in breast cancer (Pérez-Tenorio et al, 2007). 
The most common mutations are located in exons 9 and 20 hence studies have focussed on 
these two loci. Mutational analysis revealed that the MCF-7 parental cell line harbours the 
same PI3KCA mutations as the LCC1 and LCC9 cells. There are conflicting reports 
regarding PIK3CA mutations in MCF-7 cells. Bachman et al (2005) report the MCF-7 cell 
line harbours the E542K mutation. Saal et al (2005) on the other hand show that these cells 
contain the E545K mutation only. The results presented in this thesis support Saal’s 
findings. LCC1 and LCC9 cells are also positive for the E545K mutation but negative for 
the remaining mutations analysed, suggesting that PIK3CA mutations are not a 
contributing factor in acquired resistance in this cell model. 
 
Akt is also negatively regulated by PTEN which removes the 3’ phosphate group from the 
PI3K lipid product (McCubrey et al, 2008). Though PTEN mutations are relatively 
uncommon, PTEN protein loss due to promoter methylation or regulation at the 
RNA/protein level is observed in 30% of breast cancers (Singh et al, 1998; Garcia et al, 
2004). PTEN knockdown in breast cancer cell lines induce PI3K and Akt activation 
(Miller et al, 2009) therefore it was important to determine whether loss of PTEN function 
mediates increased Akt phosphorylation in our cell line model. MCF-7, LCC1 and LCC9 
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cells express equal levels of basal and activated PTEN protein levels suggesting PTEN 
deregulation is not important in conferring resistance in these cells.  
   
The components of the IGF system appear to contribute towards cellular proliferation, 
survival, angiogenesis and metastasis (Fagan et al, 2008). It is therefore not surprising that 
aberrant activation of IGF signalling has been implicated in breast cancer (Belfiore et al, 
2008). Basal IGF receptor protein levels were equal in MCF-7, LCC1 and LCC9 cells 
despite reduced IGFR mRNA levels in LCC1 and LCC9 cells. Receptor phosphorylation 
is elevated in oestrogen independent LCC1 cells and endocrine resistant LCC9 cells which 
is likely to be the result of high ligand expression as IGFI and IGFII transcription is 
significantly higher in these cells. Increased IGFR activation is often observed in breast 
tumour tissue and is associated with reduced survival (Law et al., 2008). Moreover, IGFR 
expression appears to protect against damaging agents such as radiation and 
chemotherapeutic drugs by rescuing these cells from apoptosis. It has been proposed that 
this may be mediated by the downstream activation of PI3K and MAPK pathways (Jiang 
et al, 1999; Kuhn et al, 1999). Previous studies have also shown that increased signalling 
via the IGF receptor is often present in anti-oestrogen resistant cells (Campbell et al, 2001; 
Vivanco et al, 2002). In contrast, Frogne et al (2005) and Knowlden et al (2005) have 
shown reduced IGFR expression in anti-oestrogen resistant MCF-7 cell lines despite 
elevated Akt activation. These results suggest that increased PI3K/Akt activity is not 
always connected to elevated IGF signalling.   
In line with the results presented in this chapter, IGFI and IGFII overexpression in MCF-7 
cells have been shown to promote cell proliferation and tumour formation (Pacher et al, 
2007) whilst elevated IGFI circulating levels are associated with increased breast cancer 
risk (Hankinson et al, 1998). IGFII overexpression, on the other hand, appears to inhibit 
apoptosis due to increased Akt activation (Moorehead et al, 2001). Collectively these 
results suggest that elevated IGF ligand expression may account for the elevated Akt 
phosphorylation and increased invading ability observed in LCC1 and LCC9 cells. 
Constitutive activation of Akt has also been shown to upregulate IGFR gene expression 
suggesting the Akt pathway is also involved in regulating IGFR expression (Tanno et al, 
2001). According to these results, the increased IGFR activation observed in LCC1 and 
LCC9 cells may contribute towards increased phopshorylated Akt levels in these cells 
however Akt may also activate IGFR due to this feedback loop mechanism 
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In order to further determine the role of IGFR in MCF-7, LCC1 and LCC9 cells an IGFR 
kinase inhibitor, I-OMe AG538, was used. This compound binds to tyrosines 1158 and 
1162 which undergo autophosphorylation during IGFR activation. Binding of I-OMe 
AG538 inhibits autophosphorylation and consequent IGFR inhibition (Blum et al, 2000). 
The I-OMe AG538 compound did not reduce cell growth nor did it reverse tamoxifen and 
ICI 182,780 resistance in LCC9 cells. Furthermore, cell growth was only reduced in MCF-
7 cells. This is in contrast to results reported by Knowlden et al (2005). Their studies show 
IGFR inhibitors or IGFII neutralizing antibodies significantly reduced growth of 
tamoxifen-resistant cells. Furthermore, crosstalk between IGFR and EGFR/HER2 may 
also been important as reported by Nahta et al (2005) and Camirand et al (2005). Both 
studies show IGFR blocking may or may not individually inhibit cellular growth but IGFR 
inhibition helps overcome herceptin resistance and acts synergistically with gefitinib 
(EGFR inhibitor). IGFR inhibition did not reduce cellular proliferation in LCC1 and LCC9 
cells. This could be the result of the IGFR inhibitor not actually inhibiting its target 
sufficiently. On the other hand, this could be a reflection of not high enough inhibitor 
concentration or unspecific inhibition leading to insufficient IGF repression. Finally it 
could be that the inhibition of IGFR alone is not sufficient and other membrane receptors 
may be important in this process.  
 
Akt has been postulated to phosphorylate various proteins thereby mediating several 
signalling pathways and cellular processes (Hay, 2005). Akt is consequently regarded as a 
regulatory switch. Downstream targets include BAD and Forkhead transcription factors 
which regulate the apoptotic pathway; glycogen synthase kinase-3β (GSK-3β) a promoter 
of cell growth and NF-κB which induces gene expression (McCubrey et al, 2008; Hanada 
et al, 2004; Toker et al, 2006; Fry, 2001). mTOR is also a downstream target of the Akt 
pathway. This protein is important in regulating cell cycle entry and initiation of protein 
synthesis in response to the adequate signals (Fingar et al, 2004). mTOR activation is 
elevated in LCC1 and LCC9 cells, however the basal protein levels are also high. This 
makes it difficult to determine whether increase mTOR phosphorylation is a result of 
elevated Akt signalling or simply a consequence of high protein expression. This could be 
tested by checking mTOR levels after Akt siRNA which would further help establish the 
role of Akt. Akt-mediated endocrine resistance has been shown to be reversed in the 
presence of mTOR inhibitors highlighting the role of mTOR (Beeram et al, 2007; 
DeGraffenried et al, 2004). mTOR activation has also been shown to be increased 
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progressively as normal breast epithelium develops into abnormal hyperplasia and tumour 
invasion (Zhou et al, 2004) . Reports also suggest mTOR is associated with more severe 
prognosis in breast cancer (Klos et al, 2006). 
mTOR phosphorylates members of the protein synthesis machinery such as p70 ribosomal 
six kinase (p70S6K) and eukaryotic initiation factor (eIF-4E)-binding protein (Yamnik et 
al, 2009; Wendel et al, 2004). p70S6K phosphorylates S6, the 40S ribosomal protein 
consequently initiating protein translation. In fact, LCC1 and LCC9 cells express high 
levels of phosphorylated S6 ribosomal protein suggesting elevated mTOR activation 
induces mRNA translation and protein synthesis in endocrine resistant cell lines.  
 
Serine 167 is one of the major phosphorylation sites of ERα and Akt has since been 
identified as one of the kinases mediating ERα phosphorylation at this site (Campbell et 
al, 2001). Elevated Ser167 phosphorylation has been reported to be a consequence of 
increased Akt activity in acquired tamoxifen resistance (Shou et al, 2004; Nicholson et al, 
2004). Furthermore, Ser167 phosphorylation appears to play a role in reversing the 
inhibitory effects of oestrogen deprivation (Staka et al, 2005). Phosphorylation at this 
serine site is markedly higher in LCC1 and LCC9 cells than in parental MCF-7 cells. This 
may play an important part in rendering these cells oestrogen independent and anti-
oestrogen resistant due to ligand-independent ER activation.  
These results indicate increased Akt activation in LCC1 and LCC9 cells may confer 
endocrine resistance firstly by promoting protein synthesis and secondly by inducing 
oestrogen independent ER phosphorylation. 
 
Previous studies have shown that different Akt isoform expression is observed in 
endocrine resistance. Akt 1 and Akt 2 expression is unaltered in MCF-7, LCC1 and LCC9. 
This is an interestingly result considering these two Akt isoforms are ubiquitously 
expressed in mouse tissue whilst Akt 3 expression appears to be more restricted (Hanada 
et al, 2003). However, Akt 3 protein expression is markedly elevated in oestrogen 
independent LCC1 and anti-oestrogen LCC9 cells, which seems to be a result of increased 
transcriptional rate of this gene. The Akt 3 isoform has been less studied yet evidence 
suggests that Akt 3 expression is associated with hormone-independence, ER-negative and 
more advanced breast cancers (Nakatani et al, 1999). Analysis of normal versus tumour 
tissue suggested Akt isoform expression is not altered in tumorigenesis (Zinda et al, 2001). 
On the other hand, constitutively activated Akt3 expression in MCF-7 cells promoted 
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oestrogen independent tumour growth (Faridi et al, 2003). This data supports the results 
presented here and suggest the Akt 3 isoform may be important in tumorigenesis of these 
breast cancer cell lines.  
Isoform activation is also altered in these cell line models. Immunoprecipitation 
experiments suggest Akt 3 isoform is the preferred phosphorylated target in MCF-7, LCC1 
and LCC9 cells. This is surprising considering basal Akt 3 levels are apparently very low  
in parental MCF-7 cells. Despite previous reports suggesting Akt 3 activation may play a 
part in conferring endocrine resistance (Faridi et al, 2003), Akt 3 phosphorylation is 
present in endocrine sensitive MCF-7 cells as well as in the fully resistant LCC9 cells. 
These results indicate that Akt 3 activation may be important in these cells however, it 
does not appear to mediate endocrine resistance. Interestingly, Akt 2 phosphorylation is 
elevated in LCC1 and LCC9 cells. Activation of the Akt 2 isoform has been previously 
shown to offer protection against docetaxel induced apoptosis in breast cancer cells. 
Moreover, increased Akt 2 kinase activity confers survival advantage (Xing et al, 2008) 
and appears to be present in approximately 40% of breast cancer cases (Sun et al, 2001). 
These results suggest that Akt 2 is important in breast cancer and that increased activation 
observed in LCC1 and LCC9 cells may be important in conferring resistance.  
 
RNAi studies revealed Akt 1 and Akt 3 RNAis reduce cellular proliferation in all three cell 
lines suggesting that these isoforms are important despite differential phosphorylation. 
Oestrogenic stimulation is abrogated by Akt 1 and Akt 2 in MCF-7 cells indicating they 
may play a part in mediating oestrogenic action. Akt RNAi treatment reduces cellular 
proliferation in LCC9 cells but this was not exarcebated by tamoxifen or ICI 182,780 
treatment. Hence no isolated Akt isoform RNAi treatment appears to restore anti-
oestrogen sensitivity. Pancholi et al (2008) have recently reported that proliferation of a 
tamoxifen resistant MCF-7 cell line is significantly reduced after Akt inhibition mirroring 
the results obtained in LCC1 and LCC9 cells. Akt is known to promote cell survival by 
inhibiting pro-apopotic pathways hence it has been proposed that Akt inhibition reduces 
proliferation as a result of increased apoptosis. Mouse studies revealed that the knockout 
of each individual isoform generate different phenotypes indicating they regulate distinct 
cellular mechanism (Chen et al, 2001; Cho et al, 2001; Easton et al, 2005; Tschopp et al, 
2005). Moreover, Akt RNAi studies suggest isoforms may have opposing roles since Akt 
1 is described as an inhibitor of cell migration whilst Akt 2 promotes cellular motility and 
invasion (Irie et al, 2005). A study by Maroulakou et al (2007) in mice also supports these 
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findings as they report ablation of Akt 1 and Akt 2 promoted and inhibited tumour growth, 
respectively. Akt 3 ablation appeared to have limited effects on cellular proliferation 
(Maroulakou et al, 2007). The specific role of individual Akt isoforms in endocrine 
resistance is yet to be fully determined.  
    
Previous studies have shown that Akt RNAi alone did not affect ERα phosphorylation at 
the Ser167 residue (Pancholi et al, 2008) as observed in our results. However, 
combination of Akt RNAi and MAPK RNAi did reduce phosphorylation levels (Pancholi 
et al, 2008). This indicates that Akt may not be the only protein mediating elevated ERα 
activation in LCC1 and LCC9 
      
The transcription of oestrogen responsive genes is often elevated in endocrine resistant 
cells. In fact, previous work by our group has shown pS2 and ERα basal mRNA 
expression is elevated in LCC1 and LCC9 cells (Kuske et al, 2006). Akt RNAi did not 
affect ER and pS2 transcriptional rates suggesting Akt is not responsible for the elevated 
transcriptional rates of oestrogen responsive genes often observed in endocrine resistance.   
An overview of the PI3K/Akt pathway is shown in Figure 6.21. The proteins found to be 














Figure 6.21 PI3K/Akt pathway overview. A summary of the proteins analysed in this study. The 
block arrows depict the members of the pathway whose expression is elevated in oestrogen 


























































The advent of endocrine resistance in breast cancer remains one of the major challenges in 
the treatment of this condition. Various mechanisms have been implicated in endocrine 
resistance however how the complex regulatory networks may interact has yet to be fully 
established. The thorough understanding of crosstalk between signalling cascades and their 
effect on cellular processes such as proliferation, cell cycle and apoptosis would facilitate 
the development of combinatorial therapies targeting resistance (Arlt et al, 2006).  
    
A three-stage MCF-7 cell-based model for oestrogen independence and endocrine 
resistance was used in this study to determine which intracellular signalling pathways may 
be important in conferring resistance to anti-oestrogenic drugs. The LCC1 cell line, which 
was derived in vivo from MCF-7 cells, appears to mimic clinical progression from early 
stage to a more aggressive phenotype. LCC1 cells are oestrogen independent but retain 
sensitivity to endocrine treatments suggesting this phenotype arises independently of 
endocrine resistance (Leonessa et al, 1992; Brünner et al, 1993). On the other hand, LCC9 
cells were derived in vitro following stepwise selection in the presence of the pure anti-
oestrogen ICI 182,780. This cell line is fully resistant to ICI and tamoxifen despite never 
being exposed to the latter (Brünner et al, 1997). During the acquisition of endocrine 
resistance, ER positive breast cancer cells often progress in a stepwise manner from full 
oestrogen dependence to an oestrogen-sensitive, but no longer dependent phenotype, 
culminating in complete endocrine resistance (Clarke et al, 2001; Clarke et al, 2003). The 
MCF-7-base cell line model use in this study emulates this process observed in a clinical 
setting. 
      
A number of studies using these cells lines have suggested that endocrine resistance does 
not appear to be associated with detectable copy number alterations suggesting oestrogen 
independence and endocrine resistance may result from changes in gene expression and/or 
protein activation and degradation (Brünner et al, 1993; Johnson et al, 2008). As shown 
here in Chapter 3 and by Kuske et al (2006), ERα expression is markedly elevated in 
LCC1 cell lines but not in the resistant LCC9 cells. Higher ERα protein expression is 
linked to increased cellular proliferation and to promoter occupancy and consequent gene 
activation in the absence of ligand binding (Dowsett et al, 2005; Fowler et al, 2004). 
However, while high ERα levels may be associated with enhanced oestrogen response, it 
may also render certain tumours resistant to endocrine therapies (Kuske et al, 2006). Loss 
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of ERα protein expression or function is found to confer de novo resistance to anti-
oestrogenic therapies and is present in 30 to 40% of breast cancer patients (Ma et al, 2009). 
The LCC1 cells shares similar characteristics to the long-term oestrogen deprivation 
(LTED) models generated following culturing in low-oestrogen conditions. These LTED 
cells are considered oestrogen hypersensitive due to their ability to respond to oestrogen 
levels 2 to 3-log lower that the levels required to stimulate wild-type cells (Yue et al, 2003; 
Martin et al, 2005). These cell lines, like LCC1 cells, are characterised by higher ERα 
protein expression and the ability to grow in low oestrogen conditions (Yue et al, 2002; 
Martin et al, 2005; Santen et al, 2005). Despite this, Kuske et al (2006) show that unlike 
the LTED models, LCC1 cells fail to respond to low levels of exogenous oestrogen.   
The higher ERα levels observed in LCC1 cells are probably a result of routine culture in 
low oestrogen conditions. Oestrogen reduces ERα in MCF-7 cells and its derivatives cell 
lines indicating the existence of protein turnover and proteasomal degradation of ERα 
(Nawaz et al, 1999). siRNA removal of ERα inhibited the growth of both LCC1 and LCC9 
cells indicating a dependency on the receptor (Kuske et al, 2006).  
The transcription of oestrogen regulated genes, such as trefoil factor 1 (TFF1)/ pS2, is 
elevated in LCC1 and LCC9 cells under basal conditions suggesting ligand-independent 
ERα function is an important mechanism at play in this cell line model. The oestrogen 
receptor is primarily activated by the presence of its ligand leading to protein 
phosphorylation (Reviewed in Lannigan et al, 2003). However, ligand-independent 
activation has also been extensively documented and has been shown to play a part in 
bypassing the tumour’s requirement for oestrogen. Signalling pathways such as MEK/ERK 
and Akt are able to directly phosphorylate ERα at serines 118 and 167, respectively 
(Bunone et al, 1996; Martin et al, 2000).  
 
Receptor phosphorylation at the serine 167 residue is markedly increased in oestrogen-
independent LCC1 and endocrine resistant LCC9 cells in comparison to the parental MCF-
7 cell line. Activation of Akt, which directly phosphorylates this residue, is also elevated in 
these cell lines suggesting these two events may be connected. Therefore, this pathway 
became one of the focuses of this study. However, unlike serine 167 residue and Akt, 
serine 118 phosphorylation and MEK/ERK activation are not increased in LCC1 and 
LCC9 cell lines suggesting this pathway is not important in conferring endocrine resistance 
in this cell line model. Work by Gratton et al (2001) and others have reported the existence 
of crosstalk between Akt and MEK/ERK pathways. They have observed that the activation 
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of the PI3K/Akt pathway led to the inhibition of MEK thereby reducing stress kinase 
activation and protecting cells from apoptosis (Gratton et al, 2001; Park et al, 2002; 
Zimmermann et al, 1999). This does not appear to be important in the LCC cell line 
models as MEK/ERK activation remains unchanged despite Akt phosphorylation being 
markedly elevated.  
 
The Akt kinase has become central in many cancer studies because it mediates a number of 
distinct cellular processes such as proliferation, apoptosis and cellular motility (Pecorari et 
al, 2009). Apoptosis levels after treatment with anti-oestrogens and anti-HER2 therapies, 
as measured by PARP cleavage, are reduced in endocrine resistant LCC9 cells in 
comparison to oestrogen independent LCC1 cells. This is in agreement with previous 
studies by Riggins et al (2005) which report LCC9 cells have reduced levels of ICI 
182,780 mediated apoptosis. Various studies have suggested that apoptosis bypass in these 
cell lines may be regulated by NFκB. The expression of this transcription factor is elevated 
in LCC9 cells and its regulation is also altered as oestrogen withdrawal and ICI 182,780 
treatment no longer inhibit NFκB expression (Gu et al, 2002; Pratt et al, 2003). Increased 
Akt phosphorylation is present in both LCC1 and LCC9 cell lines suggesting that perhaps 
there is a secondary mechanism further increasing apoptosis resistance in the fully 
endocrine resistant LCC9 cells. 
Previous reports have also suggested that actin is a substrate of Akt and that this kinase 
influences the organization of the actin cytoskeleton (Vandermoere et al, 2007). The 
involvement of the PI3K/Akt pathway in the control of cell migration was suggested 
following reports that the activation of this pathway led to anchorage-independent growth 
and metastasis of liver and thyroid carcinoma cells (Nakanishi et al, 2002; Kim et al, 
2005). In addition, Akt was found to down-regulate RhoB, a protein known to suppress 
migration and metastasis (Jiang et al, 2004). Migration in LCC1 and LCC9 cells remained 
either unchanged or actually reduced in comparison to the parental MCF-7 cell line. This is 
in agreement with the phenotypic data which indicates that MCF-7 cells tend to grow as a 
monolayer spreading across the surface area available whilst LCC1 and LCC9 cells 
preferentially grow in “clumps”. On the other hand, the invading ability of the latter two 
cell lines was significantly increased. This has been previously reported to be the case in 
the LCC1 cell line (Castro et al, 2005).   
As well as promoting cell invasion and survival, Akt upregulation inactivates negative cell 
cycle regulators such as p21 and p27 thereby leading to cell cycle progression and cell 
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growth (Zhou et al, 2001; Liang et al, 2002; Shin et al, 2002). Both LCC1 and LCC9 cells 
have a higher percentage of cells found at S-phase under basal conditions. This is in 
contrast to the MCF-7 parental cell line which requires oestrogen to progress through the 
cell cycle.  
The activation of mTOR, a “downstream” effector of Akt, was also found to be elevated in 
LCC1 and LCC9 cell lines. mTOR is important to for the oncogenic transformation 
induced by the PI3K/Akt pathway. Activation of mTOR results in the phosphorylation of 
the eukaryotic initiation factor 4E-binding protein 1 and the ribosomal p70 S6 kinase 
which activate protein translation (Albert et al, 2006). Phosphorylation of the S6 kinase 
was found to be increased in LCC1 and LCC9 cells presumably as a result of elevated 
mTOR activation. This may be a reflection  of increased protein translation rates in LCC1 
and LCC9 cells which could be in part responsible for increased protein levels. 
     
Together, this data indicates that Akt activates and regulates a number of different cellular 
processes which combined may confer oestrogen independence and endocrine resistance. 
These include alterations in apoptosis, cell cycle and invading ability as well as increase in 
translation. It is very likely that the exact role of Akt is different in LCC1 and LCC9 cells 
despite both these cell lines overexpressing this kinase. It is important to remember that 
LCC1 are oestrogen independent but remain sensitive to anti-oestrogen therapies unlike 
LCC9 cells. Moreover, whilst cell cycle progression is not oestrogen-dependent in LCC1 
and LCC9 cells, ICI 182,780 still induces a G0/G1 arrest in LCC1 cells only suggesting that 
the cell cycle in these cells continues to, at some level, be regulated by oestrogen 
signalling. 
      
Akt activation in breast cancer is linked to resistance to chemo-, hormone- and 
radiotherapy-induced apoptosis, predicts for a more aggressive behaviour and correlates 
with reduced overall survival (Bellacosa et al, 2005; Sutherland et al, 2005). PI3K 
activation generates second messenger PtdIns-3,4,5-P3 which bind to Akt and recruit this 
kinase to cell membrane. On the other hand, Akt is negatively regulated by PTEN. Loss of 
PTEN function and activating mutations in the PI3K gene are frequently observed in breast 
cancer tumours. Deregulation of these pathways may be responsible for elevated Akt 
activation. However, this was not found to be the case in these cell lines as PTEN 
expression was unchanged and no PI3K mutations were detected suggesting these 
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mechanisms are not responsible for the increased Akt phosphorylation levels observed in 
LCC1 and LCC9 cells. 
 
On the other hand, IGF receptor phosphorylation is increased in LCC cells. The IGF 
signalling comprises of a complex interacting network of receptors and ligands which 
activate multiple pathways such as the PI3K/Akt and MAPK pathways (Reviewed in 
Samani et al, 2007).  LCC1 and LCC9 cells were found to markedly overexpress the IGF 
ligands, IGFI and IGFII. These ligands have been identified as potent mitogens important 
in maintaining the transformed phenotype (Hollier et al, 2008). Ligand overexpresssion 
will induce increased receptor phosphorylation which in turn activates downstream 
signalling pathways such as Akt. Given that PTEN and PI3K functions are not altered in 
these cell lines, elevated IGF receptor phosphorylation was considered the most likely Akt 
activator in LCC1 and LCC9 cells. The IGF system may also be crucial in conferring 
resistance via distinct pathways and not necessarily requiring Akt. For example, the 
expression of IGFII has been shown to override the need for oestrogen in MCF-7 cancer 
cells with the ligand being the limiting factor rather than the receptor (Stephen et al, 2001). 
Furthermore, it has also been established that IGFs directly regulate the activation of the 
oestrogen receptor (Fagan et al, 2008). 
Despite these results, I-OMe AG538, an IGFR kinase inhibitor which blocks receptor 
autophosphorylation, did not restore endocrine sensitivity and oestrogen dependence in 
LCC9 and LCC1 cell lines, respectively. This is in contrast to previous studies by 
Knowlden et al (2005) where they report IGFR inhibitors reduced the growth of 
tamoxifen-resistant cells. Conversely, other groups report that IGFR inhibition alone may 
not be sufficient to illicit a reduction in cellular growth (Jones et al, 2004; Camirand et al, 
2005; Jones et al, 2006). Elevated IGFR signalling is often observed in cells lines resistant 
to anti-EGFR therapies and IGF activation is essential in EGFR-mediated cellular 
proliferation (Chakravarti et al, 2002; Stull et al, 2002). These studies highlight the 
interaction between the two pathways therefore the combination of IGF and EGF targeted 
therapies may be more efficient in inhibiting growth. Furthermore, it has been reported that 
IGFR interacts and activates HER2 (Balana et al, 2001). As observed in EGFR signalling, 
overexpression of IGFR was associated with resistance to anti-HER2 therapies (Lu et al, 
2001). A shift between IGFR, EGFR and HER2 signalling may be responsible for the 
absence of response to IGFR blocking and targeting the three receptors may be necessary 




The aberrant activation of cell membrane receptors has also been extensively linked to the 
increased signalling through downstream pathways including proliferation, survival and 
metastasis (Reviewed in Jin et al, 2008) The EGF family comprising EGFR, HER2, HER3 
and HER4 is of particular interest due to its role in malignant transformation and cancer 
progression (Hynes et al, 2005). EGFR, HER2 and HER3 are frequently overexpressed in 
breast cancer and are associated with a more aggressive behaviour, poor prognosis and 
reduced overall survival (Klijn et al, 1992; Owens et al, 2004). The protein expression of 
EGFR, HER2 and HER3 is not elevated in oestrogen independent LCC1 and endocrine 
resistant LCC9 cells. 
These results suggest that the role of these receptors may be limited in this cell line model. 
However, oestrogen regulation of HER2 expression was found to be altered in resistant 
LCC9 cells. Whilst in MCF-7 and LCC1 cells, oestrogen reduces HER2 expression at the 
transcriptional and protein levels, this is not observed in LCC9 cells. Oestrogen mediated 
HER2 downregulation has been a known mechanism for quite some time (Dati et al, 1990; 
Read et al, 1990; Russell et al, 1992) and the results shown here prove this is not confined 
to the HER2 receptor and also affects the expression of HER3 and HER4 expression. 
Moreover, the results in Chapter 4 show that oestrogen-mediated HER3/HER4 repression 
is lost in LCC9 cells. The regulatory mechanism behind oestrogen transcriptional 
inhibition was shown here and by others to be mediated by the p160 coactivator family 
(Newman et al, 2000; Hurtado et al, 2009).  The SRC-1 and AIB1 coactivators were 
shown to be transcriptional activators of HER2 which are preferentially recruited to the 
oestrogen receptor following oestrogenic stimulation. Transcriptional regulation of HER2 
in LCC9 cells is altered despite remaining responsive to action of SRC-1 and AIB1, as 
evidenced by the double knockout experiments. ChIP experiments would also help reveal 
which proteins bind and activate the enhancer region of the HER2 promoter. This would be 
likely to change following oestrogen treatment and it would be interesting to establish 
whether this is altered in the advent of endocrine resistance. 
The link studied here between p160 coactivators and the transcriptional regulation of the 
HER2 gene is likely to also be applicable to the other membrane receptors HER3 and 
HER4. Furthermore, altered transcriptional regulation of other genes including other cell 
membrane receptors despite no obvious protein overexpression may be an important 
feature of resistance. It would be interesting to establish whether this is the case for other 
receptors such as the IGF receptor. In addition, a number of proteins have now been 
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identified as inhibitors of HER2 transcription (e.g. PAX2; FOXP3; PEA3). It would be 
interesting to determine whether expression of these inhibitor proteins is at all altered in 
oestrogen-independent LCC1 and endocrine resistant LCC9 cells. 
 
In conclusion, oestrogen independence and endocrine resistance in LCC1 and LCC9 cells 
respectively may be intrinsically connected to increased/deregulated signalling via 
membrane receptors such as IGFR, HER2 and HER3. These cell membrane receptor 
activate a number of downstream signalling pathways such as Akt. As a result various 
cellular processes are affected: cell survival is increased due to the ability to bypass 
apoptosis, cell cycle arrest is overcome and invading ability is increased. These alterations 
combined are likely to contribute towards an oestrogen independence phenotype and 




Figure 7.1 Overview of pathways and mechanisms found to be altered in endocrine resistant 
LCC9 cells. The areas which were found to be altered are highlighted in red with a brief 
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The development of endocrine resistance is one of the major challenges in current 
therapeutic approaches in breast cancer treatment. Several mechanisms have been 
implicated in breast cancer endocrine resistance such as HER2 upregulation. This has 
been particularly important as it gave rise to new drug therapies (e.g. Herceptin) 
specifically targeting this protein.  
 
In this study, an MCF-7-based cell line model emulating the clinical development of 
endocrine resistance was used to establish which intracellular pathways may be 
important in conferring resistance to anti-oestrogens. Transcriptional regulation of 
HER2, 3 and 4 is altered in oestrogen independent LCC1 and endocrine resistance 
LCC9 cells in comparison to the parental MCF-7 cells. Expression of these receptors is 
downregulated in the presence of oestrogen which is not observed in LCC1 and LCC9 
cells. Therefore, despite no detectable overexpression of these receptors, HER-driven 
signalling regulation is altered in LCC1 and LCC9 cells. The p160 co-activator family 
(SRC-1, TIF2 and AIB1) were shown to be particularly important as they bind and 
activate transcription. In the parental MCF-7 cell line, the SRC-1 co-activator appeared 
to be the main activator of HER2 transcription as confirmed by the ability of SRC-1 
RNAi to mimic oestrogen in downregulating HER2 expression. In contrast, SRC-1 and 
AIB1 are both required in HER-transcription activation in LCC1 and LCC9 cell lines. 
This shift ensures that in the presence of oestrogen HER2 transcription is not 
downregulated as there are two available co-activators instead of one. Furthermore, 
herceptin and 2C4 which target HER2, are not as effective in promoting apoptosis in 
LCC9 cells suggesting by bypassing the HER2 regulatory mechanisms, these cells are 
able to reduce apoptosis and increase cellular survival.  
 
In addition to altered HER regulation, Akt activation is markedly elevated in LCC1 and 
LCC9 cells. This appears to result from increased IGF receptor signalling as both cell 
lines express high levels of IGFR ligands (IGFI and IGFII). Increased Akt activation 
mediates elevated mTOR phosphorylation thereby promoting translation and protein 
synthesis. Furthermore, Akt also induces ligand-independent ERα activation by directly 
phosphorylating the receptor at the Ser167 residue. This may be crucial in overcoming 
 141
the effects of anti-oestrogen therapies and consequently conferring resistance. Increased 
Akt 2 phosphorylation is associated with increased oestrogen independence and 
endocrine resistance since it is markedly elevated in LCC9 cells but only to a small 
extent in LCC1 cells.  
LCC9 and LCC1 cells also show enhanced invasion ability in comparison to the 
parental MCF-7 cells consistent with previous studies have shown (Vandermoere et al, 
2007) and this may be a result of increased Akt phosphorylation.  
 
Together these results indicate that oestrogen independence and endocrine resistance in 
these cells may be mediated by increased HER receptor signalling and elevated Akt 
activation. These two pathways may well be connected as these receptors are upstream 
activators of pathways such as Akt hence conferring survival advantage to the cells by 
reducing the number of cells undergoing apoptosis and increasing their invasion ability 
ability. Finally, increased activity of these pathways ensures ligand-independent 
activation of ERα and signalling cascades activated via the non-genomic pathway 
thereby conferring resistance to these cell lines. These results further suggest that 
efficient breast cancer treatments may require different drugs to target distinct parts of 
the signalling cascades. 
  
 







     A number of further studies would be very valuable and informative to perform in 
order to complete and extend the experiments in this thesis: 
 
1. As shown in Chapter 4, oestrogen downregulates HER2, HER3 and HER4. It 
would be interesting to establish whether this is the case for other receptors, such 
as the IGF receptor.  
2. A number of proteins have now been identified as inhibitors of HER2 
transcription (e.g. PAX2; FOXP3; PEA3). It would be interesting to determine 
whether expression of these inhibitor proteins is at all altered in oestrogen-
independent LCC1 and endocrine resistant LCC9 cells. 
3. ChIP experiments would also help reveal which proteins bind and activate the 
enhancer region of the HER2 promoter. This would be likely to change following 
oestrogen treatment and it would be interesting to establish whether this is altered 
in the advent of endocrine resistance. 
4. Akt RNAi and immunoprecipitation studies indicate that increased Akt 2 
phosphorylation is associated with endocrine resistance however all three 
isoforms are important in mediating cellular growth and oestrogen response. In 
order to further determine their individual roles, it would be informative to 
perform double Akt isoform knockouts. 
5. Further establish how Akt RNAi affects cellular processes such as apoptosis and 
invasion which have shown to be altered in the resistant cell line model.  
6. Investigate IGF receptor signalling and the activation of the downstream Akt 
pathway. As observed in Chapter 6, the expression of the IGFI and IGFII ligands 
is elevated in LCC1 and LCC9 cells hence activation of IGFR may be responsible 
for elevated Akt phosphorylation. Using efficient IGFR inhibitors would help 
clarify its role in oestrogen independence and endocrine resistance.  
 
